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The prostate is an exocrine gland of the male reproductive system. There is a wide array 
of techniques available for imaging prostate cancer (PCa). However, there is a need to 
develop a new PET radiotracer to image PCa as the most commonly used PET tracer 
18
F-FDG is not very successful in imaging of PCa. The aim of this project is to evaluate 
the chelator CP256 and its bifunctional modificaton (YM103), together with a new 
molecular targeting vehicle J591-scFv which shows specificity for an extracellular 
epitope of prostate specific membrane antigen (PSMA), an extensively studied antigen 
for imaging PCa. The radionuclide used is gallium-68 (
68
Ga), which is a generator based 
metallic radionuclide with a half-life of 68 min. 
A comparative study of CP256 with other gallium chelators such as NOTA, DOTA and 
HBED showed that CP256 gave a higher radiolabelling yield and greater serum 








Zr. It was demonstrated that CP256 could chelate 
68
Ga in vivo, 
allowing a pre-targeting approach in which an antibody conjugated with CP256 could 
be administered to a patient, followed hours to days later by 
68
Ga-acetate or citrate. This 
technique could be quite useful with 
68
Ga because of its short half-life. CP256 is a 
unique and promising chelator as compared to the NOTA and HBED, which are unable 
to bind with 
68
Ga which was previously bound to serum protein. 
The antibody fragment J591-scFv incorporating a His-tag for labelling with 
99m
Tc 
tricarbonyl was produced and its binding evaluated using human PCa cell lines PC3LN3 
(PSMA negative) and a variant engineered to express PSMA (PC3LN3-PSMA). It was 




 conveniently and 
efficiently. The labelled product was stable in serum. It showed selective binding to 
PSMA positive cells compared to PSMA negative cells. 
A cysteine residue was incorporated into the J591c(scFv) sequence along with a His-tag 
to facilitate radiolabelling with 
68
Ga through YM103, a bifunctional chelator which 
contains a maleimide group to attach with cysteine of J591c(scFv). Conjugated 
J591c(scFv) gave good (95%) radiolabelling yields with 
68
Ga within 5 minutes. The 
radiolabelled conjugated J591c(scFv) showed selective binding with PSMA positive 
cells (Du145-PSMA) compared to PSMA negative cells (Du145) in vitro.  
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For in vivo evaluation of 
68
Ga labelled J591c(scFv), one group of male SCID beige mice 
was injected with Du145-PSMA cells and another group with Du145 cells for tumour 
growth over the period of a few weeks. For imaging and biodistribution studies mice 
were injected with 7 MBq/10 µg of radiolabelled conjugated J591c(scFv). The PSMA 
positive tumour showed clear uptake of the radiotracer compared to the PSMA negative 
tumour with a specific vs nonspecific uptake ratio of 9.1. 
 
Conclusion: 
CP256 is a unique and versatile chelator for 
68
Ga. Its radiolabelling yield and reaction 
conditions are better than available gallium chelators such as DOTA. Its bifunctional 
version (YM103) conjugated with J591c(scFv) showed quantitative radiolabelling 
(depending upon concentration) within 5 minutes with 
68
Ga and showed specific 
binding to a PSMA positive cell line (Du145-PSMA) and high uptake in PSMA positive 
tumours as opposed to PSMA negative tumours. 
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Chapter 1: Introduction 
For most of the metallic radionuclides the radiopharmacological strategy involved has 
the following components. 
1.1-Radiopharmacological Strategy  
Metal radiopharmaceuticals are those which incorporate a diagnostic or therapeutic 
metallic radionuclide. Radiometals can provide useful pharmacological properties in 
their ionic form or can be used for labelling of various biomolecular (target specific) 





1: a targeting biomolecule (BM), which acts as a target specific vector 
2: a linker/spacer, which can be used to control pharmacokinetics (PKM, pharmaco-
kinetics modifying). 
3: a bifunctional chelator (BFC) 
4: a metallic radionuclide. 
 
Each of these components must be optimised to obtain a radiopharmaceutical with the 
best properties [1]. 
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1.2-Structure and Function of Prostate Gland 
The prostate is an exocrine gland of the male reproductive system in most mammals. It 
is a donut shaped gland and its size is about that of a walnut. It is located under the 
bladder in front of the rectum and it wraps around the urethra (a tube which carries urine 
from bladder to penis) (Fig-1.2). It is made up of 70% glandular and 30% muscular 
tissue. The prostate gland makes 30% of the fluid part of the semen. The remaining 
amount of fluid is secreted by the testes, seminal vesicles, bulbourethral and urethral 
glands. It needs male sex hormone to grow and function [2]. 
The prostatic epithelium is composed of two layers: basal layer and luminal layer. In 
these two layers three types of cell are present: basal, neuroendocrine and secretory. 
Basal cells rest on the basement membrane. They are undifferentiated and non-secretory 
cells and are not dependent on androgen for survival. Neuroendocrine cells are spread 
throughout the basal and luminal layers. They lack androgen receptors (AR). However, 
they do express serotonin and chromogranin A and play an important role in growth and 
differentiation. Secretory cells are present in the luminal layer and they form the 
exocrine region and are well differentiated. They secrete prostate specific antigen (PSA) 
and prostatic acid phosphatase (PAP) into the glandular lumina. They express high 
levels of AR and are dependent on androgen for survival [3]. 
  
  
Figure 1.2: Normal prostate gland along with surrounding tissues and organs [8] 
 




Prostate cancer (PCa) was first described in 1853 by a surgeon at the London Hospital, J 
Adams, by histological examination [4]. In his report, he noted that the condition was “a 
very rare disease”. Remarkably, 150 years later, PCa has become a significant health 
problem and disease. PCa is commonly found in elderly men and is the second leading 
cause of death among men in the USA [5]. In the UK, after skin cancer PCa is one of 
the four most common cancers along with breast, lung and colorectal cancers [6]. In the 
latest international data which covered five continents from 1988-1992, it was observed 
that occurrence of this disease is highest in North America, intermediate in Australia 
and low in Asia [7]. There are many risk factors, which include family history and 
genetics, hormone and other growth factors, diet and nutrition, and other lifestyle 
factors. 
In one study it was observed that approximately 60-70% of PCa occurs in the peripheral 
zone of the prostate gland (the largest zone, located near the rectum), and 10-20% in the 
transition zone (surrounding the proximal urethra), with only 5-10% originating from 
the central zone (involved in the connection of the seminal vesicles to the prostate) [8]. 
 
  
Figure 1.3: Prostate cancer originating from different zones of prostate gland [8] 
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1.4-Effect of Hormones and Growth Factors on Normal Prostate 
Gland and Prostate Cancer 
Androgen, Vitamin D and insulin like growth factor I (IGF-I) play an important role in 
the growth of the normal prostate gland. Androgen and Vitamin D act in an opposing 
way. Androgen stimulates cell proliferation and Vitamin D inhibits cell proliferation. 
Both interact at various levels, with one end-point of both being the IGF-1 axis [7]. In 
most of cases, any abnormality in the pathways of these hormones may result in 
abnormal hyperplastic growth or may be associated with the presence of PCa.  
 1.4.1-Effect of Androgen and Androgen Receptors 
Testosterone controls cell division in the prostate gland. After diffusing into the cell it is 
converted irreversibly into 5α-dihydrotestostrone (DHT) by the catalytic activity of 
enzyme 5α-reductase type 2. Both testosterone and DHT can bind to the AR, although 
DHT has 2- to 10-fold greater affinity for the AR and produces conformational changes 
in the receptors, dimerisation and transcriptional activity. In the early stage, 80-90% of 
PCa are dependent upon AR activity. However, androgen ablation therapy ultimately 
fails, as prostate cancer progresses to a hormone refractory state. AR is expressed 
throughout PCa progression and persists in the majority of patients with hormone 
refractory disease. The main cause of failure of androgen ablation is the alteration in the 
expression of AR co-regulators and mutation of the AR [7, 9]. 
1.4.2-Vitamin D Pathway 
Vitamin D is responsible for maintaining normal concentrations of calcium and 
phosphorus in blood plasma. It is formed in the skin by sunlight-stimulated conversion 
of 7-dehydrocholesterol. The vitamin D receptor (VDR) regulates the transcription of 
VDR-responsive genes by binding with 1α,25-hydroxyvitamin D3 (1,25D3) after 
relocating into the nucleus. In one study, various PCa cell lines were treated with 
1,25D3 and it was observed that it crippled the growth of the cells via multiple 
mechanisms, which include cell cycle arrest, the induction of apoptosis, and regulation 
of growth factor signalling. It was also observed in a separate study that high levels of 
1,25D3 resulted in lower level of PCa risk especially in older males [7,10].  
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 1.4.3-Growth Factors 
Abnormalities in certain growth factors result in the occurrence of PCa. These include 
insulin-like growth factors I and II (IGF-I and -II), epidermal growth factor (EGF), 
vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and 
transforming growth factor (TGF)-β. IGF is thought to play an important role in the 
development of the prostate and it regulates cell growth by interacting with IGF-IR 
(IGF-I receptor). AR and VDR produce some of their effects through IGF-I [7,8]. It is 
found that many prostate xenograft models express both IGF-I and -II as well as 
receptors for each. PC-3, an androgen-independent PCa cell line, secretes IGF-II. In 
addition, experiments indicate that IGF-II levels are increased in adenocarcinoma cells, 
suggesting a role in prostate carcinogenesis. Chan and colleagues observed that high 
levels of plasma IGF-I are observed in PCa. Further, there is an association between the 
circulating IGF levels and prostate cancer risk and it increased the detection rate of 
prostate cancer over PSA alone [7,8]. 
1.5-Screening of Prostate Cancer 
There are various techniques available for the diagnosis and monitoring of PCa. The 
commonly used methods to identify and diagnose PCa include DRE (digital rectal 
examination), PSA (prostate specific antigen) levels, needle biopsy and Gleason score. 
Along with these traditional methods for the diagnosis of PCa there are various modern 
imaging modalities, which are gaining popularity because of their accuracy. These 
include CT (computed tomography) [11], MRI (magnetic resonance imaging) [12], 
SPECT (single photon emission computed tomography) and PET (positron emission 
tomography) [13,14]. Among the molecular imaging techniques, PET is the most 
sensitive and has been applied in the diagnosis of PCa [15]. PET is a non-invasive 
imaging technique. It involves injection of a radiopharmaceutical followed by imaging. 
The imaging protocol depends upon the radionuclide, its physical half-life, decay mode, 
chemistry for tracer preparation, in vivo kinetics and availability/cost. 
1.5.1-DRE, PSA and Needle Biopsy 
Normally these three screening tests are carried out together. In DRE the doctor or nurse 
feels the prostate gland to assess any irregularity in its size and shape [5]. In one study 
DRE and PSA were compared and it was observed that DRE has poor performance if 
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PSA blood levels are low [16]. Usually biopsy is done after the blood test to check the 
PSA level, since if it is done before then it might raise the PSA levels in the blood. In 
needle biopsy, a thin needle is inserted through rectum and urethra to collect samples 
from the prostate gland and these are then further analysed to assess the Gleason score 
[5]. 
1.5.2-Gleason Score 
The Gleason score was developed by Donald Gleason in 1974 when very little was 
known about the disease and it is still used to identify PCa. The Gleason score is a 
system to grade the aggressiveness of the tumour. The Gleason grade has values from 1-
5, and these values are assigned to the different biopsy samples. In the end the Gleason 
grades given to the different biopsy samples are added up to give the Gleason score and 
its value ranges from 2-10. The higher the value the more aggressive is the cancer and it 
helps in staging of the cancer and ultimately management by providing proper treatment 
to the patient. Conservative management is a reasonable option for Gleason score 2 to 4 
cancer and for some patients with Gleason score 5 to 6 cancer depending upon the 
disease progression [17]. Prostatectomy or radiation therapy (RT) is recommended for 
Gleason score 7 to 10 cancer [5, 18]. 
1.6-Current Methods for Imaging Prostate Cancer 
The diagnostic imaging methods available include CT [11], MRI [12], SPECT and PET 
[13,14]. Among all molecular imaging techniques, PET is the most sensitive and has 
been applied in the diagnosis of PCa [15]. The two critical needs for PET imaging of 
PCa are early detection of primary lesions and accurate localisation of PCa bone 
metastasis. However, the most commonly used PET tracer 
18
F-FDG 
(fluorodeoxyglucose) is not very successful in imaging PCa. The main reason for this is 
that the glucose utilisation in well-differentiated PCa is often low because expression of 
GLUT-1 transporters is lower than in other tumour types, which leads to the low uptake 
of 
18
F-FDG and poor image contrast [19]. Additionally, the intense accumulation of 
18
F-
FDG in the urinary bladder, which is in close proximity to the prostate, often 
overshadows the tumour uptake and no correlation was observed between tumour 
grade/stage and 
18
F-FDG uptake in PCa [20]. Zaheer et al. in their review of new agents 
and techniques for imaging PCa have shown that although there are no definitive 
markers that can predict tumour progression for PCa, more careful study and validation 
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of markers such as PSMA and AR may provide a clue in approaching this pressing 
clinical issue [21].  
Generally speaking, AR radiolabelled ligands can be divided into two main structural 
classes, steroidal (such as 
18
F-FDHT) and nonsteroidal (such as flutamide and 
bicalutamide, labelled with 
11
C), or into two different functional classes, androgenic and 
anti-androgenic [22,23]. 
18
F-FDHT (fluoro-5α-dihydrotestrone) (Fig-1.4) was developed 




FDHT is a structural analogue of 5R-dihydrotestosterone, a principal intraprostatic form 
of androgen. In the relevant study of fluorinated androgen analogues in baboon, 
performed by the Welch group, the uptake of FDHT in the prostate was blocked by co-
administration of cold testosterone (reduced about 10-fold) [26]. To date, FDHT 
appears to bind specifically to androgen receptors in vivo and showed the most 
favourable targeting properties for non-invasive imaging among all receptor-binding 
radiotracers studied previously. In other research, 
18
F-FDHT presents some advantages 
such as fast tumour uptake and prolonged retention of radioactivity observed in human 
studies. However, limitations such as rapid metabolic rate of this labelled compound 
have been observed [24-27]. 
Nonsteroidal AR radioligands, (R)-[
11
C]-dimethylaminehydroxy-flutamide derivative 
(Fig-1.5), were designed, synthesised and radiosynthesised by Jacobson et al. in 2006 
[28]. These compounds have an electron-rich group (dimethylamine) located on the 
methyl moiety, which may confer a better stability to the molecule. Additionally, they 
Figure 1.4: Structure of 18F-FDHT (fluoro-5α dihydrotestrone), 
a steroidal AR ligand. 
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serve as an anchor for carbon-11 labelling in a more straightforward approach than 
labelling with fluorine-18 or bromine-76.  
 
 
     
 
 
1.7-PSMA and PCa 
The most extensively studied antigen in PCa for antibody-based imaging is PSMA 
(prostate specific membrane antigen) [29]. It is expressed in virtually all PCa. Recent 
studies have suggested that PSMA is also expressed in tumour associated 
neovasculature [30,31]. Its molecular weight is 100 kDa [32]. It contains an intracellular 
domain of 1-18 amino acids. Although it is quite small in size, the cytoplasmic domain 
interacts with a number of proteins and has a major impact on the localisation and 
molecular properties of PSMA. It has a transmembrane domain of 19-43 amino acids 








Figure 1.6: Schematic diagram of the globular nature of Prostate-Specific Membrane 
Antigen (PSMA). It has a small cytoplasmic domain (CD) which anchors it to the cell, a 
hydrophobic transmembrane domain (TM), and a large extracellular domain (ED) [32]. 
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One of the many functions of PSMA is to hydrolyse peptide bonds between N-
acetylaspartate and glutamate in the abundant neuropeptide N-acetylaspartyl glutamate 
(NAAG) and the glutamyl linkages in pteroylpolyglutamate, respectively, as it contains 
N-acetylated linked acidic dipeptidase (NAALADase) and folate hydrolase (FOLH). 
Thus this enzyme has been referred to alternatively as glutamate carboxypeptidase II 










The crystal structure of PSMA clarifies the epitopes recognised by monoclonal 
antibodies being studied for applications in cancer imaging and therapy. The epitope for 
the J591 antibody that is in clinical trials has been mapped by using truncated PSMA 
constructs to residues 153–347 [33]. The structure reveals that this region corresponds 
to the majority of the apical domain, which is distant from the membrane surface and 
hence generally exposed and accessible. The PSMA structure shows that Asn-476 is 
distant from the apical domain and is instead located in the membrane-proximal region 
of the molecule, where it is less accessible to antibodies [34]. The apical domain of 
PSMA (also called the protease-associated domain) consists of two β-sheets, three α-
helices, and one helical turn. It forms one side of the substrate-binding cavity (residues 
687-704). Another important function of the helical domain is in forming the dimer 
interface, which involves three helices. PSMA can convert between a dimeric and 
Figure 1.7: A mechanistic scheme for α-NAAG (glutamate is red, and NAA is blue) 
binding and cleavage by PSMA (black). The zinc-binding PSMA residues are assumed to 
remain bound during the reaction mechanism. The C-terminal carboxyl group binds the 
zinc ions in a bridging fashion, and there are electrostatic interactions between the 
glutamate side chain and the arginine patch and the aspartate side chain and Arg-210. 
The zinc-bound water molecule is poised to attack the peptide bond of the bound 
substrate, leading to a tetrahedral intermediate, bond cleavage, and product dissociation. 
An analogous mechanism would be expected for the cleavage of α-NAAG by NLD2 [33]. 
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monomeric form in vitro by addition of metal chelators or changes in salt concentration; 
only the dimeric form of PSMA has folate hydrolase and naaladase activity and is 
expressed on the surface of prostate cells. By removing the 15 C-terminal (721-747) 
residues in PSMA hinders the enzymatic activity. The crystal structure reveals two zinc 
atoms which are coordinated by three endogenous ligands: a histidine (His-553 or -377), 
a terminal aspartate (Asp-453) or glutamate (Glu-425), and a bridging aspartate (Asp-
387). Along with this, a water ligand asymmetrically bridges the zinc ions. Another 
residue that could potentially act as an active site base is Tyr-552 [33].  
      
 
In one of the studies PSMA is reported as a noncovalently associated homodimer. It was 
observed that the extracellular domain is sufficient for dimerization and that 
dimerization is required for enzymatic activity. It was also observed that PSMA dimers 
displayed a native conformation and possessed high-level carboxypeptidase activity and 
monomers did not display this behavour. The stability of the dimer is dependent upon 
the presence of metal ions, such as Zn
2+
 in the active site of PSMA. However, other 
metal ions (e.g., Ca
2+
) stabilize the dimer. It was also observed that regardless of the 
initial oligomeric state of the protein, high salt concentrations promote dimerization, 
whereas metal-chelating agents dissociate dimers into monomers [35]. 
Figure 1.8: PSMA surface rendering in which the helical domain is light red, the apical domain 
is light green, the protease domain is light blue, and zinc ions are orange. The residues lining the 
substrate-binding cavity are highlighted in a darker version of the color corresponding to the 
domain from which the residue originates [33]. 
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1.8-Small Molecules and PCa 
In the case of radiolabelled peptides for PCa imaging, bombesin (BBN) peptides and 
their derivatives, which can bind to the GRPR (gastrin releasing peptide receptor), are 
the most popular choice [36]. The full length version (
64
Cu-DOTA-[Lys3]BBN) or C-
terminal truncated form of BBN (
64
Cu-DOTA-Aca-BBN) can be used for GRPR 
targeting in vivo [37]. One study investigated the importance of various aliphatic linkers 
between the BBN analogue and the DOTA chelator to the imaging characteristics of the 
tracer. It was concluded that the use of amino acid linkers (combination of glycine, 
serine and/or glutamic acid) between the DOTA, NOTA and CB-TE2A chelator and the 
BBN analogue could reduce non-specific tissue uptake, while maintaining good PCa 
uptake of the tracer [38,39,40]. However in a more recent study it was observed that 
negatively charged linkers may minimize non-specific binding and decrease overall 
background. These negatively charged linkers have been used to connect urea inhibitors 
and bulky radionuclide chelates for in vivo imaging and biodistribution studies with the 
radiolabeled tracers [41]. In one study of five 
64
Cu-labeled inhibitors of PSMA based on 
the lysine–glutamate urea scaffold used a variety of macrocyclic chelators, namely 
NOTA, PCTA, Oxo-DO3A, CB-TE2A, and DOTA, to determine which provides the 
most suitable pharmacokinetics for in vivo PET imaging. The favorable kinetics and 
high image contrast provided by CB-TE2A chelated 
64
Cu suggest it as the most 
promising among the candidates tested. That could be due to the higher stability of 
64








Cu-DOTA chelates in vivo [42]. 
Multi-presentation of a targeting molecule on a single entity has been recognized as a 
practical way for imaging signal amplification. In one study image signal amplification 
was achieved by using a bivalent imaging probe design built upon a bifunctional 
chelator scaffold using a small molecular PSMA inhibitor (GPI: 2[(3-amino-3-
carboxypropyl)(hydroxy)(phosphinyl)-methyl]pentane-1,5-dioic acid) for specific 
PSMA detection and imaging quantification. For study purposes both monovalent 
(H2CBT1G) and bivalent (H2CBT2G) conjugates were prepared and labelled with 
64
Cu 
for evaluation. PET imaging studies were conducted on mouse xenograft models 
established with a PSMA
+
 cell line, LNCaP, and PSMA
-
 PC3 and H2009 cell lines. It 
was observed that bivalent H2CBT2G gave 4-fold enhancement of PSMA binding 
affinity compared to monovalent H2CBT1G [43]. 
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Furthermore, in another study it was demonstrated that the 
86
Y-labelled peptide 
(MP2346 (DOTA-(Pro(1),Tyr(4))-bombesin(1-14)) exhibited better PET image quality 
in all PCa models for delineation of GRPR (gastrin-releasing peptide receptor)-positive 
tumour as compared to 
64
Cu-MP2346 due to lower uptake in clearance organs and lower 
background activity [44]. 
68
Ga was also used to label the dual-receptor targeting 
heterodimer, BBN-RGD [45].  In one investigation it was observed that the 
99m
Tc-





mercaptoacetyltriserine-N-hydroxysuccinimide ester) demonstrated gamma imaging of 
living human PCa cells. The 
99m
Tc labelled complex takes only 25 min to prepare and 
gives greater than 99% radiochemical purity [46]. 
 In one comparison study, 15 patients were imaged within 7 days and the rate of 





F-fluorocyclobutane-1-carboxylic acid), a new synthetic amino acid in 
comparison with 
11
C-choline, an established tracer used for detection of PCa relapse 
[47]. 
11
C-choline is considered sufficient for restaging patients with rising PSA levels. 
Anti-3-
18
F-FACBC uptake was found to correlate with the expression level of the amino 
acid system ASC (alanine, serine, cysteine) on the PCa cells, along with the expression 
of LAT1 (sodium-independent “L” large neutral amino acid transport system).  
Physiological uptake of anti-3-
18





FACBC showed uptake in the pancreas and liver, and mild and diffuse uptake in the 
bone marrow. On the other hand 
11
C-choline showed uptake in spleen and kidneys 
along with liver, pancreas and bone marrow. The detection rates using the two 
compounds were determined and the target–to-background ratio (TBR) of each lesion 
was measured.  No adverse reactions were observed. The detection rate with 
11
C-choline 
PET/CT was 20% and anti-3-
18
F-FACBC PET/CT 40%. The TBR of anti-3-
18
F-FACBC 
was greater than that of 
11
C-choline, as were image quality and contrast. These results 
indicate that anti-3-
18
F-FACBC may be superior to 
11
C-choline for the identification of 
disease recurrence in the setting of biochemical failure. Further studies are required to 
assess efficacy of anti-3-
18
F-FACBC in a larger series of prostate cancer patients [47]. 
It was also observed that 
11
C-choline (a quaternary ammonium salt containing the 
N,N,N-trimethylethanolammonium cation) as well as 
11
C-acetate have insufficient 
diagnostic accuracy for the staging of the primary tumour and are unable to differentiate 
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PCa from benign prostate hyperplasia, chronic prostatitis and high-grade intraepithelial 
neoplasia [48]. Regarding lymph node staging, choline tracers have demonstrated a high 
specificity. Unfortunately, the sensitivity is only moderate. For staging recurrent 
disease, sensitivity depends on the level of serum PSA (PSA should be >2 ng/ml). This 
applies to both choline and acetate. However, despite these limitations, a significant 
number of patients with recurrent disease can benefit from PET imaging by a change in 
treatment planning [48]. 
11
C-methionine is one of the earliest amino acid based PET 





F-DCFBC) have been developed [49,50]. 
In one study 
18
F-Choline was used to image 46 consecutive patients with PCa 
previously treated by definitive radiotherapy and with suspicion of relapse with negative 
or inconclusive conventional imaging. Twelve out of 46 were treated with 
brachytherapy and 34 with external beam radiation therapy. Twenty-three patients were 
under androgen depriviation therapy at the time of the examination.  PSA was measured 
within 1 month before the treatment. Patients were subdivided into four groups 
according to their PSA level: 1.0 < PSA ≤ 2.0 ng/ml (11 patients), 2.0 < PSA ≤ 4.0 ng/ml 
(16 patients), 4.0 < PSA ≤ 6.0 ng/ml (9 patients) and PSA > 6.0 ng/ml (10 patients). 
Correlation between androgen depriviation therapy and positive detection rate was 
investigated as well as between PSA and distribution of metastatic spread. The overall 
positive detection rate of 
18
F-Choline was 80.4 %. Positive detection rate of 
18
F-Choline 
was not influenced by androgen depriviation therapy (82.6 %). The majority of the 
patients (59 %, 22/37 patients) showed local relapse only, confined to the prostatic bed; 
22 % of the PET/CT-positive patients (8/37 patients) showed distant relapse only (bone 
localizations in all of them), while the remaining 19 % (7/37 patients) showed both local 
and distant (lymph node and bone) spread. 
18
F-Choline is proposed as a first-line 
imaging procedure in restaging prostate cancer patients primarily treated with 
radiotherapy [51]. 
Recently, synthesis, in vitro binding, biodistribution and imaging of two new 
68
Ga-
labelled, conjugated PSMA inhibitors were reported. These compounds demonstrated 
PSMA-specific tumour imaging in vivo [52]. A small-molecule based approach using 
radiolabelled urea-based PSMA inhibitors as imaging agents has shown promise for 
PCa imaging. 
18
F labelled phosphoramidate is a representative of a new class of PSMA 
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targeting peptidomimetic molecules that shows great promise as imaging agents for 
detecting PSMA+ prostate tumours [53]. The design strategy of this class of compounds 
is largely based on the binding features of PSMA endogenous substrates and potent 





F-SFB) was conjugated to S-2-((2-(S-
4-amino-4-carboxybutanamido)-S-2-carboxyethoxy)-hydroxyphosphorylamino)-




amino)-pentanedioic acid, which has 20-fold more inhibiting capacity. In another 
clinical study direct comparison of 
68
Ga-labelled small molecule targeting PSMA was 
done with 
18
F-choline and it was observed that 
68
Ga-Glu-NH-CO-NH-Lys(Ahx)-
HBED-CC showed better detection of small lesions compared to 
18
F-choline in patients 
with low PSA values. The main reason for this better detection is high intensification of 
radiopharmaceutical in small metastasis and quick clearance from background. 
Considering the growing accessibility of 
68
Ga from a generator and the ease of labelling, 
68
Ga PSMA-targeted imaging has high potential to become a valuable diagnostic agent 
in recurrent PCa and therapy monitoring [54,55,56]. 
In more recent research, a novel 
18
F-labelled small molecule inhibitor of PSMA 
enzymatic activity (BAY 1075553), a 9:1 mixture of (2S,4S)- and (2R,4S)-2-[
18
F]fluoro-
4-phosphonomethyl-pentanedioic acid), was synthesized from pure precursors 
dimethyl-2-{[bis(benzyloxy)phosphoryl]methyl}-4-(tosyloxy)pentanedioate. In vivo 
imaging and biodistribution studies were conducted in mice bearing LNCaP, 22Rv1 and 
PC-3 tumours. The radiotracer showed high tumour accumulation specific to PSMA-
positive tumour-bearing mice. Fast clearance resulted in overall low background signals 
in other organs except for high uptake in kidney and bladder due to renal elimination of 
the compound. A modest uptake into bone was observed which decreased over time, 
indicating organ-specific uptake. Pharmacokinetic, toxicology and safety pharmacology 
studies support the application of BAY 1075553 in a first-in-man microdose study with 
single i.v. administration [57]. 
For treatment of PCa it was observed that PSMA-VRP (vaccine replicon particles) 
increased the expression of cell surface PSMA in vitro. Anti-PSMA responses were 
produced after a single injection of PSMA-VRP, and these responses were boosted on 
repeated dosing. The cellular immune responses in BALB/c and C57BL/6 mice were 
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determined to be directed toward different defined peptide sequences within PSMA. 
Anti-PSMA immunity was elicited with a favourable safety profile both in mice and in 
a rabbit toxicology study and it represents a promising approach for immunotherapy of 
prostate cancer [58]. Another study which involving Phase I/II clinical trials for the 
treatment of prostate cancer showed 50% reduction in PSA using dendritic cells and 
PSMA peptide HLA-A0201 [59].  
Molecular Insight has developed a number of radiopharmaceuticals both for diagnostic 
and therapeutic purposes. One of these is Trofex, which is radiolabelled with 
123
I. It is a 
small molecule inhibitor of PSMA which binds to PCa cells. It could play an important 
role in diagnosis and monitoring of PCa and potentially therapy with 
131
I-Trofex [60]. A 
Phase II study is ongoing in metastatic PCa. In parallel studies using the same targeting 
principle, 
99m
Tc-MIP-1340 and MIP-1404 (Trofolastat) are being evaluated. MIP-1404 
was evaluated in two Phase I studies to differentiate clinically significant PCa from 
silent or indolent. 
99m
Tc-MIP-1404 cleared rapidly from the circulation, showed 
minimal urinary activity, but moderate (15-20%) liver and kidney uptake. In men with 
metastatic PCa, 
99m
Tc-MIP-1404 rapidly accumulated in lesions in lymph nodes and 
bone as early as 1 h post injection. In this study it was also observed that SPECT/CT 
images demonstrated excellent lesion contrast. This result led to a multi-centre, 
international Phase II study with 
99m
Tc-MIP-1404 in patients scheduled for 
prostatectomy which is in progress [61]. 
131
I-MIP-1095 administered intravenously 
circulates throughout the body, binds to the extracellular domain of PSMA and is 
subsequently internalised by PCa cells. In pre-clinical tumour models, 
131
I-MIP-1095 
was retained within the prostate cancer cell, allowing beta particles from 
131
I to cause 
targeted cell death of PCa. One of the experiments employed spheroids derived from 
LNCaP prostate carcinoma cells to determine the radiosensitizing potential of various 
chemotherapeutic drugs in combination with 
131
I-MIP-1095. It was also used in studies 
to detect and treat metastatic castration resistant prostate cancer (mCRPC). To estimate 
radiation dosimetry, tissue kinetics has been studied for the potential therapeutic use of 
131
I-MIP-1095 in men with mCRPC. In a study 28 consecutive patients were treated 
with a single cycle of 
131
I-MIP-1095. Sixteen patients with known prostate cancer 
underwent PET/CT imaging 1, 4, 24, 48 and 72 h post injection of 
124
IMIP-1095. The 
images showed excellent tumour uptake and moderate uptake in liver, proximal 
intestine and within a few hours post-injection also in the kidneys. High uptake values 
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were observed only in salivary and lacrimal glands. Dosimetry estimates for 
131
I-MIP-
1095 revealed that the highest absorbed doses were delivered to the salivary glands (3.8 
mSv/MBq), liver (1.7 mSv/MBq) and kidneys (1.4 mSv/MBq). The absorbed dose 
calculated for the red marrow was 0.37 mSv/MBq. PSA values decreased by >50% in 
60.7% of the men treated. Of men with bone pain, 84.6% showed complete or moderate 
reduction in pain. No adverse effects on renal function were observed. Targeted tumour 
therapy was able to deliver unprecedented doses to tumour lesions. Lymph node and 
bone metastases were exposed to estimated absorbed doses of 300 Gy [62]. 
Various chemotherapeutic drugs were investigated for synergistic interaction: olaparib 
(PARP-1 inhibitor), topotecan (topoisomerase I inhibitor), docetaxel (mitotic spindle-
targeting agent), nutlin-3 (inhibitor of the P53-MDM2 interaction) and DSF:Cu (the 
copper-chelated form of disulfiram). It was observed that DSF:Cu enhanced the efficacy 
not only of external beam radiation but also of targeted radionuclide therapy [63]. MIP-
1500 and -2100 are second generation analogues of 1095 and are under further 
investigation [60,64]. In one study with MIP-1466, considerable reduction (50%) in the 
blood PSA level was observed in the patients with late metastatic PCa [60].  
In another study, four PSMA inhibitors MIP-1427, MIP-1404, MIP-1428, and MIP-
1405 derived from the glutamate-urea-glutamate or glutamate-urea-lysine 
pharmacophores conjugated to CIM or TIM chelators were radiolabeled with 
99m
Tc and 
evaluated in vitro and in vivo. It was observed that 
99m
Tc-MIP-1404 showed the best 
combination of high tumour uptake and rapid clearance from kidney and non-target 
tissues. 
99m
Tc-MIP-1404 specifically bound to PSMA in vivo [65]. 
 1.9-Antibodies and PCa 
Radiolabelled antibodies against PSMA have been used in the clinic for diagnosis of 
PCa and the 
111
In-labelled monoclonal antibody (7E11), capromab pendetide 
(Prostascint), has been extensively evaluated for SPECT imaging applications. The 
PSMA epitope recognised by monoclonal antibody (mAb) 7E11 is located in the 
cytoplasmic (i.e. intracellular) domain. In theory, antibody imaging with 111In-capromab 
allows for a specific molecular diagnosis of primary and secondary PCa lesions. A 
limitation of 
111
In-capromab imaging is that it is suboptimal for the detection of bone 
metastases, and is significantly less sensitive than bone scans in this regard. 
Furthermore, 
111
In-capromab is not currently considered a promising agent for lesion 
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detection within the prostate gland or for determining extracapsular extension, primarily 
because the internal target of 
111
In-capromab requires that cell membranes be damaged 
before the antibody can bind. Excess unbound antibody leads to high background signal 
and poor spatial resolution [66]. Recently, an in vivo method to quantify antibody 
uptake by using 
111
In-capromab SPECT combined with CT was developed [67]. 
The immunohistochemical characteristics of the antibodies 7E11, J591, J415, PEQ226.5 
and PM2J004.5 have been studied. Each of these antibodies binds to a distinct epitope 
of PSMA. Their characteristics were evaluated using the steptavidin-biotin method [31]. 
It was also observed that 7E11 is not available for binding in viable PCa cell lines 
because it recognises an intracellular epitope [33]. However, J591, J533, J415 and E99 
showed binding with viable PCa cell lines, as they recognise extracellular epitopes [33]. 
It was also found that PSMA has two distinct extracellular epitopes, PSMAext1 and 
PSMAext2 [68]. Laser scanning confocal microscopy was used to demonstrate that 
J591 accumulates in endosomes after internalisation [68]. Another antibody (MU J591) 
that recognises the extracellular domain of PSMA has been designed and investigated 
for localisation and staging of PCa [69]. In one approach, docetaxel encapsulated 
targeted nanoparticles developed using PLA and PLGA polymer systems were 
conjugated with the A10 2′-fluoropyrimidine RNA aptamers. These nanoparticles target 
PSMA on the surface of PCa cells (LnCaP) and are engulfed by these cells specifically 
and efficiently, in vitro and in vivo resulting in significantly enhanced in vitro cellular 
toxicity as compared with nontargeted nanoparticles that lack the PSMA aptamer 
[70,71,72]. More recently, J591-targeted controlled release nanoparticles have been 
developed for effective gene delivery to prostate cancer cells [73,74]. An anti-PSMA 
antibody was also conjugated with QDs (quantum dots, tiny particles of a 
semiconductor material such as CdSe or ZnS, ranging from 2 to 10 nanometers in 
diameter) that emit light in the near-infrared (NIR) 800 nm range (QD800). QD800 is 
superior and more sensitive than QD655 for detecting human C4-2 and C4-2B prostate 
tumours in mouse tibia and is not compromised by autofluorescence interference. 
QD800 accumulated maximally in intratibial sites within 30 min after tail vein 
administration. The QD800 images could be detected <1 h after tail vein administration. 
This represents an approximately 1000-fold better sensitivity than other currently 
available technologies [75]. 
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In one of the experiments superparamagnetic iron oxide nanoparticles (SPIONs) were 
attached to an antibody (J591) that binds to the extracellular domain of PSMA, to 
specifically enhance the contrast of PSMA-expressing prostate cancer cells. 
Conjugation of mAb J591 to commercial SPIONs was achieved using a 
heterobifunctional linker, sulfo-SMCC. Two types of prostate cancer cell lines LNCaP 
(PSMA+) and DU145 (PSMA−) were used in the experiments. MRI and cell uptake 
experiments demonstrated the high potential of the synthesized nanoprobe as a specific 
MRI contrast agent for detection of PSMA-expressing prostate cancer cells [76]. 
In recent years there has been massive development in antibody design. Full length 
mAb are broken down into various fragments. The smaller size and target affinity of the 
fragments affects the penetration properties into tissues which are inaccessible to full-
size mAbs, clears rapidly from blood circulation and this also matches with the short 
half-life of some of the radionuclides [77]. The engineering of single chain variable 
region fragments (scFv) of mAb is another route to improve their kinetics for imaging. 
Full length mAb have long serum half life, but due to the short half-life of 
68
Ga blood 
clearance needs to be rapid [78]. The scFv can be produced in large quantitites and is 
cost effective as compared to the full length mAb [79]. Lack of the Fc region in single 
chain fragments results in low immunogenicity and makes them better therapeutic 
agents. Rapid clearance also minimises the damage to the healthy tissue compared to the 
full length mAb except for the kidneys [79]. 
A chimeric mAb that binds phosphatidylserine was labelled with 
74
As for PET imaging 
of PCa in a rat model [80]. 
124
I-labelled IG8 mAb against PSCA (prostate stem cell 
antigen) was more PCa specific [81]. A hu1G8-based minibody was engineered for PET 
imaging of PCa in xenograft models upon 
124
I-labelling [82]. PET imaging results with 
the diabody, engineered from the same parent mAb, were also encouraging [83]. In one 
of the recent studies the scFv was engineered starting from the variable heavy and light 
domains of the murine anti-PSMA mAb D2B, a small protein that can better penetrate 
tissue. It was then analysed in vitro for activity, stability, internalisation ability and in 
vivo for targeting specificity. Maintenance of function and immunoreactivity as well as 
extremely high radiolabelling efficiency and radiochemical purity were demonstrated by 
in vitro assays and under different experimental conditions. Despite its monovalent 
binding, D2B-scFv retained a good strength of binding and was able to internalise 
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around 40% of bound antigen. In vivo it specifically target only PSMA expressing PCa 
xenografts. Due to these advantageous properties, D2B-scFv has the potential to 
become a good theranostic reagent for early detection and therapy of PCa [84]. Another 
prostate tumour-targeting scFv, UA20, along with a nonbinding control scFv, N3M2, 
gave promising results when labelled with 
99m
Tc and evaluated for binding and rapid 
internalization into human PCa cells in vitro and in vivo using xenograft models. The 
tumour-to-blood and tumour-to-muscle ratios were 12:1 and 70:1, respectively. In 
contrast, the control antibody exhibited a tumour uptake of only 0.26 %ID/g, similar to 
that of muscle and fat. Kidney uptake was nonspecific, consistent with the route of 
excretion by scFvs [85]. 
One of the radionuclides which is used to radiolabel these mAb fragments is 
99m
Tc, 
which is the most commonly used radioisotope in nuclear pharmacy. Radiolabelling of 
scFv with 
99m
Tc tricarbonyl is achieved via a His-tag. The basis of 
99m
Tc tricarbonyl kit 
formulation is disodium boron carbonate, which serves as CO source and reducing 
agent [86]. The group at the Paul Scherrer Institute and Pluckthun et al. have 
successfully developed a direct labelling protocol for scFv and minibodies carrying and 
N or C terminal His-tag with 
99m
Tc tricarbonyl [87].  
PSMA was also suggested as a marker for angiogenesis and could represent a target for 
deliverable agents recognising the prostatic tumour and serve as unique target for 
treatment of patients in their development of prostatic metastasis [88].  The J591 
monoclonal antibody has been shown to deliver an alpha–emitting radionuclide 
(actinium-225) to PCa both in vitro and in vivo. In vivo studies conducted in male 
severe combined immune deficient (SCID) mice bearing PSMA-positive, subcutaneous 
LNCaP tumour demonstrated that tumour-specific uptake of 
89
Zr-DFO-J591 could be 
visualised by both immuno-PET and CLI (Cerenkov luminescence imaging). 
Biodistribution studies were found to correlate well with both modalities [89]. The 
64
Cu-labelled mAb 3/A12 showed high and specific uptake in PSMA-positive tumours 
and is an excellent candidate for prostate cancer imaging [90].  
177
Lu-J591 was administered to thirty-five patients with progressing androgen-
independent PCa. All patients underwent 
177
Lu-J591 imaging, therapy and 





 and multiple doses of 30 mCi/m
2
 were well tolerated. Acceptable toxicity, 
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excellent targeting of known sites of PCa metastases, and biologic activity in patients 
with androgen-independent PCa warrant further investigation [91]. At Johns-Hopkins 
University, Sedelear and colleagues designed two imaging and therapeutic drugs which 
are PSMA and PSA activated pro-drugs. They retooled chemotherapy agents for drug 
delivery, accurate treatment, monitoring and follow-up imaging drugs with a core of 
thapsigargin, a nonspecific highly cytotoxic agent. These therapeutic agents were 
modified by adding a tyrosine ring for imaging. The prodrugs are bound by a specific 
amino acid sequence, which causes them to be inactive until the sequence is clipped off 
by either PSMA or PSA proteases [5]. Provenge is another drug, created by Dendreon 
Ltd., which is reported to increase the survival rate for patients with PCa [92]. Progenics 
Ltd, which has now bought Molecular Insight, is currently working on development of 
two drugs for prostate cancer, both of which are PSMA based. Another novel antibody-
drug conjugate (ADC) was generated for treatment purposes by linking a fully human 
PSMA mAb to chemotherapeutic monomethylauristatin E (MMAE), a potent inhibitor 
of tubulin polymerisation. The PSMA ADC was evaluated for antitumour activity in 
vitro and in a mouse xenograft model of androgen-independent PCa. The PSMA ADC 
eliminated PSMA-expressing cells with picomolar potency and >700-fold selectivity in 
culture. When used to treat mice with established human C4-2 tumours, the PSMA 
ADC significantly improved median survival 9-fold relative to vehicle or isotype-
matched ADC without toxicity. Treatment effects were also manifest as a significant 
reduction in serum levels of PSA. Importantly, 40% of treated animals had no 
detectable tumour or measurable PSA at day 500 and could be considered cured. The 
findings support development of PSMA antibody-auristatin conjugates for therapy of 
PCa. The second drug is in Phase I clinical trials and involves a therapeutic recombinant 
protein vaccine, a genetically engineered form of PSMA protein combined with potent 
immunological stimulant, which is designed to stimulate patients’ immune system to 
recognise and destroy PCa cells [58]. In a more recent article Lourdes Castaneda et al 
presented a novel acid-cleavable linker strategy for antibody-drug conjugation. 
Functional disulfide bridging of the single interchain disulfide bond of a trastuzumab 
Fab fragment yields a homogeneous antibody-drug conjugate bearing a thiomaleamic 
acid linker. This linker is stable at physiological pH and temperature, but quantitatively 
cleaves at lysosomal pH to release the drug payload [93]. 
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In one investigation liposomes were loaded with 
225
Ac which emits alpha particles and 
coupled with antihuman PSMA J591 antibody or with the A10 PSMA aptamer. The 
targeting selectivity, extent of internalization, and killing efficacy of liposomes were 
tested on monolayers of prostate cancer cells expressing PSMA and HUVEC induced to 
express PSMA. J591-coupled liposomes displayed higher levels of total specific binding 
to all cell lines than A10 aptamer-labeled liposomes. Cytotoxicity studies demonstrated 
that radiolabelled J591-labelled liposomes were most cytotoxic in killing PSMA-




This project exploits gallium-68 (
68
Ga), a generator produced positron emitting 
radionuclide with a half-life of 68 minutes. The most commonly used and successful 
PET tracer 
18
F-FDG is not very useful in imaging some tumour types including PCa. 
The main reasons for this are low uptake of 
18
F-FDG, poor image contrast, and intense 
accumulation of 
18
F-FDG in the urinary bladder, which is in close proximity to the 
prostate, overshadowing tumour uptake. No correlation was observed between tumour 
grade/stage and 
18
F-FDG uptake in PCa [19,20]. Recently, the application of 
68
Ga-
labelled peptides has attracted considerable interest for cancer imaging because of the 
physical characteristics of 
68
Ga. Gallium, an element in group 13 of the periodic table, 




Ga) and 10 radioactive isotopes as shown in Table 1. 
68
Ga is a positron emitter whose 68 minute physical half-life is compatible with the 
pharmacokinetics of many radiopharmaceuticals of low molecular weight such as 
antibody fragments, peptides, aptamers, and oligonucleotides. 
68
Ga decays 89% by 
positron emission and 11% via electron capture and the average energy per 
disintegration is 740 keV [95]. The maximum positron energy of 
68
Ga is 1.92 MeV, 
which is higher than 
18
F (max=0.63 MeV) and thus would be expected to result in 
somewhat poorer spatial resolution. However, in one study of spatial resolution, which 





Ga in soft tissues in humans. 
68
Ga can be introduced into 
biomolecules through chelators, which allows possible kit formulation and wide 
availability of the corresponding imaging agents [52]. This has stimulated interest in the 
development of 
68
Ga-labelled compounds for medical imaging.  
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Ga Generator System 
One of the benefits of 
68




Ga generator system. The generator system is quite easy to handle, cost-effective 




Tc generator system in traditional nuclear medicine. 
68
Ga can form complexes with chelators, either free or conjugated with biomolecules. 
These characteristics make 
68
Ga an alternative to 
18
F as a PET radionuclide for centres 
without a cyclotron and straightforward preparation of a tracer using radiometal 
chelation with a generator produced radionuclide, resulting in a kit type production of 
PET radiopharmaceuticals.  That is the goal, once various technical and regulatory 
challenges have been overcome. 
The daughter isotope 
68
Ga has a half-life of 68 min and the parent isotope 
68
Ge has a 
very long half-life of 271 days that allows routine manufacture, shipment, and use of the 





sufficiently different to allow several different methods of efficient separation. The use 
of a generator allows the development, at least in principle, of a range of cold, freeze-
dried kits, which can be reconstituted and labelled when required. There is a well 
Table 1- Radioactive isotopes of gallium, along with their half-life, decay mode and type of 
emission. 
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established coordination chemistry of Ga
3+
 which allows development of agents 




. The preferred production route of 
68
Ge is 











Usually the column in the generator is made up of solid oxides which can be organic or 
inorganic in nature and used to achieve the efficient separation of the daughter from 
parent radionuclide by elution with dilute HCl. The radioactivity in aliquots of the 
generator elute are measured using an ionisation chamber and a NaI(Tl) scintillation 
detector immediately after and 24-48 h later in order to determine the 
68
Ge breakthrough 
in the eluate [96]. The generator eluates have been analysed for the content of trace 
metals by inductively coupled plasma atomic emission spectrometry (ICP-AES). In 
general, the second elution is used for labelling purposes instead of first because of its 
low metal content and low 
68
Ge breakthrough [96]. There are at least four 
68
Ga 
generators available in the market but this project is based on the Eckert & Ziegler TiO2 
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based generator (IGG100) (Fig-1.10). One part of the experimental section in this work 
also includes the comparison of IGG100 with the Obninsk generator (Fig-1.10) from the 
same company. The column material in both generators is titanium dioxide. 
68
Ge 
breakthrough in the case of Obninsk is 0.01% and IGG100 is 0.001%. Total impurities 
(Pb, Zn, Al, Ni, Cu) in case of IGG100 is <2 ppm (total) whereas in Obninsk it ranges 
from 5-150 ppm (total). Guaranteed useful life in both the cases is 1 y or 300 elutions.  




 in 0.1 M HCl [97].  
1.11.1-Concentration and purification methods of the 
68
Ga eluate 
Different methods have evolved to purify and concentrate the 
68
Ga generator eluate. It 
can involve a cation or anion exchange column or fractional elution. In the case of 
ModularLab, a microchromatography column carrying a strongly basic cation-exchange 
resin is used to concentrate the eluate and to reduce the acidity [97] (Fig-1.9). 
Zhernosekov et al. also used a cation exchange column, further improving the Rosch et 
al. technique [98]. They developed an efficient route for the processing of 
68
Ga eluates, 
including the labelling and purification of biomolecules. They performed the 
preconcentration and purification of the generator eluate by using a miniaturised column 
with organic cation exchanger resin and hydrochloric acid/acetone as eluant. The 
purified fraction was used for the labelling of nanomolar amounts of octreotide 
derivatives either in pure aqueous form or in buffers. Greater than 97% of the initially 
eluted 
68
Ga activity was obtained within 4 min as a 0.4 ml volume of HCl/acetone. The 
amount of 
68
Ge was decreased by 10
4





 and 10, respectively, after the processing of generator eluate. The processed 
68
Ga fraction was directly transferred to a solution containing labelling precursor, 
DOTATOC. Greater than 95% radiochemical yield was obtained within 10 min by 
using manual labelling approach [99]. Ocak et al. described a fully automated approach 
for the synthesis of 
68
Ga-labelled DOTA-peptides based on preconcentration and 
purification of the generator eluate by using both resin based and a disposable cation 
exchange cartridge [100].  
Alternatively, in the case of a strong anion-exchange column, the column adsorbs 
68
Ga 
in the form of 
68




present in 4 M HCl. This 
method removes any cationic impurities and concentrates the generator eluate. This 
strategy separates 
68
Ge, but does not allow direct loading of 
68
Ga onto the anion 
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eluted with 6 ml 0.1 N HCl, to which was added 30% HCl, making final HCl 
concentration of 4.0 M. The resulting solution was then passed through an anion-




Ga was then eluted with small fractions of 
deionised water (50-200 µl). Finally, the pH was adjusted by adding sodium acetate 
[101]. Similarly, in Mueller et al method an anion exchange column was used to purify 




 via the addition of 
concentrated HCl (5 M). It is trapped on the anion exchange cartridge and then 
subsequently eluted with a small volume of water directly into the buffer 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) for the labelling step. After 
labelling, further purification steps were necessary in order to remove HEPES. In 
addition, 
68
Ge that might still be present was removed by solid-phase extraction, while 
the final product was eluted with ethanol [102]. Another method which involves both 
anion exchange and cation exchange columns was developed, taking advantage of the 
occurrence of different Ga species, both cationic and anionic, depending on varying pH 
and chloride concentrations. In this procedure, 
68
Ga was trapped on a strong cation 




and eluted with a small 




 was adsorbed on a strong anion 




 was subsequently eluted with water [102].  
Another approach to overcome these problems is to fractionate the initial generator 
eluate as described by Breeman et al. [103]. The rationale resides in the fact that, 
although the total eluate volume is 5-6 ml, about two-thirds of the 
68
Ga activity elutes 
within a 1–2 ml activity peak. However, 68Ge and metallic impurities are only 
minimised, because of the lower eluate volume, rather than being chemically removed 
[103]. Another method was developed for the removal of chemical impurities with 
simultaneous preconcentration of the radionuclide by ion-exchange chromatography 
[104]. An automated computer controlled 
68
Ga milking and concentration system was 
developed based on the Scintomics modular system [105].  Another new and simple 
method reported by Mueller et al. involved a sodium chloride based 
68
Ga eluate 
concentration and labelling technique, which enables rapid and very efficient labelling 
of DOTA-conjugated peptides in high radiochemical purity (97 ± 2%). The SCX 
cartridge used in this method was from Varian, Bond Elut-SCX, 100 mg, 1 ml. The 
column was preconditioned with 1 ml 5.5 M HCl and 10 ml water prior to the elution 





Ga generator was eluted with 10 ml of 0.1 M HCl. On a SCX cartridge, 
99.9% of 
68
Ga in the generator eluate was collected and subsequently eluted with 
minimal loss using a mixture of 12.5 μl of 5.5 M HCl and 500 μl of 5 M NaCl. The pH 
was neutralised by adding it into 200-400 μl of ammonium acetate buffer (1 M) [102]. 
1.12-Ligands for Gallium 
The Ga
3+
 ion is classified as a hard Lewis acid, forming thermodynamically stable 
complexes with ligands that are hard Lewis bases [106]. Gallium (III) is suitable for 
complexation with polydentate ligands, both cyclic and open chain structures. The 
majority of the ligands designed for Ga
3+
 have denticity 6 or higher than 6, although 
several chelates have been reported which are stable in vivo and have denticity of four 
and five [95]. The extent of complexation increases with pH, owing to the release of 
protons but there may also be competition by hydroxide ions. Electron-withdrawing 
substituents such as halogens, nitriles, carbonyls and nitro group decrease the stability 
of the complex [106]. The pM value takes into account the ligand basicity, metal-ion 
hydrolysis, metal-ligand stoichiometry, dilution effects and other conditions. The larger 
the pM value (pM = -log[Ga(H2O)6]), (pM values evaluate how effective a ligand is at 
binding a specific metal ion in solution by measuring the concentration of the free metal 
ion under a predetermined set of conditions like pH) the better is the ligand for Ga
+3
. 
This value provides a direct head-to-head comparison among the various chelating 
agents under physiological conditions. Under these conditions transferrin (TFK1-pM = 
21.3; TFK2-pM = 20.3), the iron–binding protein in the blood, has a stability constant 
and pM comparable to DTPA (pM = 22.8) and EDTA (pM = 21.7). The OH
- 
(pM = 
19.1) has also high value, only one order of magnitude lower than one of the TF binding 
sites, which suggests that if blood levels of TF were reduced by an order of magnitude 
[Ga(OH)4]
-
 would be thermodynamically favoured. A reduction in the concentration of 
available TF sites increases the gallate concentration. This would increase gallate 
kidney excretion and could dramatically alter the biodistribution. The speed with which 
Ga transfer occurs is also equally important with pM values [106]. A bifunctional 
chelator should meet the following criteria: (1) when linked the macromolecule it 
should chelate the radiometal rapidly and efficiently; (2) the obtained chelate should be 









) [81]. Along with this it has to be resistant to competing 
endogenous chelators.           
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For radiolabelling of macromolecules using the 
68
Ga generator eluate, both direct and 
indirect methods can be used. In the direct method, the chelating ability of a 
macromolecule itself is used, e.g. lactoferrin [107]. However, if the macromolecule 
lacks the ability to form a complex with the radiometal and requires site-specific 
labelling then it can be conjugated with a bifunctional chelator before radiolabelling. 
Various chelators are available and they can be broadly classified in to acyclic chelators 
(HBED, DTPA) and cyclic chelators (NOTA, DOTA). However, we have used an in-
house produced tripodal hexadentate hydropyridinone chelator (CP256) and its 
bifunctional version (YM103) [108]. CP256 has three bidentate 3-hydroxy-4-pyridinone 
groups attached to a tripodal network as shown in Fig-1.15. Initial work with this 
chelator showed its Ga complex to be quite stable in serum and radiolabelling is 
possible at room temperature within a few minutes. In its bifunctional version (YM103), 
a maleimide group in the side chain is used to attach this group to a free thiol on the 
biomolecule as in Fig-1.16. 
1.12.1-Acyclic bifunctional chelators 
Acyclic chelators such as DTPA (diethylenetriamine pentaacetic acid), DFO 
(Desferrioxamine-B), HBED (N,N′-bis (2-hydroxybenzyl) ethylenediamine-N,N′-
diacetic acid) (Fig-1.11) can be labelled with gallium. DFO complexes Ga
3+
 rapidly 
with high affinity and radiochemical yield. It has three hydroxamate groups as metal 
coordinating sites [109]. Our in-house produced gallium chelator CP256 gives more 
than 80% radiolabelling yield at 1 µM chelator concentration. Cutler et al. have shown 
the Ga
3+
 complex of the tetradentate tripodal ligand NS3 is neutral and lipophilic. It 
retains its tetrahedral geometry and its conjugation with phenylalanine will result in 
stable 
67/68
Ga–labelled peptides. However, it requires a long reaction time and has to be 
purified by liquid chromatography before it can be used in vivo [110].  
              
DTPA HBED 





                              
                                                                                               
                                                                     
1.12.2-Macrocyclic chelators  
Macrocyclic chelators provide more thermodynamic and kinetic stability but many of 
these require heat during the labelling step. Triaza ligands display conformational and 
size selectivity towards metal ions. The thermodynamic stability of the Ga
3+
 chelates of 
triazamacrocyclic ligands is due to good fit of the relatively small cation in the cyclic 
cavity [1] (Fig-1.12). This category of chelators can encapsulate a metal ion with high 
efficiency, keeping it away from competitor species such as blood transferrin. TACN-
TM, a triaza ligand with three mercaptoethyl pendent arms; NOTA, a triazatricarboxylic 
ligand; NOTP and NOTPME, two phosphonate–bearing triaza ligands, are appropriate 
hexadentate chelators for Ga.  This is illustrated by the neutral Ga(NOTA), which only 
undergoes acid–catalysed dissociation at non-physiological low pH values. NODASA is 
a very stable Ga chelator that additionally has potential for biomolecule coupling using 
the pre labelling approach (i.e. the radiometal-chelate complex is formed prior to 
conjugation with the target molecule). It has a free carboxylate group available for 
coupling to biomolecules whereas the other three carboxylates are protected by the 
metal ion. This chelate has been rapidly coupled to D-phenylalanine amide as a model 
peptide which renders the coupling of 
68
Ga(NODASA) to peptides. The same type of 
chelator has been derivatised (NODAGATOC) in order to make it available for the 
post–labelling approach (i.e. the chelator is conjugated with the target molecule before 
radiolabelling with the radiometal) [1]. The thermodynamic stability constant of the 
Ga
3+
 complex of the tetraaza tetra acetic acid chelator DOTA is much lower than that of 
Ga(NOTA) due to the larger dimensions of its cavity. Despite the lower value of its 
stability constant, Ga(DOTA) is sufficiently stable to be used in clinical practice. 
DOTATOC, a somatostatin receptor targeting peptide, showed very promising in vivo 
Figure-1.11: Structures of acyclic bifunctional chelators. 
 
DFO-B 
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and in vitro properties when labelled with 
67
Ga [11]. As an alternative to thermal 
heating, we can use microwave activation, which serves as an attractive tool for 
accelerating the labelling process. The chemical reaction time is shortened by this 
method and the reaction is completed within 2 min instead of 10 min. Microwave 
heating will lead to fewer side reactions and high chemical yield due to increased rate of 
reaction, as shown by Velikyan et al. They have used microwave technique to 
accelerate the rate of reaction between the purified 
68
Ga eluate and DOTATOC. The 
reaction is completed within 10 min [96,111]. 
                                                                                                   
 
              
                                                              
                                                                                                            















                                            
 
                                  
  




1.12.3-New generation of gallium chelators:                        
 
A new generation of Ga chelators includes TRAP (1,4,7-triazacyclononane-1,4,7-
tris[methyl(2-carboxyethyl)phosphinic acid]). Its properties include substantially 
improved selectivity for Ga
3+
, allowing more robust and reliable 
68
Ga labelling 
procedures compared to DOTA and NOTA [112].  




A New Gallium-68 Labelled Imaging Agent For Prostate Cancer                        Chapter 1 
47 
 






Compared to NOTA- and DOTA-peptides, achievable specific activity (AS) for TRAP-
peptide is approximately 10 and 20 times higher, respectively. The TRAP-peptide could 
be 
68
Ga-labelled with excellent reproducibility and  > 95% radiochemical yield for 
precursor amounts as low as 1  nmol at the elevated temperature of 95oC for 5 min. The 
other advantage of TRAP is that it can also be labelled over a wide pH range and thus 
does not require buffering before the labelling reaction [112]. High 
68
Ga labelling 
efficiency of TRAP-peptides could facilitate realisation of kit labelling procedures.  
 
Figure 1.13: TRAP( 1,4,7-triazacyclononane-1,4,7-
tris[methyl(2-carboxyethyl)phosphinic acid]). 
Figure 1.14: TRAP ( 1,4,7-triazacyclononane-1,4,7-tris[methyl(2-carboxyethyl)phosphinic 
acid]) conjugated with RGD peptide. 






in synthesing this chelator was to develop a gallium chelator which can 
bind with the biomolecules at room temperature efficiently and quickly, thus reducing 
the need for heating as in the case of DOTA.
 
The synthesis of hexadentate HP 
(hydroxypyridinones) involves the attachment of three bidentate 3-hydroxy-4-
pyridinone synthons to a tripodal framework. The acidic oxygen of the 
hydroxypyridinone synthons is protected by a benzyl ester to prevent binding of trace 
iron and other metal contaminants during synthesis.  These protecting groups are then 
removed in the final step of the synthesis [108]. CP256 was synthesised in 13 steps and 
characterised by NMR and mass spectrometry. Radiolabelling studies with 
67
Ga-citrate 
showed that radiolabelling took less than 5 min at room temperature and neutral pH.  In 
vitro stability studies in transferrin solution showed the 
67
Ga-complex to be 100% stable 
for at least 4 hours at pH 7 and chelator concentration of 227 nM. A further 130-fold 
excess of apotransferrin was used to check the stability of the CP256 complex in 
apotransferrin (a 260-fold excess in terms of Ga-binding capacity since there are two 




Ga-CP256 shows stability when 
incubated with human serum, using 
67
Ga-citrate as a control. It remained stable even 
after 24 h compared to 
67
Ga-citrate [108]. The chelator is effective and worthy of further 
studies and development. This is a class of ligand that could be very suitable for 
imaging with the Ga radioisotopes. A bifunctional chelator (YM103) which has two 
active sites and can bind with the radiometal and biomolecule simultaneously has also 
been synthesised in order to produce bioconjugates. 
                           
 Figure 1.15: Tripodal Hexadentate Chelator (CP256) 
[108,113]                                                                                    
 
 




                       
 
 
1.13-The Pre-targeting Approach for CP256: 
Traditionally radioimmunotherapy (RIT) involves the radiolabelling of an antibody with 
a radionuclide to deliver cytotoxic radiation to the tumour. It is quite good in the 
treatment of hematologic malignancies such as non-Hodgkin lymphoma. However, for 
solid malignancies it was not proved to be very effective due to lower radiosensitivity, 
difficult penetration of the antibody into the tumour, and potential excessive radiation to 
normal tissues. To overcome these shortcomings of traditional RIT, pretargeted 
radioimmunotherapy (pRIT) was developed [71]. The concept of pre-targeting was 
introduced in late 1980s and can improve the target to non-target ratio as compared to 
traditional RIT and the delivery of a higher therapeutic dose. The essence of pre-
targeting involves the use of a macromolecule that is capable of binding with a high 
affinity to a radioactive agent of low molecular weight and can also selectively target a 
tumour antigen. The macromolecule is injected first, followed by the radioactive agent 
(effector) given at later time, ideally when the concentration of the macromolecule in 
the tumour is greater than in other tissues, particularly the blood pool. This sequence of 
events is normally referred to as the Two Step Protocol. An alternative is the Three Step 
Protocol which involves injecting a chaser (a specific scavenger molecule to remove 
residual macromolecule) before the effector (radioactive agent) to clear any residual 
macromolecule from the bloodstream to further enhance the tumour to blood ratios [11].  
Figure 1.16: YM103, bifunctional version of CP256 containing maleimide group. 
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Promising results have been reported using streptavidin-antibody constructs with biotin-
radionuclide conjugates in the treatment of patients with malignant gliomas, and of 
bispecific antibodies with hapten-radionuclides in the therapy of tumors expressing 
carcinoembryonic antigen, such as medullary thyroid and small-cell lung cancers [115]. 
1.14-Aims and Objectives: 
 1.  Evaluate the full potential of the CP256 chelator for Ga in comparison with its 
competitors. 
2. Test a bifunctional derivative of CP256 suitable for linkage to a cysteine residue in a 
biomolecule.  
 3. Produce an anti-PSMA scFv with a modification for site specific incorporation of 
radiolabel.  
4. Evaluate the targeting ability of these 
68
Ga labelled bioconjugates in cultured cell 
lines relevant to prostate cancer, and select the tracers that show promise in vitro and 
evaluate them in animal xenograft models of PCa using PET imaging and 
biodistribution studies. 








Ga are two important components of this project. The bifunctional chelator 
(YM103) for 
68
Ga is derived from CP256. The main aim of this chapter is therefore to 
characterise CP256 and 
68
Ga and evaluate the efficacy of the chelator for 
68
Ga. To 
achieve this objective we have compared CP256 with other chelators available 
commercially for gallium, including DOTA, NOTA and HBED to demonstrate that 
CP256 is better than the other chelators. This involved studies of the effect of time and 
concentration on the formation of the 
68
Ga complex, a comparative study of the stability 
of different 
68
Ga complexes in human serum and the discovery of a novel potential 
pretargeting approach employing the unique features of CP256. Radiochemical binding 
of CP256 not only with 
68
Ga but also with other radionuclides was studied.
 111
In is a 
cyclotron produced radionuclide with a half-life of 67 h which emits gamma photons of 
173 keV and 247 keV. It is widely used in gamma scintigraphy. Majority of the 
111
In 
radiopharmaceuticals are biomolecules such as peptides and proteins. In aqueous 
solution it is stable in the +3 oxidation state. 
99m
Tc has a half-life of 6 h and is widely 
used as a diagnostic imaging radionuclide. Its coordination chemistry is diverse because 
of the available oxidation states (-1 to +7), a wide number of coordination geometries 
and its ability to bind with large range of donor ligands to fulfill its coordination 
requirements. 
90
Y is a beta emitter with a half-life of 64 h and it has utility in therapy 
applications. Its maximum β– energy is 2.27 MeV and maximum particle range is 11 
mm in tissue. 
89





Zr disintegrates through positron decay (22.7%) and electron capture 
(73.3%). The maximum positron energy is 897 keV. Its most prominent gamma photon 
has an energy of 909 keV. 
89
Zr is employed in specialised diagnostic applications 
requiring a long half-life PET radionuclide.  
The second important factor in this project is the generator produced 
68
Ga radionuclide, 
so one part of this chapter involved comparison of eluates from the different generators 
available in the market (effect on radiochemical yield with chelators) and the effect of 
first and second elution on the radiochemical yield. 













Ga generator (IGG100) from Eckert & Ziegler of 1.1 GBq nominal activity 
was eluted with 0.1 N HCl of high purity and low in trivalent metals, using a syringe 
without a metal needle. This syringe was attached to the inlet valve and an empty vial in 
a lead pot was connected to the outlet valve. A volume of 5 ml 0.1 N HCl was pushed 
through by a syringe slowly over 2 min. The activity in the eluate was measured in a 
dose calibrator (Capintec CRC-15R).  
Another method of eluting the generator to get concentrated activity is by fractional 
elution. In this case 5 ml of 0.1 N HCl was used and it was collected in 1-2-2 ml 
fractions, with >90% of activity concentrated in middle 2 ml fraction. 
2.1.2-General Radiolabelling Methods 
A 200 µl aliquot of generator eluate was mixed with 600 µl of buffer (sodium citrate or 
sodium acetate ~pH 6) and allowed to incubate at room temperature. Stock solutions of 
chelator were prepared in PBS by dissolving 1 mg of chelator in 1 ml of PBS (0.1 M). 
The remaining concentrations were prepared by serial dilutions of 100 µl of chelator 
solution with 900 µl of PBS. For each labelling reaction 800 µl of chelator solution was 
mixed with 200 µl (~100 MBq) of radionuclide solution in buffer. 
2.1.3-Thin Layer Chromatography (TLC)  
Five different TLC methods were developed and used in this project. Details of these 
TLC systems are in the following along with there results. Method 1 was used to 
analyse the CP256, Method 2 was used for the quality control of 
99m
Tc tricarbonyl. 
Methods 3 and 4 were developed for CP256 complexes, as these chelates are quite 
hydrophobic and stay at the base-line in most of the TLC techniques including Method 
1, so these two methods were developed to have a TLC system in which CP256 
complexes can move to the solvent front. Method 5 was for NOTA, HBED and DOTA 
complex analysis.  




Strips of ITLC-SG (Pall Gelman, later Agilent), 10 x 80 mm, were marked with the 
origin at 10 mm from the bottom. Chromatograms were spotted with the reaction 
mixture at different times ranging from 0 min to 10 min. The drop was allowed to dry 
and the ITLC strip was placed in the mobile phase of 0.1 M trisodium citrate. When the 
solvent reached the solvent front, the strip was removed, dried for few minutes, and 
analysed with a radio-TLC scanner (Raytest Mini Gita with Gina Star software). 
2.1.3b-Method-2 
For quality control purposes to check the formation of 
99m
Tc-tricarbonyl, glass-back 
TLC(sg) plates were developed in the mobile phase of 1% HCl in 99% methanol. Any 
colloid will stay at the baseline, free pertechnetate moves to the solvent front and 




Ga-CP256 did not migrate in any of the standard chromatography systems, an 
alternative system was developed which used ITLC-SG strips presaturated with human 
(or bovine) serum albumin.  Strips were immersed in HSA or BSA solution (5 mg/ml) 
for 30 min, then washed with distilled water for 5 sec, dried and stored in a fridge.  The 
mobile phase was a freshly prepared mixture of water, ethanol and ammonium 
hydroxide (14 M) in the ratio of 5:2:1 [117]. 
The strips with origin marked at 10 mm were spotted with a 1-5 μl drop from the 
reaction mixture. The drop was allowed to dry and the ITLC strip was placed in the 
mobile phase. When the solvent reached the solvent front, the strip was removed, dried 
for a few minutes, and analysed with the radio-TLC scanner.  
2.1.3d-Method 4 
In this method, although we have used two different mobile phases with stationary 
phase of ITLC-SG we are presenting them together as they were developed side by side 
as a new TLC method development for 
68
Ga- CP256 in which CP256 moves with the 
solvent front and 
68
Ga acetate stays at the origin (Figure-2.0). The results were also 
attached with this section as this method was not further used. The main reason to 
develop this method is to have some easy and straightforward TLC technique for 
68
Ga-
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CP256 as it does not require preparation of the ITLC strips impregnated with HSA or 
BSA.   
Mobile Phase 1 was composed of ammonia (14 M), acetone, and water in a ratio of 
5:3:2, while Mobile Phase 2 contained acetone, water, and ammonia (14 M) in a ratio of 
5:4:1 respectively.  
     
         (A)  (B) 
   
       (C) (D) 
 
2.1.3e-Method 5 
In another TLC system the mobile phase was composed of NaH2PO4 (0.4 M, pH 4-4.5, 
0.552 g/10 ml) and stationary phase was composed of ITLC-SG [118]. ITLC-SG strips 
were cut in the dimensions of 10 x 80 mm and marked with the origin at 10 mm. The 
strips were finally analysed with the radio-TLC scanner. This method is used to analyse 
HBED, NOTA and DOTA labelling. In this case 
68
Ga acetate stays at the origin with Rf 
value of 0 and the radiolabelled complex of chelator moves toward the solvent front 




















































































































Figure-2.0: Mobile phase 1 and stationary phase of ITLC-SG, 
68
Ga stays at origin with Rf value 
of 0 (A). 
68
Ga –CP256 moves with the solvent front with Rf value of 1 (B). Mobile phase 2 and 
stationary phase of ITLC-SG, 
68
Ga stays at origin with Rf value of 0 (C) and 
68
Ga-CP256 moves 
with the solvent front with Rf value of 1 (D). 
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with an Rf value of 0.7 for NOTA, 0.9 for HBED and 1 for DOTA. Results for HBED, 
NOTA and DOTA analysed by this method are shown in Fig 3.3. 
 2.1.4-Size exclusion column chromatography 
PD-10 columns containing Sephadex G25 (Pharmacia) were equilibrated with 25 ml of 
PBS before 50 μl (~200 kBq) of the reaction mixture was applied. Twenty fractions of 
0.5 ml were collected with PBS as eluent in numbered tubes and counted in a gamma 
counter with a window set to include the 511 keV annihilation gamma photons (Perkin 
Elmer 1480 automatic gamma counter Wizard 3, 10 seconds per sample). The results 
were plotted as histograms. 




Five different concentrations of CP-256 from 1.0 mg/ml to 0.0001 mg/ml were prepared 
in PBS (1.186 mM, 118 µM, 11.8 µM, 1.18 µM, 118 nM). The number of moles used in 




Ga Generator was eluted according to the method described above. A 200 µl 
aliquot of generator eluate was mixed with 600 µl of buffer (sodium citrate or sodium 
acetate ~pH 6) and allowed to incubate at room temperature. For each labelling reaction 
800 µl of chelator solution was mixed with 200 µl (~100 MBq) of radionuclide solution 
in buffer. The samples were analysed by using TLC Method 1. In this method 
radiolabelled 
68
Ga-CP256 stays at the origin and free 
68
Ga moves with the solvent front. 
2.1.6-Changes in radiolabelling yield of CP256 with 1st and 2nd elution 
over time 




 elutions of the day to see any difference in 
binding of 
68
Ga with CP256 at a concentration of 11 µM. The time difference between 
the two elutions was 2 h. The generator was eluted by fractional elution. This CP256 
concentration (11 µM) was selected based on the above experiment because it was likely 
to be most sensitive to effects of eluate composition. A 200 µl aliquot of generator 
eluate was mixed with 600 µl of buffer (sodium acetate ~pH 6). For the labelling 
reaction 800 µl of chelator solution was mixed with 200 µl (~100 MBq) of 
68
Ga acetate 
and incubated at room temperature. TLC analysis was performed using Method 1. 
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Ga-acetate was prepared by adding 20 µL (1 – 5 MBq) of 68GaCl3 (obtained by 
fractional elution) to 60 µL of 1 M ammonium acetate solution.  To obtain pH 4.5 for 
NOTA labelling, 1-2 µL of 1 N HCl and for pH 7 for HBED, 1-2 µL of 10 mg/ml 
sodium carbonate solution was added to the chelator solutions. For radiolabelling 
reactions, 20 µl of 
68
Ga-acetate was added to 80 µl of NOTA solution and incubated for 
7 min (time is based on the increase in radiolabelling yield with time experiment) at 
room temperature before analysis. The stock solution of NOTA (p-SCN-Bn-NOTA, 
Macrocyclics, MW = 559.9) was prepared by dissolving 1 mg in 1 ml of PBS (1.78 
mM).  Five different concentrations were prepared by diluting this stock solution with 
PBS, i.e.1 mM, 100 µM, 10 µM, 1 µM, and 100 nM.  The 1 mM solution was prepared 
by diluting 56 µl of stock solution with 34 µl of PBS.  The remaining concentrations 
were prepared by serial dilutions of 10 µl with 90 µl of PBS. The same radiolabelling 
and dilution method was used for HBED (MW = 424.89). The stock solution was 
prepared by dissolving 1 mg in 1 ml of PBS (2.35 mM). A 1 mM solution was prepared 
by taking 42 µl from the stock solution and diluting it by adding 58 µl of PBS. The 
remaining concentrations were prepared by serial dilutions. Similarly, for DOTA (MW 
= 404.42), the stock solution was prepared by dissolving 1 mg in 1 ml of PBS (2.4 mM). 
A 1 mM solution was prepared by taking 41.6 µl from stock solution and diluting it by 
adding 58.4 µl of PBS. The remaining concentrations were prepared by serial dilutions 
of 10 µl with 90 µl of PBS. 
In the case of NOTA and HBED radiolabelling reactions were performed at room 
temperature. On the other hand, for DOTA different concentrations of chelator were 
incubated with 
68
Ga for 30 min at 100
o
C. Finally, the samples were analysed by TLC 
Method 5, in which 
68
Ga acetate stays at the origin with Rf value of 0 and the complex 
moves toward the solvent front with an Rf value of 0.7 for NOTA, 0.9 for HBED and 1 
for DOTA.  
2.1.8-Stability in human blood serum 
Stability in human blood serum was analysed using PD-10 columns containing 
Sephadex G25. For CP256, NOTA and HBED the stability of a sample (
68
Ga + CP256 
or HBED) in serum was measured at two time points, 5 min and 60 min. There were 
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three reference standards: one was human blood serum preincubated with 
68
Ga acetate, 
the second was 
68
Ga buffered with either citrate or acetate and the last reference was the 
chelator (CP256 or HBED) radiolabelled with 
68
Ga. The chelator was radiolabelled with 
68
Ga and once the complex was formed it was incubated in human serum at 37
o
C. The 
first reading was taken after 5 min of incubation and the second after 60 min. To further 
analyse the stability of the 
68
Ga-CP256 complex in human serum, TLC Method 3 was 
used [117].   
2.1.9-Radiolabelling of CP256 and NOTA with eluates from different 
generators 
A 20 µl (5 MBq) aliquot of a fresh second elution from the generator (Eckert & Ziegler 





 decayed eluate from an Obninsk generator (courtesy of the Royal Marsden 
Hospital and Barts Health) and 0.1 N HCl and buffered with citrate (60 µL, 0.1 M, pH 
6). These elutions were then used to radiolabel CP256 and NOTA by taking 20 µl from 
each solution and adding it to 80 µl of CP256 (11.8 µM) and NOTA (11 µM). After 5-7 
min a 1 µl drop was spotted on ITLC-SG strips and analysed by Method 1.  
2.1.10-Radiolabelling of C2A protein with 
68
Ga 
The conjugated protein was obtained from the group of Dr Greg Mullen, Imaging 
Sciences, King’s College London [108,116]. A 30 µl (20 µg) aliquot of conjugated C2A 
protein was mixed with 20 µl (20MBq) 
68
Ga-citrate and analysed after 0, 5 and 10 min 
using TLC Method 1. 




A 50 µl aliquot of acetate buffer (pH 6) was added to vial containing 
111
InCl3 (Covidien 
Healthcare) (7 MBq) in HCl (50 µl).  A 589 µM solution of CP256 was prepared by 
dissolving 0.5 mg of CP256 in 1 ml of PBS. A 100 µl aliquot of CP256 was mixed with 
50 µl of 
111
In-acetate and analysed using TLC Method 3. Along with binding of 
111
In 
with CP256, its stability in human blood serum was also tested at different time 
intervals using PD-10 column chromatography. Radiolabelled CP256 (100 µl) was 
incubated in human serum protein (300 µl) and samples (50 µl) were taken out at three 
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YCl3 (~20 µl) (Yttriga, Eckert & Ziegler) was neutralised by adding 60 µl of acetate 
buffer (pH 6) and 20 µl of this solution was then added to the 80 µl of CP256 (1 mM). 
Both TLC Method 3 and the PD-10 column method were used to check the 







Tc tricarbonyl was prepared by using the ISOLINK tricarbonyl kit (Covidien). Up to 
1000 MBq of 
99m
Tc pertechnetate can be used to prepare the kit. The pH of the kit 
contents was adjusted to 7 by adding 1 M HCl (~120 µl). To check the formation of 
99m
Tc-tricarbonyl, TLC Method 2 was used. 
99m
Tc tricarbonyl was then incubated with 





Zr (IDB, Amsterdam) comes in the oxalate form. It is converted in to citrate form by 
adding citrate buffer (60 µl, pH 6) [119]. Following incubation with CP256, the 
formation of radiolabelled complex was analysed by TLC Method 1. 
89
Zr-CP256 (100 
µl) was incubated with human serum (300 µl) and samples were taken at different time 
points (1, 2, 3, 5, and 24 h) and analysed by the PD-10 column method. 
2.1.12-Formation of 
68
Ga-CP256 complex in serum 
Hexadentate chelator (CP256) stock solutions were prepared by adding the required 
amount of CP256 to 1 ml of PBS and adjusting the pH to 7-7.5. Different concentrations 
of the chelator from 2 mg/ml to 0.01 mg/ml (2.35 mM, 1.17 mM, 589 μM, 117 μM, 23 
μM and 11.7 μM) were assessed. Two different radiolabelling techniques were used. In 
the first, 100 μl of CP256 (all concentrations mentioned above) was added to 300 μl of 
human serum. After 10-15 minutes 20 μl of 68Ga-citrate was added and binding was 
assessed after 15-20 minutes. For time studies human serum was incubated at 37
o
C in a 
plastic tube. In the second method, 20 μl of 68GaCl3 was added to 300 μl of human 
serum. After 15-20 minutes 100 μl of chelator was added.  
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Three reference standards were prepared. The first consisted of 300 μl of chelator 
solution in PBS without any serum mixed with 20 μl of 68Ga-citrate. The second 
reference was composed of 300 μl of human serum incubated at 37oC and radiolabelled 
with 20 μl of 68Ga-citrate. The third reference was composed of simply 68GaCl3 with no 
chelator or serum buffered with 60 μl citrate.This approach was also assessed with 
NOTA and HBED (1 mg/ml) using the same protocol as CP256 and size exclusion 
chromatography.  
2.2-Results 




Five different concentrations of CP256 used were shown in Table 2. The samples were 
analysed by using method 1 of the TLC. In this method radiolabelled Ga-CP256 stays at 
the origin and free 
68
Ga moves with the solvent front. The results are presented in Table 
3. 
Table 2  
Concentration (CP256) No of Moles (CP256) 
1.186 mM 1.18 µmol 
118 µM 118 nmol 
11.8 µM 11.8 nmol 
1.186 µM 1.18 nmol 




Table 2-Five different concentrations and no of moles of CP256, to analyse the 
effect of time and concentration on radiolabelling yield. 





Time (min) 1.186 mM 118 µM 11.8 µM 1.186 µM 118 nM 
0 89% 49% 11% 0% 0% 
1 95% 98% 63% 8% 8% 
2 100% 98% 64% 11% 9% 
3 100% 100% 73% 13% 8% 
4 100% 100% 79% 14% 8% 
5 100% 100% 87% 15% 8% 
6 100% 100% 91% 16% 10% 
8 100% 100% 94% 22% 11% 
10 100% 100% 97% 25% 11% 
 
It is observed that there is very little change in the radiolabelling yield of  
CP256 by increasing time from 0 min to 10 min at very high concentration and low 
concentration. At concentrations of 118 μM and higher, quantitative labelling was 
achieved within 1 min. However, time is the critical factor in case of intermediate 
concentration (11.8 µM). Radiolabelling increased from ~60% at 2 min to 100% at 10 
min. Most probably, the low yield at low concentration is limited by time (slow rate). 
2.2.2-Changes in radiolabelling yield of CP256 with 1st and 2nd 
generator elutions over time 





generator elution with time are summarized in Table 4. There was 5% radiolabelling 




 elution of the generator. The first elution gave 95% 
radiolabelling yield in 10 min and 2
nd
 elution gave 100% radiolabelling yield in same 
time period.  The 1
st
 elution was done to remove any build-up of trace metals and to 
increase radiolabelling yield in the second elution. However, this result indicates that 




 elution and extent of radiolabelling yield; we can 
use the first elution directly instead of doing the first elution and then waiting for 2 
hours for the 2
nd
 unless special circumstances demand it. However, it is better to do a 
2
nd
 elution to remove any build-up of metallic impurities in the eluant and the 2
nd
 
elution might make a difference in the case of very small amounts of chelator. 
Table 3-% radiolabelling yield obtained with five different concentrations of CP256 at 
different time points. 




Time (min) Radiolabelling (%)with 1st Elution Radiolabelling (%)with 2nd Elution 
0 3 5 
1 21 29 
2 37 43 
3 49 54 
4 61 65 
5 70 79 
6 79 87 
8 88 95 








The reaction conditions and radiolabelling yield obtained at different concentrations are 
summarised in Table 5. Each sample was analysed three times using TLC Method 5, in 
which 
68
Ga acetate stays at the origin and the complex moves toward the solvent front 
with an Rf value of 0.7 for NOTA, 0.9 for HBED and 1 for DOTA. NOTA showed 
quantitative labelling with 
68Ga at concentrations ≥100 µM, with reduced yields at 
lower concentrations and no binding at 100 nM. NOTA showed slightly different 
behaviour at two different pH values and a lower concentration of 1 µM. NOTA with 
pH=7 still showed 40% binding, whereas at pH=4.5 the radiolabelling yield was almost 
zero after the incubation time of 7 min. In the case of HBED there was 100% binding 
till 100 µM and almost 90% binding at 10 µM. It sharply decreased to 70% at 1 µM and 
almost negligible binding at 100 nM after incubation of 10 min. 


















CP256 DOTA HBED 
 7 min at room 
temp 
7 min at room 
temp 
3 min at room 
temp 




10 min at room 
temp 
100 nM 0% 0% 0% 0% 0% 
1 µM 41% 2% 84% 0% 70% 
10 µM 64% 57% 100% 35% 93% 
100 µM 97% 97% 100% 100% 100% 
1 mM 100% 100% 100% 100% 100% 
 
 
The comparison of the radiolabelling yield of CP256, NOTA, HBED and DOTA shows 
that CP256 and HBED gave best binding with 
68
Ga (i.e high yield persisted at lowest 
ligand concentration). Results with NOTA were intermediate between DOTA and 
CP256.  All four chelators showed 100% binding at the two higher concentrations, i.e. 1 
mM and 100 µM. However, the behaviour of the chelators differed at lower 
concentrations. At 10 µM CP256 and HBED still showed maximum binding around 
100% and 90% respectively but the radiolabelling yield of DOTA reduced to almost 
40% and in case of NOTA at both pH values was ~60%. Further below at 1 µM CP256 
still showed a radiolabelling yield of more than 80% and HBED gave a radiolabelling 
yield of 70%. NOTA at pH 7 was ~40%. With both DOTA and NOTA (pH 4.5) there 
was almost no binding. At the concentration of 100 nM all the chelators showed 0% 
binding with 
68
Ga. Another ligand, Desferrioxamine-B (DFO), is reported to complex 
Ga
3+
 rapidly with high affinity and radiochemical yield [70]. In summary, CP256 
(incubation time 3 min) and HBED (incubation time 10 min) gave a better 
radiolabelling yield even at lower concentrations and at higher concentration showed 
100% binding and stability (Table 5) at neutral pH.  
The effect of time on the critical concentrations of both NOTA (10 µM) and HBED (10 
µM) was studied. It was observed that for both NOTA and HBED radiolabelling yield 
increased from 40% at 2 min to 85% at 10 min (Fig-2.1). 
Table 5- Comparative study of the radiolabelling yield of different concentrations of the various 
chelators, when radiolabelled with 
68
Ga. 





2.2.4-Stability in Human Blood Serum 
Direct comparison of the three reference standards and the sample at two different time–
points, i.e. 0 min and 60 min showed that CP256 and HBED have higher affinities for 
68
Ga than do the metal binding components of human serum. The complexes were 
stable even after 60 min in serum (Fig-2.2, 2.4, 2.5). These two time points give an 
ample window to ascertain any dissociation of the complex in human serum with time. 
On the basis of size, human serum elutes from the PD-10 column first, followed by the 




Ga acetate elute in the form of broad peak in the last fractions from 7-
10.5 ml. In the case of 
68
Ga-CP256, it elutes in the middle fractions from 5-7 ml. 
Radiolabelled CP256 in the presence of human serum also elutes in the same fractions, 
which indicates that the radiolabelled complex is quite stable even in the excess of 
serum (Fig-2.2a). Similarly, radiolabelled HBED and NOTA eluted at 6.5-10 ml, which 
is similar to 
68
Ga acetate. However, when the radiolabelled complexes of both these 






Ga acetate, which showed that these radiolabelled 
complexes were quite stable, otherwise free 
68
Ga would attach to the serum and elute 
around 3-3.5 ml. In Fig-2.2a, where human serum was incubated with 
68
Ga, the first 
peak is most probably 
68
Ga-transferrin. This is assumed on the basis of MSc thesis 

























Figure-2.1: Changes in radiolabelling yield of 10 µM HBED and NOTA after different time 
periods. For HBED, maximum radiolabelling yield of 90% was achieved in 7 min. For HBED 
maximum radiolabelling yield of 80% was obtained in 9 min. 
 










































Ga-human serum with 
68
Ga-
CP256 in human serum protein by using PD-10 column method at two different time points 
i.e.5-min and 60-min. It was observed that even after 60-min 
68
Ga-CP256 stayed stable in 
human serum.  
Figure-2.2b: Apo-transferrin was incubated with 
67
Ga-Citrate. Samples wre taken out at different 
time-points and analysed by PD-10 column. 30-fractions were collected at each time point [140]. 




            
 (A)                                                                         (B)  
         





Figure 2.3 presents results obtained with TLC Method 3, which uses HSA-saturated 
ITLC-SG strips. Fig-2.3-A,B show that 
68
Ga-citrate and labelled human serum stayed at 
the origin. Fig-2.3-C shows that 
68
Ga-CP256 moved with the solvent front. 
68
Ga 
preferred to bind with the chelator even in the presence of human serum (Fig-2.3-D). 
CP256 is quite hydrophobic in nature and sticks to the origin in hydrophilic systems. 
This is the first TLC method in which it migrates with the solvent front, probably 
because of the hydrophobic nature of the stationary phase and the presence of ammonia 
in the mobile phase (Fig-2.3-C,D). On the other hand 
68
Ga-citrate stayed at the origin 
because of its hydrophilic nature (Fig-2.3-A). Human serum also stayed at the origin 
because of its high molecular weight (Fig-2.3-B). 
 





































































































Figure-2.3: HSA-ITLC(sg) chromatography results. 
68
Ga-human blood serum stays at origin 
(A).  
68
Ga-citrate stays at origin because of its hydrophilic nature (B). 
68
Ga-CP256  moves with 
the solvent front because of its hydrophobic nature (C). 
68
Ga-CP256 in serum moves with the 
solvent front (D). 
 








Figure -2.4: Comparative study of 68Ga acetate, 68Ga-HBED and 68Ga-human serum with 68Ga-
HBED in human serum by using the PD-10 column method at two different time points i.e. 5-
min and 60-min. Even after 60-min 
68
Ga-HBED stayed stable in human serum.  
Figure -2.5: Comparative study of 68Ga-acetate, 68Ga-NOTA and 68Ga-human serum with 68Ga-
NOTA in human serum by using the PD-10 column method at two different time points i.e. 5-
min and 60-min. Even after 60 min 
68
Ga-NOTA stayed stable in human serum.  
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2.2.5-Radiolabelling of CP256 and NOTA with eluates from different 
generators 
The main purpose of this experiment was to compare the elutions from two different 
generators and to check the difference in extent of binding with two chelators under the 
same conditions. It was observed in case of CP256 that binding in the presence of the 1
st
 
elution from the Obninsk generator showed only 40% radiolabelling yield and the 3
rd
 
elution, which is done 2 hrs after the 2
nd
 elution gave 65-70% binding. In contrast, a 
previous elution from the IGG100 generator and a reference which contained 0.1 N HCl 





of the Obninsk generator contains metal contaminants which interfere with labelling. 
This does not appear to be a problem with the IGG100 generator. 
The same experiment was repeated using NOTA and it was observed that the IGG100 
generator gave 85%-100% binding whereas the 1
st
 elution from the Obninsk generator 
gave 30% binding and the 3
rd










Figure-2.6: Changes in radiolabelling yield of CP256 (11.8 µM) with 
68
Ga eluted from Obninsk 
and IGG 100 generators and spiked with fresh elution from IGG 100 (20 µL, ~5 MBq). Each 
value is mean and standard deviation for three experiments. 





2.2.6-Radiolabelling of C2A protein with 
68
Ga 
The C2A protein (Complement C2) is a protein that in humans is encoded by the C2 
gene and is part of the classical pathway of complement system. Activated C1 cleaves 
C2 into C2a and C2b. C2A leads to activation of C3. Deficiency of C2 has been 
reported to be associated with certain autoimmune diseases. It binds to 
phosphatidylserine and has potential use as imaging agent for apoptosis/cell death [75]. 
This protein is used as a model protein here, to see how 
68
Ga binds with the protein. The 
protein contains a cysteine, which was used
 
to conjugate with YM103, a maleimide 












Figure-2.7: Changes in radiolabelling yield of NOTA (11 µM) with 
68
Ga eluted from Obninsk 
and IGG100 generators spiked with fresh elution from IGG 100 (20 µL, ~5 MBq). Each value is 
mean and standard deviation for three experiments. 
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.         
(A)                                                              (B) 
         
(C)                                                                (D) 
 
Fig-2.8-A shows that reference 
68
Ga-Citrate moved with the solvent front. Conjugated 
C2A protein showed 87% radiolabelling yield within 1-2 min (Fig-2.8-B). After 5 min 
binding increased to 97% (Fig-2.8-C) and within 10 min it gave 100% radiolabelling 
yield at room temperature and pH of 7 (Fig-2.8-D). 
2.2.7- Evaluation of CP256 binding with other radionuclides 
Although 
68
Ga is the main radioisotope used in this project, to further ascertain the 
importance and versatility of this novel chelator (CP256), it was radiolabelled with 









Simple radiolabelling of the above mentioned radioisotopes was carried out and 
analysed by TLC, followed by stability in human serum, analysed by the PD-10 column 
method. 



































































































































Ga-Citrate (A) moved with the solvent front. 
68
Ga-Conjugated C2A 
protein remained at the origin after 1-2 min, with some unbound 
68
Ga-citrate at the solvent front 
(B).  
68
Ga-Conjugated C2A protein at the origin after 5 min. The amount of unbound 
68
Ga-citrate 
reduced at the solvent front (C).  
68
Ga-Conjugated C2A protein at the origin with no unbound 
68
Ga-citrate at solvent front after 10 min (D). 






Radiolabelling of CP256 with 
111
In was analysed with TLC Method 3. In this method
 
111
In-acetate stays at the origin in ITLC-SG (HSA) (Fig-2.9), whereas 
111
In-CP256 









.    
111
In formed a complex with CP256 in appreciable quantities although it is not 100% 
binding as there is still some unbound 
111
In after the incubation of 20 min. The 
radiolabelling yield obtained was around 95% (Fig-2.10). 
Along with radiolabelling, binding of 
111
In with CP256 and its stability in human blood 
serum was also tested at different time intervals. In PD-10 column chromatography, 
human serum eluted in fractions 3-3.5 ml followed by 
111
In acetate from 4.5-6.5 ml and 
CP256 radiolabelled with 
111
In eluted from 5.5-8.5 ml. Radiolabelled CP256 was 
incubated in human serum and samples were taken out at three time-points: 5 min, 60 
min and 120 min. It was observed that the complex remained stable in human blood 



















































In-acetate stayed at the origin with Rf value of 0.  
Figure-2.10: HSA-ITLC-SG+
111
In-CP256 Complex moved with solvent front because of its 
hydrophobic nature and small amount of 
111
In-acetate remained at the origin. 
95% 
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serum even after 2 h and 
111
In has higher affinity for CP256 even in serum and there 
was no dissociation of radiolabelled complex and association with serum (Fig-2.11). 
Both In and Ga belong to the same group in periodic table (III A). Both elements have 
oxidation state of +3 [106]. In is a larger ion with a higher expected coordination 
number, so we expect some differences in their behaviour. Radiolabelling of CP256 
with 
68
Ga was 100% within a few minutes, however with 
111
In we achieved 95% 
radiolabelling yield after 20 min of incubation. CP256 forms quite a stable complex 
with 
68








To analyse the radiolabelling of CP256 with 
90
Y, TLC Method 3 was used. In Fig-2.12, 
90
Y-acetate stayed at the origin and 
90
Y-CP256 moved with the solvent front (Fig-2.13). 
The yield of 
90
Y-CP256 appeared to be quantitative within 10 min at room temperature. 




In-CP256, and serum with 
111
In-CP256 
complex in serum at 3 different time-points, i.e. 5-min, 60-min and 2 h, to evaluate the stability 
of 
111
In-CP256 in serum. 
111
In-CP256 stayed stable in serum even after 2 h.  





 .              
 
.                 
Stability of 
90
Y-CP256 in human serum was tested by the PD-10 column method. The 
90
Y-CP256 complex (100 µl) was incubated with human serum (300 µl) and samples 
were taken at 10 min, 60 min and 4 h and applied to a PD-10 column. However, it was 
evident that 
90
Y-CP256 was not very stable in human serum, as most of the 
90
Y became 
attached to components of serum and eluted with the serum fractions (Fig-2.14). 
Although the oxidation state of Y is also +3 and it belongs to the III-B group, there are 
many differences in the chemical behaviour of Y with respect to Ga and In [106,120]. 

















Y-acetate stays at the origin with Rf value of 0. 
Figure-2.13: HSA-ITLC-SG, 
90
Y-CP256 moves with the solvent front with Rf value of 1. 










 complex can also be described as a semi aqua ion. One half of 
the coordination sphere is shielded, whereas the other half is prone to substitution with 
classical or nonclassical ligands. Three carbonyl ligands of small size and low 
molecular weight are tightly bound, while three water ligands can be exchange by 
incoming chelators. 
For quality control purposes to check the formation of 
99m
Tc-tricarbonyl, glass-backed 
TLC-SG plates were developed with 1% HCl in methanol. Any colloid will stay at the 
baseline, free pertechnetate moves to the solvent front and tricarbonyl will be at centre 
(Rf=0.4) (Fig-2.15) [116]. 
99m
Tc tricarbonyl was incubated with CP256 and the 
radiolabelled complex was analysed using TLC Method 1. A radiolabelling yield of 
60% was obtained within 5 min (Fig-2.17, 2.18) and it increased to 90% within 30 min 
at room temperature (Fig-2.18). The complex was quite stable even after 4 h and there 
was no evidence of dissociation between tricarbonyl and CP256 (Fig-2.16, 2.17, 2.18). 
 






Y human serum, 
90
Y+CP256 
incubated in human serum and samples were taken at 10 min, 1 h, 2 h and 4 h for PD-10 column 
analysis. 






          (A)                                                                               (B) 
 


































































































Figure -2.15: QC for 
99m
Tc tricarbonyl showed that 80% of 
99m
Tc tricarbonyl was formed 
(region 1) and the remaining 20% was in the form of free pertechnetate (region 2).using TLC 
Method 2. 
Figure-2.16: TLC Method 1 was used for analysis. 
99m
Tc tricarbonyl moved with the solvent 
front (A) because of its hydrophilic nature. Free pertechnetate (hydrophilic) also moved with 
solvent front (B) and thus Method 1 was unable to distinguish the two species.                  
Figure-2.17: TLC Method 1 was used for analysis. Unreated 
99m
Tc tricarbonyl and/or free 
pertechnetate moved with the solvent front and the CP256-tricarbonyl complex stayed at the 
origin. At 10 min 80% radiolabelling yield was obtained (C) and at 60 min 100% radiolabelling 
yield is obtained (D). We have to keep in mind that we started with 80% of tricarbonyl.               









Zr (IDB, Amsterdam) comes in the oxalate form (C4O8Zr). It was converted to the 
citrate form by adding citrate buffer (60 µl, pH 6) [119]. It was observed that 
89
Zr bound 
with CP256 within 20 min of incubation at room temperature. 
89
Zr-citrate moved with 
the solvent front and 
89
Zr-CP256 stayed at the origin because of its hydrophobic nature 
in TLC Method 1 as shown in Fig-2.19. When 
89
Zr-CP256 was incubated with human 
serum and samples were taken at different time points and analysed by the PD-10 
column method, it was evident that the Zr complex of CP256 was quite stable in human 
serum (Fig-2.20). Zr belongs to group IVB of the periodic table, forms an extremely 
hard acidic 4+ cation and because of its coordination number requirements it forms 
stable complexs with octadentate lanthanide chelators (DOTA-L39) [120]. 
 




































Figure-2.18: Graphical representation of radiolabelling yield obtained at different time points, 
when CP256 was incubated with 
99m
Tc tricarbonyl and samples were taken out at different time 
points to be analysed by the TLC Method 1. 
Figure-2.19: TLC Method 1 was used for analysis.
 89
Zr citrate moved with the solvent front (A). 
However in the same system 
89
Zr-CP256 stayed at the origin (B). 









Ga-CP256 complex in serum 
The extremely high affinity and rapid chelation of CP256 for Ga prompted us to test the 
hypothesis that CP256 could chelate 
68
Ga in vivo, allowing a pre-targeting approach in 
which an antibody conjugated with CP256 could be administered to a patient, followed 
hours to days later by 
68
Ga-acetate or citrate. The elution profile of human serum 
radiolabelled with 
68
Ga with incubation time of 30 min (Reference 2) showed that most 
of the 
68
Ga eluted in 4-4.5 ml (Figure 2.21-E) showing that it became bound to serum.  
            
(A)                                                                                (B) 
                
 (C)                                                                            (D) 






Zr human serum, 
89
Zr+CP256 incubated in human serum with samples are taken up to 24 h. 
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Ga-CP256 (Reference 1) eluted at 5.5-6 ml (Figure 2.21-D) and simple 
68
Ga-acetate or citrate (Reference 3) eluted in 8.5-10 ml as a broad peak (Figure 2.21-
A). 
68
Ga-NOTA eluted in 9-10 ml and 
68
Ga- HBED eluted in 8-9 ml. 
    
   (A)                                                                                                (B) 
 
The elution profile of the sample (CP256+human serum+
68
GaCl3) shows that there was 
binding between CP256 and 
68
Ga, as the radioactivity eluted in the middle fractions 
(Figure 2.22) i.e. 5.5-6 ml, like Reference 1 
68
Ga-CP256. The complex between the 
chelator and 
68
Ga formed in the presence of human serum even at a low chelator 
concentration of 23 µM or 0.02 mg/ml (Figure-2.23, 2.24). However, when the 
concentration of the chelator was as low as 0.01 mg/ml, 
68
Ga started binding with the 
human serum (Figure 2.24). 
Figure-2.22: Elution profile of 
68





Ga preferred to bind with CP256 in serum after 60 min and 





again preferred to bind with CP256 instead of serum and also removed most of the 
68
Ga which 
had been attached to serum. 











Ga-human serum (E) using PD-10 column. 
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In the second study which used a different sequence of addition (i.e. human serum+ 
68
GaCl3+CP256), comparison of Reference 1 (
68
Ga-CP256) with pre-sample (human 
serum+
68





Ga in the pre-sample combined with human serum or eluted as free 
68
Ga. 
However, in the post-sample when the chelator was added to the pre-sample, not only 
the free 
68
Ga bound with the chelator but the 
68
Ga which was previously bound to serum 




Figure-2.23: Comparative study of 
68
Ga-CP256 with two different concentrations of CP256 in 




Ga preferred binding with CP256 instead of human serum. 
Figure-2.24: Formation of 
68
Ga-CP256 with two different concentrations of CP256 in human 
serum and 
68
Ga analysed using PD-10 column method. 
68
Ga CP256 complex formed in serum at 
a concentration of 0.02 mg/ml. At the concentration of 0.01 mg/ml of CP256 
68
Ga starts 
dissociating from CP256 and binding with serum. 






For further evaluation of the pretargeting approach, size exclusion chromatography was 
supplemented by studies in which the protein was precipitated with absolute ethanol, the 
activities in the supernatant and pellet were measured, and the supernatant was analysed 
by TLC Method 1. In the first sample CP256 was added to human serum which already 
contained 
68
Ga and in the second sample CP256 was added to serum followed by the 
addition of 
68
Ga. Both samples were incubated for 60 min, then diluted with an equal 
volume of absolute ethanol to precipitate serum proteins. Tubes were centrifuged for 2 
min at 12000g. The supernatant was transferred to separate tubes and the activity of 
both supernatant and pellets (serum protein) was measured in the dose calibrator. It was 
observed that the entire radioactivity stayed with the supernatant and there was no 
activity in the pellet.  
Further, supernatant samples were analysed using TLC Method 1, in which 
68
GaCl3 
moves with the solvent front (Fig-2.26-A) and 
68
Ga-CP256 stays at the origin (Fig-2.26-
B). The TLC of supernatant samples showed that the activity stayed at the origin, 
indicating formation of 
68
Ga-CP256 (Fig-2.26-C,D). There was zero activity in the 
pellets, showing that there is no binding of
 68
Ga to serum. 
Figure-2.25: In this study we have radiolabelled human serum with 
68
Ga-and this sample is 
called Pre-Sample (
68
Ga+serum). Then CP256 was added to this Pre-sample and now this 
sample is called Post –Sample (68Ga+serum+CP256). It is evident that 68Ga attached to serum in 
Pre-sample became detached from it and preferred to bind with CP256 in the Post–sample, 
which indicates that pretargetting is possible with CP256. These results indicate that 
68
Ga-
CP256 is not only stable in serum, but it can also snatch 
68
Ga which is already attached to 
serum. 




       
(A)                                                                             (B) 
        
       (C)                                                                                 (D)                    
 
For comparison with the results obtained with CP256, similar experiments were 
performed with NOTA and HBED. 
In evaluation of pretargeting approaches with NOTA, the elution patterns of the 




Ga-NOTA eluted in the last fractions from 8.5-9.5 ml (Figure 2.21). However, 
68
Ga-
binding components of human serum eluted in 4.0-4.5 ml (Figure 2.21). In both the 
addition sequences evaluated for pretargetting it was observed that most of the activity 
eluted in 3.5-4 ml, which shows that 
68
Ga is bound to the serum, instead of chelator, 
NOTA (Figure 2.27, 2.29). This behaviour of NOTA is quite opposite of CP256 and 
thus NOTA does not appear to be suitable for a pretargeting approach.         




















































































































GaCl3 moved with the solvent front (A). 
68
Ga-CP256 stayed at the origin because 
of its hydrophobic nature (B). Supernatant sample (1 mg/ml) stayed at the origin, suggesting it 
contained 
68
Ga-CP256 (C). Supernatant sample (0.1 mg/ml) also stayed mainly at the origin 
with a small amount of free 
68
GaCl3 moves with the solvent front (D). 
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                                                            (A) 
 
    
                               (B)                                                                           (C) 
 
Similar experiments were conducted with HBED. Most of the 
68
Ga-HBED eluted from 
7.5-8.5 ml (Figure 2.28). Serum stability studies indicated that the complex eluted in the 
same volume, 7.5-8.5 ml (Figure 2.28-A). 
Figure-2.27: Elution profile of 
68
Ga-NOTA in human serum using a PD-10 column. 
68
Ga-NOTA 




Ga was added to the solution containing serum and NOTA in a sequence 
(NOTA+serum+
68
Ga) it preferred binding with serum and eluted in 4 ml (B). Similarly, when 
NOTA was added to serum which was already radiolabelled with 
68





Ga remained attached to serum and eluted in 3.5-4 ml fraction (C). 
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(A)                                                                                                    (B)                            
 
                             
                                                                           (C) 
 
However, when the pretargeting approach (both addition sequences) was evaluated with 
HBED its behaviour was different from CP256 and NOTA. Labelled serum eluted in 
fraction 4-4.5 ml as shown earlier. 
68
Ga-HBED eluted in a broad peak from 7.5-8.5 ml 
and in pretargetting using both sequences it eluted in a broad 4.5-7.5 ml fraction (Figure 
2.28, 2.30), showing no clear evidence of either serum or HBED binding. These results 
were quite different from CP256, which showed very prominent binding to 
68
Ga in the 
presence of serum, even extracting 
68
Ga that was already bound to serum (Figure 2.22-
2.25). At the same time the behaviour of HBED was not as poor as NOTA in 
pretargetting. The behaviour of HBED was more complex and intermediate between the 
Figure-2.28: Elution profile of 
68
Ga-HBED in serum using PD-10 column. 
68
Ga-HBED was quite 
stable when incubated in serum (A). However, the behaviour of HBED was quite complex  
compared to CP256 and NOTA. When 
68
Ga was added to a solution containing serum and 
HBED in a sequence (HBED+serum+
68
Ga) (B) and when HBED was added to serum which was 
already radiolabelled with 
68
Ga in the sequence (
68
Ga+serum+HBED) (C) it eluted in a broad 
peak at 4.5-7.5 ml. In comparison, serum eluted at 4-4.5 ml and radiolabelled HBED eluted at 
7.5-8.5 ml. This showed that the behaviour of HBED was intermediate between NOTA and 
CP256. 
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CP256 and NOTA. The (
68
Ga+serum+HBED) peak (4.5-7.5 ml) was different and 
overlapping with both 
68
Ga-serum (4-4.5 ml) and 
68











Ga-serum with two 
different sequences of pretargetting with NOTA using PD-10 column. Both the sequences of 
pretargetting showed that 
68
Ga preferred to bind with serum instead of NOTA. 






Ga-serum with two different 
sequences of pretargetting with HBED using PD-10 column. Both the sequences of pretargetting 
showed intermediate results. 




The Obninsk generator was the first which provided cationic 
68
Ga. Both the IGG100 
and Obninsk generators are based on a closed system composed of borosilicate glass 
containing titanium dioxide in which 
68
Ge is embedded and then the decay product 
68
Ga 





from the IGG100 generator showed that there was little difference in radiolabelling 




 elution and therefore the 2 h waiting time 
between the elutions can be omitted, although by doing the pre-elution we can minimise 
the extent of metallic contamination in the eluant. When 11.8 µM CP256 was 
radiolabelled with 
68
Ga from the 1
st
 elution it gave a radiolabelling yield of 95%. The 
same concentration of CP256 gave 100% radiolabelling yield with the 2
nd
 elution of the 
day (Table 4).  
The eluate of the IGG100 generator gave a better radiolabelling yield compared to the 
Obninsk generator when eluant from these generators was used to radiolabel CP256 and 





 elutions of both generators, though the difference was minimal in the case of 
IGG100. On the other hand, the 1
st
 elution from the Obninsk generator gave only 40% 
radiolabelling yield with CP256 and 30% with NOTA, increasing to 70% in 3
rd
 the 
elution with CP256 and 59% with NOTA. It appears that metal contaminants from the 
Obninsk generator interfere with the radiolabelling of chelator with 
68
Ga.  
The effect of chelator concentration and time on the radiolabelling yield of CP256 was 
also analysed. At very high concentrations of CP256 (1 mM) 100% radiolabelling yield 
was achieved within 2-3 min and at low concentrations (118 nM) it gave only 11% 
radiolabelled complex even after 10 min. However, for intermediate concentrations of 
chelator (11.8 µM) time of incubation was quite critical as radiolabelling yield increased 
from 11% at 2 min to 97% at 10 min (Table 3). 
The utility of the CP256 chelator may not be limited to 
68
Ga. CP256 in a series of 









main purpose of these experiments was to fully assess the ability of CP256 for 
radiolabelling with some other imaging and therapeutic radiostopes. CP256 showed an 








Zr, which makes it 
potentially quite a versatile and unique chelator (Figures 2.9, 2.10, 2.13, 2.19, 2.16). Its 
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stability was further analysed in human serum, with the exception of 
99m
Tc. It was 
observed that the CP256 complex with 
90
Y (group III) was not very stable in serum 




Zr-CP256 complexes seemed to be fairly stable 
in serum (Fig-2.11 and 2.20). 
In order to fully evaluate the potential of CP256, we have also done a comparative study 
with the other chelators available in the market for 
68
Ga including DOTA, NOTA and 
HBED. Although, DOTA is considered to be the “gold standard” but it is not fair to 
make the comparison of CP256 with DOTA and other chelators because of the 
differences in the conditions for radiolabelling; e.g. DOTA requires 30 min heating at 
100
o
C for complete radiolabelling, NOTA and HBED require 7 and 10 min incubation 
at room temperature, whereas for CP256 only 3-5 min of incubation with 
68
Ga at room 
temperature and neutral pH is enough to obtain 100% radiolabelling yield depending 
upon the concentration of ligand (Table 5). At nanomolar levels all the chelators 
behaved similarly, zero (0%) radiolabelling yield. At 1 µM concentration NOTA (pH 7) 
gave 41% radiolabelling yield, NOTA (pH 4.5) gave 2% radiolabelling yield, DOTA 
gave 0%, HBED gave 70%, while for CP256 84% radiolabelling yield was obtained 
(Table 5). Thus, DOTA was the worst performing chelator in this case, as it required 
high temperature and longer incubation time, which is not compatible with the short 
half life of 
68
Ga, followed by NOTA and HBED. CP256 gave good radiolabelling yield 
(84%) at low concentration (1 µM) with minimum time for incubation (3 min) at room 
temperature and pH 7, which is a great advantage for CP256 compared to the other 
available chelators. 
The human serum stability of radiolabelled complexes of these chelators was also 
analysed. The biological environment in vivo is quite different from the in vitro 
environment because of the presence of the various types of protein such as albumin and 
transferrin. Human blood serum proteins show affinity for metals such as Fe and Ga. 
So, in vivo if the complex between the radiometal and chelator dissociates then 
radiometal will bind to blood serum proteins, which are quite abundant in the biological 
environment and they compete with the chelator, which is in most cases in pM 
concentration. The only thing which we can do under these conditions is to delay the 
process of dissociation between the radiometal and chelator to enable the complex to 
reach its target. That is, to make it kinetically stable. In one of the experiments the 
radiolabelled complex of NOTA (Fig-2.5), HBED (Fig-2.4) and CP256 (Fig-2.2, 2.3) 
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was incubated with human serum and samples were taken out at two different time 
points, 5 min and 60 min, to analyse the stability of these radiolabelled complexes in 
human serum via PD-10 column. It was observed that the radiolabelled complexes with 
all these chelators were quite stable in human serum at both time points and no binding 
of 
68
Ga with the serum was observed for any of the chelators.  
The high affinity of CP256 for 
68
Ga and the speed with which the complex forms under 
mild conditions prompted us to evaluate the potential for the use of CP256 in a 
pretargeting approach. An antibody derivatised with YM103 would be administered to 
the patient, allowed to distribute for several days, then a simple 
68
Ga chelate such as 
citrate or acetate would be given. In theory the 
68
Ga would rapidly distribute and find 
the derivatised antibody in the tumour, bind to it and allow imaging within the half life 
of 
68
Ga. This has never been done before using chelate chemistry. An in vitro model 
was used to check the binding and stability of 
68
Ga with CP256 in human blood serum 
in a pretargeting approach, with analysis by a PD-10 column, which is a type of size-
exclusion column and it allows the large molecules or proteins to leave the column first 
followed by smaller molecules in order of their size. This is the reason that we have 
human blood serum proteins in seventh and eighth fractions (4 ml) of the elution profile 
(Fig-2.21-E). In the first set of experiments, human serum was exposed to chelator first 
and then radiolabelled with free 
68
Ga instead of the usual method of radiolabelling the 
chelator first and then exposing it to serum. It was observed that 
68
Ga showed higher 
affinity for the chelator even in the presence of the human serum transferrin. 
Furthermore, even after 60 min and at chelator concentrations as low as 0.02 mg/ml 
68
Ga showed higher affinity for the chelator than for components of serum (Fig-2.22, 
2.27).  
In the second set of experiments, 
68
Ga was first added to the human serum followed by 
the chelator and it was observed that not only the free 
68
Ga in the pre-sample bound to 
the chelator, almost all of the 
68
Ga which bound with the serum in the pre-sample 
(
68
Ga+serum) detached from it and exhibited high affinity for CP256 instead of serum 
in the post-sample (
68
Ga+serum+CP256) (Fig-2.25). 
The same pretargeting model was evaluated with HBED and NOTA, two other 
chelators which bind 
68
Ga at room temperature. However, NOTA showed no promise 
for pretargetting using the same techniques with 
68
Ga and CP256. On the other hand the 
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behaviour of HBED was quite complex and intermediate between the CP256 and 
NOTA. HBED, when incubated with serum according to the above mentioned 
techniques, eluted around 4.5-7.5 ml. This fraction overlapped with radiolabelled serum 
(4-4.5 ml) and with radiolabelled HBED (7.5-8.5 ml), suggesting that some of the 
activity bound to serum and HBED was also able to hold to some 
68
Ga (Fig-2.26, 2.30). 
We cannot say with certainty with respect to the behaviour of HBED related to 
pretargetting but it was not as good as CP256 and not as bad as NOTA. 
Different TLC methods were developed which are quite simple and able to differentiate 
between the reference standard and the radioactive complex formed. TLC is the most 
common method used to check radiochemical purity (RCP) around the world in the 
radiopharmacies. It gives easy, quick and quite reliable results within a short period of 
time. The solvent systems used in TLC methods were 0.1 M sodium citrate (Method 1), 
in Method 3 water: ethanol: ammonia (5:2:1) and in Method 5 NaH2PO4 (0.4 M, pH 4-
4.5). The hexadentate chelator CP256 stayed at the origin in the case of 0.1 M sodium 
citrate and ITLC-SG as a stationary phase, which reflects that the complex is quite 
hydrophobic in nature as the mobile phase is polar and hydrophilic in nature (Fig-2.26). 
The reference standard (free 
68
Ga) moved with the solvent front (Fig-2.26). ITLC 
further confirmed the results of the PD-10 column. As human serum was separated from 
the sample with denaturation with ethanol and centrifugation, measuring the 
radioactivity in the supernatant and protein pellet it was observed that all the activity 
remained in the supernatant. A drop of supernatant was then applied to ITLC strip and 
developed in the mobile phase and it was observed that the activity stayed at the origin, 
indicating the presence of 
68
Ga-CP256 (Fig-2.26). However, in the other system in 
which water, ethanol and ammonia (5:2:1) was employed as a mobile phase and HSA-
ITLC-(SG) as a stationary phase, 
68
Ga-CP256 moved with the solvent front and free 
68
Ga stayed at the origin (Fig-2.3). For NOTA and HBED, ITLC-SG was used as a 
stationary phase and NaH2PO4 as a mobile phase. In both the cases free 
68
Ga stayed at 
the origin and the chelator complex moved with the solvent front. 
Another new method (Method 4) for ITLC was developed in which CP256 moved with 
the solvent front and free 
68
Ga stayed at the origin; this is quite simple and easy (Fig-
2.0) compared to the HSA or BSA saturated ITLC-SG strips (Method 3), avoiding the 
need to pretreat the strips. Two mobile phases were used. The mobile phase 1 was 
composed of ammonia, acetone, and water in a ratio of 5:3:2, while mobile phase 2 
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contained acetone, water, and ammonia in a ratio of 5:4:1 respectively. This method is 
quite useful for the routine purposes in radiopharmacy as it is quick and easy. 
2.4-Summary 
We have seen that CP256 forms a stable complex with 
68
Ga at lower concentrations, 
room temperature, neutral pH and with very short time of incubation compared to other 
68
Ga chelators available in the market, which makes it a unique chelator. CP256 may be 




Zr, and there is possibility of 
exploring its usage as a chelator for therapeutic radionuclides. CP256 shows promise for 
a novel pretargeting approach since it can also bind with 
68
Ga which is first bound to the 
transferrin in human serum by snatching it from transferrin. It is quite stable in human 
serum, at least for the time scale which is required for PET imaging with 
68
Ga. It opens 
the door to true kit based 
68
Ga protein labelling as shown by the labelling of conjugated 
C2A protein with 
68
Ga very efficiently within 5 min. The simplicity of labelling at very 
high specific activity is a huge step forward for the routine, low cost availability of PET 
molecular imaging agents in centres without a cyclotron or extensive radiochemistry 
expertise. 




Chapter 3: Production of J591(scFv) and J591c(scFv) 
3.0-Introduction 
Several PSMA mAb have been developed, including 
111
In-labelled mAb 7E11, 
capromab-pendetide (Prostascint). It has been extensively evaluated for SPECT imaging 
applications. However, Prostascint requires a long period of time between injection and 
imaging. Furthermore, 
111
In-capromab is not currently considered a promising agent for 
lesion detection within the prostate gland or for determining extracapsular extension, 
primarily because the internal target of 
111
In-capromab requires that cell membranes be 
damaged before the antibody can bind. Excess unbound antibody leads to high 
background signal and poor spatial resolution [66]. In contrast, another full-length mAb 
that targets PSMA, J591, recognises and binds an extracellular epitope on PSMA. 
In recent years there have been massive advances in antibody design. Full length 
antibodies are broken down into various fragments. The smaller size of the fragments 
improves the penetration properties into tissues which are inaccessible to full-size mAbs 
and this also matches the short half-life of some of the radionuclides for imaging [77]. 
The engineering of single chain variable region fragments (scFv) of mAb is another 
route to improve their kinetics for imaging. The J591(scFv) not only binds specifically 
to PSMA but also competes for the same extracellular epitope of PSMA as the J591 
mAb [121]. 
Construction of the J591(scFv) genes encoding the VH and VL chains of the J591 mAb 
was carried out by IDT (Integrated DNA Technologies, Inc., Coralville, IA, USA). A 
17-amino acid linker sequence fused the VH and VL chains to generate a single 0.7 kb 
peptide. The PCR amplified J591(scFv) fragment was sub-cloned with the pCR2.1 (Life 
Technologies, Carlsbad, CA, USA) [121]. The scFv can be used to make fusion proteins 
such as for treatment and detection of cancer growth and metastasis. The targeting 
biomolecule which we have developed is a single chain fragment (scFv) of J591 instead 
of full length antibody (Fig-3.0).  
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We used J591(scFv) plasmid (PET26bJ591) which was kindly provided by Dr. John 
Maher, King’s College London [79]. The C-terminal cysteine was introduced in house 
by Dr. Florian Kampmeier (PET26bJ591c). Both VH and VL sequences of J591(scFv) 






The main reason to select the scFv is that its pharmacokinetic characteristics matched 
perfectly with the short half-life of 
68
Ga (68 min). This scFv has a His-tag attached to it, 
which can be used for radiolabelling with 
99m
Tc tricarbonyl. Near this His-tag a cysteine 
is attached in case of J591c(scFv), which can be further used for conjugation with thiol-
reactive bifunctional chelators, such as (YM103) for radiolabelling with 
68
Ga.  
The main aim of Chapter 3 is to deal with the production of J591(scFv) and J591c(scFv) 
on small and large scale purification and storage. Initially bacterial BL21 cells were 
used to produce the scFv via peri-plasmic extraction followed by Ni-NTA purification. 
However, later mammalian 293T cells were used to produce the scFv, as the yield was 
much better compared to the bacterial BL21 cells. Different techniques were employed 
to get purified scFv involving AKTA and analysis by HPLC. For storage of scFv, 
Figure 3.0: A full length antibody and single chain fragment [139] 
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different temperatures were evaluated by HPLC to find optimum conditions for storage 
which prevents formation of dimers in scFv. 
3.1-Methods 
Some of the buffers used in the preparation and purification of the scFv are listed in the 
Table 6:  
Table 6 
Buffer Composition Concentration 
4x binding buffer (Ni-NTA 




200 mM   
1.2  M 
40 mM 
Wash buffer (Ni-NTA 





300 mM  
40 mM 
Elution buffer (Ni-NTA 





300 mM  
500 mM  
LB (pH 7)  NaCl  
Peptone  




SOC  Peptone  










10 mM  




3.1.1-Preparation of Chemically Competent BL21 Cells 
BL21 strains are descended from the E. coli B strain and have been specifically 
constructed for high-level expression of recombinant proteins. For the preparation of 
BL21 cells, 5 ml of overnight culture of BL21 cells was grown in LB media. This 
culture was diluted by adding 40 ml of fresh LB media and the flask was put in an 
Table 6: Buffers and media used in the preparation and purification of scFv 





C until an optical density at 600 nm of 0.2-0.5 was obtained, measured 
by spectrophotometer. The flask was centrifuged for 10 min to get a hard pellet at 875g 
at 4
o
C after cooling it down on ice for few minutes. The pellet was resuspended in 4 ml 
of chilled TSS buffer by vortexing. Aliquots of 100 µl were transferred to chilled 
microcentrifuge tubes and stored at -80
o
C. 
3.1.2-Transformation of E-Coli with Plasmid DNA 
LB agar plates were prepared with kanamycin (50 μg/ml) and warmed to 37oC. The 
BL21 cells were removed from the freezer, thawed on ice, and the cells were 
resuspended by vortexing. The purified plasmid DNA (1 µl of pET26b J591-Clone 1 or 
pET26b J591c-Clone 3) obtained from Dr. John Maher, King’s College London 
(cysteine added in-house by Dr. Florian Kampmeier) was added to BL21 cells and 
mixed gently. The cells were incubated on ice for 30 min followed by heat shock 
treatment of the cells by incubating them at 37
o
C for 45 sec and then returning them to 
ice immediately for 2 min. After addition of 450 µl of SOC medium at room 
temperature, the cells were transferred to a 15 ml polypropylene tube with a loose cap 
for air exchange for full recovery. The cells were incubated at 37
o
C with shaking at 225-
250 rpm for 1 h. Aliquots of 5-10 µl of SOC media were pipetted onto an LB agar plate 
containing antibiotics and 20 µl of transformed cells were transferred to this SOC media 
and spread evenly by using a sterile spreader. The plates were sealed and stored at 4
o
C.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
3.2-Expression in BL21 (DE3)-T1R Competent Cells 
For production of BL21 cells 5-6 well-isolated colonies were selected from each 
transformation reaction and cultured in 20 ml LB broth containing antibiotics 
(kanamycin, 20 µl) at 37
o
C overnight with constant shaking. An aliquot of 8000 µl of 
overnight culture was diluted by adding 400 ml of fresh LB media containing 400 µl of 
kanamycin in pre-weighed flasks. This culture was then incubated at 30
o
C with constant 
shaking until the OD600 was roughly 0.6.  An aliquot of 1 ml of this culture was taken 
out as a pre-induction control. Expression in the cells was induced with 1 mM IPTG. 
The induced culture was then kept for 3-4 h at 30
o
C, after which a 1 ml sample was 
removed for SDS-PAGE and the rest was centrifuged at 10,000g for 10 min at 4
o
C to 
obtain a pellet. The bottle was weighed again to find out the increase in the weight of 
the bottle and hence the weight of the pellet. 
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3.2.1-Peri-plasmic protein extraction 
The pellet was resuspended in 20% sucrose buffer followed by the addition of 1 
mmol/L EDTA, and the mixture was cooled down by incubating on ice for 10 min. A 
hard pellet was obtained after centrifugation at 10,000g for 20 min. The pellet was 
resuspended in 150 ml of MgSO4 (5 mM) and incubated on ice for 10 min with 
occasional vortexing, and again centrifuged at 10,000g for 20 min. The supernatant was 
further analysed by SDS-PAGE and Western blot. Peri-plasmic extract was filtered 
through a 0.22 µm filter, and concentrated using a cross-flow membrane. The 
concentrated peri-plasmic extract was further purified using a Ni-NTA column (Qiagen 
-Amersham, 1 ml His trap fast flow column) using AKTA (FPLC) at a maximum 
pressure of 0.5 MPa and flow rate of 1 ml/min. After the sample was loaded onto the 
column, it was washed with binding buffer (10 mM imidazole) followed by wash 2 with 
wash buffer (20 mM imidazole) and finally the protein was eluted using elution buffer 
(250 mM imidazole). The protein buffer was adjusted to PBS (pH 7) by dialysis 
overnight (spectra/pro dialysis membrane MWCO 3500) in 4 L of PBS. 
3.3-Production of J591(scFv) and J591c(scFv) from Mammalian 293-T 
cells 
For production of J591(scFv) and J591c(scFv) from mammalian HEK 293-T cells 
(human embryonic kidney 293 T cells), the growth medium used was RPMI 1640 with 
10% FBS, 1 µl of penicillin/streptomycin: 100 µl of growth medium antibiotic pen-strep 
(penicillin + streptomycin) and Zeocin (1 µl of zeocin:1000 µl of growth medium) in a 
T-75cm
3
 (20 ml) bottle. Cells were cultured in 5% CO2 at 37
o
C. When the medium was 
acidified it changes its colour to yellow from phenol red because of the decrease in pH 
indicating that growth medium needs to be changed. For large scale production, cells 
were scraped from T-75cm
3
 flasks and transferred to a triple flask bottle. The triple 
flask was then filled with 150 ml of growth medium and kept at 37
o
C. The media were 
collected every three days and replaced with fresh media. The supernatant was stored at 
4
o
C. When a sufficient amount of supernatant had been collected (1600 ml), it was 
filtered through 0.22 µm filters and 400 ml of 4x binding buffer was added. 
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3.3.1-Purification through Ni-NTA column using AKTA 
Purification of the filtered supernatant was performed using a 5 ml Ni-NTA column 
(Qiagen) using AKTA (FPLC) at a maximum pressure of 0.5 MPa and flow rate of 1 
ml/min. The sample was loaded onto the column overnight, then the column was 
washed with binding buffer (10 mM imidazole) followed by wash 2 with wash buffer 
(20 mM imidazole) and finally the protein was eluted with elution buffer (250 mM 
imidazole). The elution fractions were concentrated by using centrifugal concentrators 
(Vivaspin 6 PES, MWCO 5000, Fisher-Sartorius). Proteins were further purified by a 
size exclusion chromatography step. 
3.3.2-Size-exclusion chromatography 
The buffer in the J591(scFv) and J591c(scFv) solutions was adjusted with AKTA and a 
size exclusion column (Superdex 75 10/300 GL from GE) at a flow rate of 0.5 ml/min 
and maximum pressure of 1.8MPa. The main purpose of this step is further purification. 
The column was equilibrated with water followed by PBS of pH 7. J591(scFv) or 
J591c(scFv) (500 µl) was injected from the injection loop. All the fractions were 
collected automatically. The fractions containing protein were separated from the rest of 
the fractions as they were eluted in the form of peak and at the same time UV detector 
of AKTA gave an enhanced signal (Fig-3.5, 3.7).  
3.3.3-SDS-PAGE and Western Blotting 
After the size–exclusion step the protein was analysed by SDS-PAGE using pre-cast 
polyacrylamide gels (Nupage 12% with MES buffer, Life Technologies) and Western 
blotting. For the preparation of samples 10 µl aliquots of scFv (J591 or J591c) were 
placed in microcentrifuge tubes and 5 µl of LDS loading buffer (4x) was added. For 
reduced samples, the reducing agent (Nupage reducing agent of strength 10x, 2 µl) was 
added along with LDS buffer of 4x concentration (5 µl). All the samples were placed on 
a heating block for 5 min at 95
o
C and afterward put on ice for 1 min. The Nupage 
chambers were filled with the MES buffer (50 ml of 20x MES buffer + 950 ml of 
deionised water). The samples were loaded on the gel with a pipette (10 µl). The gels 
were 12% Nupage Novex Bis-Tris mini gels. The Novex sharp pre-stained protein 
standard was loaded in one of the wells. The voltage used was 200 V with constant 
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current (125 mA) and the gel was run for 40 min, after which the gel was removed and 
developed with simple blue safe stain for 1-2 h, then destained with water overnight. 
In the case of Western blotting, the 12% gel was prepared in the same way as in SDS-
PAGE but instead of developing it in simple blue safe stain the gel was loaded on 
nitrocellulose plates (transfer membrane) and then developed in non-reduced transfer 
buffer (Nupage transfer buffer (20x) 50 ml + methanol (100 ml) + deionised water (850 
ml)). The gel was developed for 1 h at 30 V constant and current of 170-130 mA. After 
1 h the transfer membrane was removed and placed in a blocking agent (4% milk in 50 
ml of PBS with 0.05% Tween 20) for at least 90 min. The transfer membrane was 
washed briefly with PBS to remove any traces of milk, then placed in a solution 
containing antibody against His-tag (6.3 µl of antibody diluted (1:4000 dilution) by 
adding 25 ml of PBS with 0.5% BSA, which is almost 0.125 g/25ml of BSA) overnight 
at 4
o
C with shaking. The transfer membrane was washed four times with 10 ml of PBST 
(1 L of phosphate buffered saline with 0.05% Tween 20) before incubating with 
secondary antibody (goat anti-mouse HRP, horseradish peroxidase) for 60 min (1:5000 
dilution, approximately 4 µl of HRP in 20,000 µl of PBS). The transfer membrane was 
washed with PBST at least four times before immersing it in the solution of substrate. 
DAB [(3,3-Diaminobenzidine) Peroxidase Substrate Tablet Set from Sigma Aldrich] 
was used as a substrate to detect HRP (one DAB tablet and one Urea Hydrogen 
Peroxide tablet dissolved in 15 ml of ultrapure water). DAB produces an intense brown-
black stain. The transfer membrane was developed in the dark until the brown–black 
precipitation was visible.  
3.4-Effect of temperature and glycerol on dimer formation 
Twenty four samples of J591(scFv) and J591c(scFv) each of equal concentration (0.5 
µg/µl) were placed in microcentrifuge tubes. The volume of each sample was 20 µl. 






C. Five percent 
glycerol was added into half of the samples (4) at each time point. Samples were 
removed from all the temperature points every week of both with glycerol and without 
over the period of 3 weeks to analyse the formation of dimers in each sample. Samples 
were analysed with HPLC using PBS as a running buffer and a size-exclusion column 
(SEC-2000, Phenomenex). 




3.5.1-Production of J591(scFv) and J591c(scFv) 
Initially, J591(scFv) and J591c(scFv) were produced using bacterial BL21 (DE3)-T1R 
cells. The yields of J591(scFv) and J591c(scFv) obtained using this method were not 
very high (6 mg/L for J591(scFv) and 2 mg/L for J591c(scFv)). In order to achieve 
higher expression yields the production system was switched from bacterial cells to 
mammalian HEK293T cells. In expression system HEK293T cells are transfected with 
expression vector and the recombinant targeted protein is secreted into the culture media 
supernatant. The yield of J591(scFv) using mammalian 293T cells was better than 
bacterial cells, reaching 10-12 mg/L for J591(scFv) and 4-6 mg/L for J591c(scFv). 
3.5.2-Purification through Ni-NTA column using AKTA 
Most of the J591(scFv) was eluted in the elution fractions 2, 3, 4 with a small amount in 
5 (1.5 ml each) from the Ni-NTA column in the form of single peak (Fig-3.1). The total 
amount of protein obtained in these fractions was roughly 12.0 mg in 6 ml according to 
the measurement using a NanoDrop device (Thermo-Scientific). One of the common 
problems observed with the scFv is the formation of dimeric aggregates; however, it 
was observed that monomeric form is purified during the size-exclusion step. There 
were no dimers (non-covalent or covalent association between the molecules) in these 
fractions with the exception of 1 as analysed by SDS-PAGE. Strong bands of protein 
were obtained roughly at 30 kDa for fractions 2, 3 and 4 (Fig-3.2). In the case of 
J591c(scFv) most of the protein was collected as a single peak in fraction 2 (Fig-3.3). 
Dimers were present in all the fractions which can be reduced using a reducing agent 
(DTT) as seen in SDS-PAGE (Fig-3.4). The total amount of protein obtained in these 
fractions was roughly 4-6 mg/L. 
 














Figure-3.1: UV Chromatogram showing different fraction of J591(scFv) eluted 
from Ni-NTA column using FPLC. Wash 1 (10 mM imidiazole), Wash 2 (20 mM 





2 1 3 4 
60 Kda 
30Kda 
Figure-3.2: SDS-PAGE gel of J591(scFv) after Ni-NTA step. 
1: Wash 1. 2: Wash 2. 3: Elution fraction. 4: Marker 





                                                                                                            
 




After the Ni-NTA step the J591(scFv) and J591c(scFv) were in elution buffer (250 mM 
imidazole), so the buffer was adjusted to PBS (pH 7) in the gel filtration step. In the 






Figure-3.3: Chromatogram showing different fractions of J591c(scFv) eluted from Ni-
NTA column using FPLC. Wash 1 (10 mM imidiazole), Wash 2 (20 mM imidiazole) 
and elution fractions (250 mM imidiazole).  
 
3 2 
1 4 5 6 
Figure-3.4: SDS-PAGE gel of J591c(scFv) after Ni-NTA step. 
1: Marker. 2: Wash 1. 3: Wash 2. 4: Elution fraction 2. 5: 
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(Fig-3.5). However, in the case of J591c(scFv) in the size exclusion step two peaks can 
be seen, one representing the monomer and the other representing the dimer because of 
covalent or non-covalent interactions and they are quite fused together as observed from 
the chromatogram (Fig-3.7), so elution fractions contain a mixture of monomer and 
dimers. It was further confirmed by SDS-PAGE. According to SDS-PAGE in the case 
of J591(scFv) fractions 8 and 9 contained both monomers and dimers and fractions 10, 
11 and 12 were monomers (Fig-3.6). Starting with 12 mg of protein, 8-10 mg was 
recovered after the size-exclusion step. On the other hand SDS-PAGE (Fig-3.8) for 






                                                                                                                            
Monomer fraction. 
Dimer fraction. 
Figure-3.5: Chromatogram showing monomer and dimer fractions of 
J591(scFv) as eluted from size-exclusion column using FPLC. 
1 2 3 4 5 6 
Figure-3.6: SDS-PAGE gel of J591(scFv) after buffer adjustment using Superdex 
75 10/300GL column. 1:  Marker. 2: Fraction 8 (monomer & dimer). 3: Fraction 
9 (monomer & dimer). 4: Fraction 10 (monomer). 5: Fraction 11 (monomer). 6: 
Fraction 12 (monomer). 
60Kda 
30Kda 










The fractions obtained after size-exclusion chromatography were further analysed by 
size-exclusion HPLC (SEC-2000, Phenomenex). PBS was used as a running buffer with 
Figure-3.7: Chromatogram showing monomer and dimer fractions of J591c(scFv) as eluted from  
size-exclusion column using FPLC. 
 
Figure-3.8: SDS-PAGE gel of J591c(scFv) after buffer adjustment 
using Superdex 75 10/300GL column. 1: Marker. 2: Fraction 8. 3: 
Fraction 9 (monomer & dimer). 4: Fraction 10 (monomer & 
dimer). 5: Fraction 11 (monomer & dimer). 6: Fraction 12 
(monomer & dimer). 
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a flow rate of 1 ml/min. Dimers eluted at 8 min and monomer eluted at 9 min (Fig-3.9, 
3.10). Formation of J591(scFv) and J591c(scFv) was also analysed by Western blotting 
and a strong band was observed at 30 kDa. For J591c(scFv) a dimer band was formed at 
60 kDa (Fig-3.11). 
 
           (A)                                                        (B)                                               
 
 
   
     









































































Figure-3.9: HPLC of the fractions of J591(scFv) obtained after size-exclusion 
chromatography via FPLC. Mixture of monomer (9 min) and dimer (8 min) in SEC-
2000 column (A) using PBS as running buffer. Monomer fraction of J591 at 9 min (B). 
 
Figure-3.10: HPLC of the fractions of J591c(scFv) obtained after size-exclusion chromatography 
via FPLC J591c predominantly monomer (9 min) and small amount of dimers (8 min) in SEC-
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3.5.4-Effect of storage temperature and glycerol on dimer formation 
The effect of dimerisation was measured by HPLC (SEC-2000, PBS as running buffer). 
It was observed that glycerol did not have any effect on the degree of dimerisation in 





C and then -20
o
C. It increased with time over 3 weeks, but it was least at 
-80
o







Figure-3.11: Western blot with anti His-tag 
antibody   
1: Markers        2: J591(scFv).     3: J591c(scFv). 
2 1 3 
60Kda 
30Kda 









It was observed that both J591(scFv) and J591c(scFv) are capable of forming dimers 
under certain conditions, and the extent of dimerisation appears to depend on linker 
length, antibody sequence, and external factors such a temperature, pH, concentration 
etc. We have analysed only one parameter in the above mentioned experiment i.e 










Figure-3.12: J591(scFv) and J591c(scFv) were analysed by size-exclusion chromatography using Sec-
2000 column and PBS as a running buffer. Least dimers are formed at -80
o
C over the time period of 3 
weeks. (A) 1
st
 week; (B) 2
nd
 week; (C) 3
rd
 week. 




Initially the proteins were produced through bacterial BL21 cells growing in LB media. 
Lac Z promoter controls the expression of the scFv gene, which is induced by IPTG 
[122] and these cells secrete the scFv into the periplasm and supernatant. However, it 
was observed that yields of J591(scFv) and J591c(scFv) were not very high using 
bacterial BL21 cells (6 mg/L for J591(scFv) and 2 mg/L for J591c(scFv)). Therefore, 
we switched to another method in which mammalian HEK293T cells (10-12 mg/L for 
J591(scFv) and 4-6 mg/L for J591c(scFv)) were used to produce the scFv in the 
supernatant, which is then collected over the period of a few weeks and then purified by 
Ni-NTA chromatography using FPLC (Fig-3.1, 3.3, 3.13).  
                          




The chelators commonly used as ligands for IMAC (immobilised metal affinity 
chromatography) are nitrilotriacetic acid (NTA) and iminodiacetic acid (IDA). Once 
IDA-agarose or NTA-agarose resin is prepared, it can be "loaded" with the desired 
divalent metal (e.g. Ni, Co, Cu, Fe). NTA has four chelation sites for nickel ions, and 
binds nickel more tightly than IDA that only have three sites available for interaction 
with metal ions. The extra chelation site prevents nickel-ion leaching and results in a 
greater binding capacity and protein preparations with higher purity. Nickel is the most 
widely available metal ion for purifying histidine-tagged proteins. The Ni-NTA column 
shows high affinity and selectivity for 6xHis-tagged recombinant proteins and purity 
1 1 2 3 4 5 6 7 8 3 2 
Figure-3.13: In panel (A) protein is obtained through 293T cells by collecting supernatant 
1:Marker.2-5: different fractions of J591(scFv).6-8:different fractions of J591c(scFv). In panel 
(B) protein is obtained from peri-plasmic extract using bacterial BL21 cells. 1: Marker. 2: 
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was confirmed by SDS-PAGE analysis (Fig-3.2, 3.4). In Ni-NTA chromatography scFv 
was eluted in the form of a single peak. In Western blotting, both monomers and dimers 
were observed. Normally, during metal affinity chromatography, proteins bind to beads 
when they have an opposite charge than the bead, therefore elution buffers must alter 
this charge in order to release the protein efficiently. This can be done either by 
decreasing the pH or by increasing the NaCl concentration [123]. After Ni-NTA 
purification the buffer was adjusted to PBS of pH 7 by using the size-exclusion column 
(Superdex 75 10/300 GL) and FPLC. Both monomer and dimer can be seen in the 
chromatogram as two separate peaks, which are quite close together. The dimer elutes 
first followed by monomer because of higher molecular weight (Fig-3.5, 3.7). Two 
types of dimers are observed in this case: covalent and non-covalent because the two 
scFv molecules that form dimers which are not linked covalently can be readily 
dissociated when changes in environmental conditions such as pH or temperature occur, 
or during freeze/thawing [124]. The environment in which a protein is synthesised and 
allowed to fold is a significant determinant of its final shape. J591(scFv) has only non-
covalent dimers and J591c(scFv) has both covalent and non-covalent dimers. Covalent 
dimers are formed because of cysteines, which are used for conjugation with maleimide 
of YM103. They are reduced by adding reducing agent like TCEP prior to the 
conjugation with YM103. In size-exclusion chromatography, such aggregated proteins 
pass through at a faster rate as compared to the monomer because of higher molecular 
weight than expected [125]. The presence of monomers and dimers was further 
established using Western blotting (Fig-3.11), SDS-PAGE (Fig-3.6, 3.8) and HPLC 
using size-exclusion column (SEC-2000) (Fig-3.10) in which monomer eluted around 9 
min and dimer around 8 min. Further strong bands at 30 kDa for monomer and 60 kDa 
for dimer were observed both in Western blotting and in SDS-PAGE gel. 
The effect of temperature and glycerol on the formation of aggregates during storage 






C) on both J591(scFv) 
and J591c(scFv) with and without glycerol and it was observed that dimerisation was 
reduced considerably by keeping the protein samples at the temperature of -80
o
C (Fig-
3.12). It was also observed that glycerol has little effect on the extent of dimerisation. 
The monomeric form is favoured in a dilute solution; however in a concentrated form 
dimerisation is favoured. Dimer to monomer ratio is an equilibrium reaction and it 
depends on several factors like temperature, pH and ionic strength [79]. 




We were able to produce 12 mg/L J591(scFv) and 4-6 mg/L J591c(scFv) using 
HEK293-T cells. Each was purified by using Ni-NTA column and buffer was adjusted 
to PBS using size-exclusion chromatography. HPLC chromatograms showed that it was 
pure with some extent of dimerisation, which we have tried to overcome by storing the 
protein at low temperature (-80
0
C) after purification and separation of monomeric and 
dimeric form by size-exclusion chromatography. 




Chapter 4: Radiolabelling of J591(scFv) with Technetium-
99m Tricarbonyl 
4.0-Introduction 
Inorganic chemistry is challenged to find easy ways to introduce physiologically stable 
99m
Tc cores into biomolecules without altering their bioactivity. Proteins seem to be an 
interesting target for direct labelling with low-valent organometallics. On one hand, a 
protein offers various sites for attaching an organometallic moiety but monodentate 
coordination only is probably not sufficient to block cross-linking to other proteins and 
formation of larger aggregates. The histidine-tagged recombinant scFv proteins are an 
exception to this expected behaviour as coordination is not monodentate in His-Tag. 
They carry a chain of 3–6 histidines at the N-terminus which are vital for purification 
but not for receptor binding. This histidine tag can be treated as a multidentate ligand 
since two or more imidazoles from histidine can coordinate at the same time. In 
comparison to the direct unspecific labelling, improved stability against cross-linking is 
expected along with site-specificity and in vivo stability. Histidine-tagged scFv has been 
labelled at 37°C to a high degree and labelling occurred specifically at the His-tag 
[82,83]. It was observed that recombinant scFv antibodies which bear a histidine tag can 





Labelling of the same protein without His-tag gave very low yields. These histidine 
derivatives are easily introduced into biomolecules. The complex [
99m
Tc(His)(CO)3] is 
hydrophilic and can be combined with hydrophilic peptides. HPLC typically shows that 
retention times of the native and labelled peptide do not differ much. Histidine is a very 
competent ligand and quantitative labelling occurs, in general, at the micromolar level. 
The radiolabelling procedures involving scFv with His-tag are quite simple and 









 followed by the one-step labelling procedure with scFv with 
His-tag.  




+   
using 
99m
Tc pertechnetate and a tricarbonyl kit with high purity 
and then use this 
99m
Tc tricarbonyl to radiolabel the J591(scFv). To achieve this aim it 
was necessary:  
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1. To optimize the labelling conditions to get maximum radiolabelling yield. 
2. To analyze the serum stability of the radiolabelled compound. 
3. To perform cell binding studies using PSMA positive and PSMA negative cell lines 
to show that radiolabelling did not damage the ability of J591(scFv) to bind 
specifically with PSMA. 
4.1-Method 
4.1.1-Preparation of tricarbonyl kit 
Two methods have been used for the preparation of tricarbonyl kits (Isolink, Covidien 
Healthcare). One involved splitting of the kit contents into three equal parts and then 
radiolabelling an individual part with pertechnetate. This is an in house modification. 
The other involved the use of the full kit. Which method is adopted depended upon the 
number of users of the tricarbonyl kit on a particular day. 
4.1.2-Splitting of tricarbonyl kit and radiolabelling 
The contents of an Isolink kit were dissolved in 1 ml of distilled water. After mixing the 
contents of the kit by gently shaking, the kit contents were removed with the same 
syringe and divided into three equal parts (0.33 ml) each stored in a microcentrifuge 
tube with a screw top (Wheaton vial, Pierce). These tubes were immediately frozen in 
liquid nitrogen followed by lyophilisation (freeze drying) for 24 h at -4
o
C [116]. 
For radiolabelling of this split kit 500-600 MBq (90 µl) of pertechnetate (
99m
Tc 
generator eluate) was used. After adding the pertechnetate to the tricarbonyl split kit, the 
tube was heated at 100
o
C for 25 min. The kit contents were then neutralised by adding 1 
M HCl (~40 µl) and checking the pH with pH paper. For quality control purposes to 
check the formation of 
99m
Tc-tricarbonyl, silica gel TLC plates (Sigma Aldrich) were 
developed with 1% HCl in methanol. Any colloid will stay at the baseline, free 
pertechnetate moves toward the solvent front (Rf  = 0.7), and tricarbonyl will be at Rf=  
0.4. 
99m
Tc-tricarbonyl was then used to radiolabel the protein, J591(scFv). 
4.1.3-Radiolabelling of full kit 
For preparation of tricarbonyl from a full kit, up to 1000 MBq (500-700 µl) of 
99m
Tc 
pertechnetate was used. After adding the activity, the contents of the kit were dissolved 
by gentle shaking. The kit was then heated at 100
o
C for 25 min. The contents of the kit 
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were transferred to a microcentrifuge tube (1 ml) after cooling as it is easy to handle. 
The pH of the kit contents was adjusted to 7 by adding 1 M HCl (~120 µl) and checking 
its pH with pH paper. For quality control purposes, the formation of 
99m
Tc-tricarbonyl 
was checked as described above. 
4.2-General method of radiolabelling of J591(scFv) and effect of time 
on radiolabelling yield 
For radiolabelling of J591(scFv), the appropriate amount of tricarbonyl (230 MBq, ~90 
µl) was added to 100 µl of J591(scFv) (1 µg/µl) in PBS and heated at 37
o
C for 60 min. 
Samples were taken out at 30 and 60 min for analysis on iTLC-SA strips (Agilent) 
developed in 0.1 M citrate buffer (sodium tribasic citrate) of pH 6. 
99m
Tc tricarbonyl 
moves with the solvent front and radiolabelled J591(scFv) stays at the origin. 
4.2.1-MiniTrap purification step  
The Sephadex G-25 MiniTrap column (GE Healthcare Life Sciences) was used for 
purification. This is efficient in separation of high molecular weight substances from 
low molecular weight substances. Furthermore, it was also used for desalting, buffer 
exchange and sample clean up. Small molecules like salt, free labels and other 
impurities were efficiently separated from the high molecular weight substances of 
interest. The chromatography technique was gel filtration and molecules were separated 
on the basis of differences in size. The column was pre-washed with 60 ml of PBS. The 
crude 
99m
Tc-J591(scFv) reaction mixture was applied to the MiniTrap column in order 
to remove any free pertechnetate and 
99m
Tc tricarbonyl. Thirty fractions of 100 µl were 
collected. The activity in each fraction was measured in a dose calibrator. The fractions 
with highest activity were 8, 9 and 10. These fractions were analysed by iTLC-SA. If 
radiochemical purity was satisfactory the three fractions 8, 9 and 10 were mixed (~300 
µl). 
4.3-Radiolabelling of different concentrations of J591(scFv) 
Different concentrations of J591(scFv) (from 72 µM to 4 µM) were prepared by diluting 
the stock solution of J591(scFv) with PBS. These different concentrations were then 
radiolabelled with the same amount of 
99m
Tc tricarbonyl (30 MBq in 10 µl), and after 
incubating for 60 min at 37
o
C the radiochemical purity was analysed by iTLC-SA. 
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4.4-Difference between 140 mM and 500 mM salt concentration 
J591(scFv) was in PBS, which contains roughly 140 mM NaCl, along with 2.7 mM 
KCl, 10 mM Na2HPO4 and 2 mM KH2PO4. For a comparative study of J591(scFv) in 
140 mM salt solution with high salt concentration, 5 M NaCl solution was added to the 
original 140 mM solution to increase its molarity to 500 mM. The same amount of PBS 
was added to the samples containing 140 mM NaCl so that concentration of protein 
remained the same in all the samples. In total there were four samples of two different 
salt and protein concentrations.  
i) 140 mM NaCl, 0.5 mg/ml J591(scFv). 
ii) 140 mM NaCl, 1 mg/ml J591(scFv). 
iii) 500 mM NaCl, 0.5 mg/ml J591(scFv). 
iv) 500 mM NaCl, 1 mg/ml J591(scFv).  
99m
Tc-tricarbonyl was used to radiolabel all the samples (225 MBq in 125 µl each). 
Samples were taken in triplicate at four different time points, i.e. 30, 60, 90 and 120 
min, and analysed by iTLC-SA. 
4.5-Serum stability 
After addition of 90 µl of 
99m
Tc tricarbonyl (260 MBq) to 50 µl of J591(scFv) (3.78 
µg/µl, 500 mM salt), the tube was incubated on a heating block at 37
o
C. Samples were 
taken at 30 min and 60 min and analysed by iTLC-SA. After purification by MiniTrap 
column, the 3 combined fractions (~300 µl) were added to human serum (300 µl of 
serum plus 150 µl of 0.9% saline). The first sample was taken at 0 min. The tube was 
incubated at 37
o
C and samples collected 30, 60, 120, 180, 240 min and 24 h (5 µl in 
each case) and stored at -80
o
C until the last sample was taken.  A human serum standard 
was also prepared by adding 10 µl of 
99m
Tc-tricarbonyl to 50 µl of serum. An aliquot of 
5 µl was taken out after incubation of 120 min and stored at -80
o
C as a reference. A 
sample of 
99m
Tc-J591(scFv ) (5 µl) was also stored at -80
o
C as a reference so that we 
know exactly where the radiolabelled protein migrates on SDS-PAGE gel. All these 
samples were analysed by radioelectrophoresis via SDS-PAGE. All the samples were 
stored at -80
o
C to stop the further reaction as they were analysed after collecting last 
sample at 24 h. 
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Fresh samples were also analysed by iTLC-SA. However, iTLC was not of great help in 
this assay because human serum protein radiolabelled with 
99m
Tc tricarbonyl stays at the 
origin and radiolabelled J591(scFv) also stays at the origin, while free pertechnetate and 
99m
Tc tricarbonyl move with the solvent front. Thus, with this method we cannot detect 
any dissociation between the J591(scFv) and association of radioactivity with human 
serum, as both them stay at the origin but it can detect any release of free pertechnetate 
or 
99m
Tc tricarbonyl as they move with the solvent front. 
For analysis by SDS-PAGE, the samples (5 µl) were mixed with 10 µl of LDS buffer 
(lithium dodecyl sulfate, pH 8.4) and applied on the gel (10 µl). The gel was developed 
in MES buffer (2-ethanesulfonic acid) for 40 min at the voltage of 200 V and variable 
current of 120-130 A. Afterwards the gel was removed, activity markers were placed for 
analysis by phosphorimager and the gel was finally stained with Coomassie blue. 
4.6-FACS analysis 
Flow cytometry simultaneously measures and analyses multiple physical characteristics 
of cells as they flow in a fluid stream through a beam of light. It depends on the use of a 
fluorescent marker, e.g. fluorescein isothiocyanate (FITC), which is conjugated to a 
mAb that specifically binds to the primary antibody bound to the target of interest. Flow 
cytometry can measure the relative size of the cells, their relative granularity or internal 
complexity, and their relative fluorescence intensity. The results can be represented 
graphically [126]. FACS analysis was performed to measure PSMA expression on cell 
lines. For FACS analysis, the medium was removed from the 75 cm
3
 flasks in which the 
PSMA negative and PSMA positive cells (PC3LN3 and PC3LN3-PSMA, respectively) 
were growing and replaced with 10 ml of PBS. After a few minutes the PBS was 
removed. A 1 ml aliquot of 0.25% w/v trypsin-0.53 mM EDTA was added and 
incubated for 60 s at 37
o
C. Addition of 10 ml of fresh media (RPMI) stopped the 
trypsinisation reaction. The cells were scraped and homogenised by pipetting. A volume 
of 8 ml was transferred to a 15 ml polypropylene tube and centrifuged for 4 min at 1000 
rpm to obtain the cell pellet. After removal of the supernatant, the pellet was 
resuspended in PBS and the cells were counted in a Cell Countess (Invitrogen). There 
were three samples each for PSMA positive (PC3LN3-PSMA) and negative (PC3LN3) 
cell lines. J591(scFv) was used in a quantity of 1 µg/µl. The three samples were: 
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1. Cells alone (PSMA positive and negative cell lines). 
2. Penta–His mAb conjugated to Alexa fluor fluorescent dye (Penta-His-Alexa Fluor 
488 conjugate, Qiagen). The penta-His mAb recognises an epitope comprising five 
consective histidines and cells (PSMA positive and negative cell lines). 
3. J591(scFv) and Penta–His-Alexa Fluor 488 conjugate and cells (PSMA positive and 
negative cell lines). 
For FACS analysis 950 µl aliquots of cells were placed in FACS tubes and centrifuged 
at 1000 rpm for 4 min. The supernatant was discarded and the pellet was resuspended in 
500 µl of PBS by vortexing. An aliquot of 1 µl of J591(scFv) (primary antibody) was 
added, mixed and incubated on ice for 20 min. The tubes were then centrifuged for 4 
min. The supernatant was removed and 2 ml of PBS was added to resuspend the pellet. 
This process was repeated twice. An aliquot of 1 µl of detection antibody (secondary 
antibody, Penta-His-Alexa Fluor 488 conjugate) was added, mixed and placed on ice for 
20 min in the dark. The tubes were then centrifuged and the supernatant was removed. 
The pellet was resuspended in 2 ml of PBS, again centrifuged for 4 min at 1000 rpm, 
the supernatant removed and this process was repeated thrice. Finally, the pellet was 
resuspended in 300 µl of PBS and the samples were analysed by FACS. 
4.7-Cell-binding experiments with labelled antibodies  
The cell binding experiments were done in triplicate using 24-well plates both for 
PC3LN3 and PC3LN3-PSMA cell lines. The 24-well plates were prepared 24 h before 
the experiment. For preparation of the plates RPMI-1640 media was removed from the 
T-75 cm
3
 flasks in which the cells were growing and the flasks were washed with 5 ml 
of PBS to remove any dead cells. Then 1 ml of trypsin-EDTA was added to loosen the 
cells from flask surface. The bottle was kept at 37
o
C for 60 s in an incubator. Then 10 
ml of fresh RPMI-1640 was added and the cells were scraped and mixed using a pipette 
to obtain a homogeneous suspension of cells. In order to measure the number of cells, 
an aliquot of 10 µl of the cell suspension was transferred to a microcentrifuge tube and 
mixed with 10 µl of Trypan blue for few seconds and an aliquot of 10 µl was placed on 
the slide to measure the number of cells using Cell Countess. The bulk cell suspension 
was then diluted with RPMI-1640 so that each well in 24-well plate received equal 
number of cells (4x10
5
) in a volume of 500 µl. The 24-well plate was incubated at 37
o
C 
for 24 h. 




Tc-tricarbonyl was prepared according to the above mentioned method. The protein 
J591(scFv) (117 µg in 100 µl) was labelled with 
99m
Tc tricarbonyl (139 MBq in 100 µl) 
at 37
o
C for 60 min. After 60 min the formation of radiolabelled complex was checked 
by iTLC-SA using 0.1 M citrate buffer. A 1:3 dilution of the radiolabelled protein was 
prepared in triplicate for both PC3LN3 and PC3LN3-PSMA cell lines. Starting with 90 
µg in 450 µl, for 1:3 dilution a volume of 150 µl was removed from this radiolabelled 
mixture and added to 300 µl PBS to make the volume up to 450 µl. This was continued 
for 10 dilutions. Thus each set in the triplicates started with 15 µg in 75 µl, from which 
was taken out 25 µl (5 µg) and made up the rest of the volume by adding PBS for 1:3 
dilution to produce 10 dilutions [7220 nM (15 µg in 75 µl), 2410 nM (5 µg in 75 µl), 
770 nM (1.6 µg in 75 µl), 240 nM (0.5 µg in 75 µl), 89.05 nM (0.185 µg in 75 µl), 
28.88 nM (0.06 µg in 75 µl), 9.63 nM (0.02 µg in 75 µl), 4.81 nM (0.01 µg in 75 µl), 
1.44 nM (0.003 µg in 75 µl), and 0.4 nM (0.001 µg in 75 µl)]. 
The 24-well plates were removed from the incubator and the supernatant was aspirated 
carefully without disturbing the cells. A volume of 450 µl of Hanks solution was added 
to each of the wells along with 50 µl of the prepared dilution of radioactive complex. 
The incubation of the cells with the labelled antibody was carried out at 4
o
C for 60 min. 
The reduced temperature will result in less internalisation and thus result in better 
detection of the antibody bound to the cell surface. After incubating the cells for 60 min, 
the cells were washed three times carefully with 500 µl HBSS to remove any unbound 
protein. The cells were then lysed with 0.5 M NaOH (200 µl) and the lysate was 
collected in FACS tubes to count the activity in the lysate using a gamma counter.  
4.8-Mass spectrometry 
The spectrometer used to analyse the samples was Agilent 6500 Series Q-TOF LC/MS. 
It is a liquid chromatograph Q-TOF mass-spectrometer that supports atmospheric 
pressure ionization (API) and performs MS/MS using a quadrupole, consisting of four 
cylindrical rods, set parallel to each other. The quadrupole is the component responsible 
for filtering sample ions, based on their mass-to-charge ratio (m/z). For mass 
spectrometry direct injection of J591(scFv) was used. The amount of J591(scFv) used 
was 20 µl, which contained ~30 µg protein.  









Tc tricarbonyl was performed by two methods. One involved splitting 
of the kit and the other used a full kit. The choice of method depended on the amount of 
tricarbonyl required for the particular experiment and the results of the two methods 
were same; i.e. the radiochemical yield of 
99m
Tc tricarbonyl obtained in both the 
methods was the same. Typically, we obtained 90-95% 
99m
Tc tricarbonyl and 5-10% 
free pertechnetate. Figure 4.1 shows a typical chromatogram for analysis of 
99m
Tc 
tricarbonyl formation. In this case we achieved 90% total radiolabelling yield for 
99m
Tc 
tricarbonyl and ~10% free pertechnetate. In the mobile phase of 1% HCl in methanol 
with glass backed TLC(SG), any colloid will stay at the origin with Rf value of 0, free 
pertechnetate will move towards the solvent front with Rf value of 0.7 and tricarbonyl 
will stay in the centre with Rf value of 0.4.        
          
 
 
4.9.2-Time course of radiolabelling of J591(scFv) 
For radiolabelling of J591(scFv) the 250 MBq (100 µl) of 
99m
Tc tricarbonyl was added 
to 50 µl of J591(scFv) (1 µg/1 µl) and heated for 60 min at 37
o
C. To follow the time 
course of radiolabelling, samples were taken at different time points from 0 min to 180 
min as shown in Figure 4.2. With time the radiolabelling yield increased, with almost 


































Figure-4.1: QC for tricarbonyl: mobile phase is 1% HCl in methanol with glass backed 
TLC(SG). Any colloids would stay at base line with Rf value of 0, tricarbonyl moves to 
the centre of strip with Rf value of 0.4 and free pertechnetate with Rf value of 0.7. 
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We have to keep in mind that there is some unreacted pertechnetate also present in the 









4.9.3-MiniTrap purification step 
The MiniTrap step was introduced to remove any unreacted 
99m
Tc tricarbonyl or free 
pertechnetate from the reaction mixture on the basis of size. Thirty fractions of 100 µl 
each were eluted from the MiniTrap column using PBS. The protein was eluted in the 
fractions 8, 9 and 10 as shown in Figure 4.3. Unreacted 
99m
Tc tricarbonyl eluted in 
fractions 17 and 18 and free pertechnetate eluted around 29 and 30. Different fractions 
obtained after the MiniTrap step were also analysed by iTLC-SA and HPLC. On iTLC-
SA developed with 0.1 M citrate buffer, both 
99m
Tc tricarbonyl and free pertechnetate 
moved with the solvent front, while any colloid and J591(scFv) stayed at the origin 
(Fig-4.5). In the case of HPLC a size-exclusion column (SEC-2000) was used to analyse 
the different fractions. The monomer fraction eluted at 9 min, dimer at 8 min, 
99m
Tc 
tricarbonyl at 12 min and free pertechnetate at 14 min. Samples before the MiniTrap 
showed some unreacted tricarbonyl, which was efficiently removed by the MiniTrap 
step (Fig-4.4, 4.5).  
Figure-4.2: Radiolabelling yield (%) against time. Figure shows increase in 
radiolabelling yield of J591(scFv) with time. 
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A: Free pertechnetate elutes at 14min SEC.



























B: Unreacted tricarbonyl eluted at 12 min in SEC.






















C: J591 before mini-trap. Some tricarbonyl at 12min.























D: J591 after mini-trap without any tricarbonyl.
Figure-4.4: HPLC of free pertechnetate (A), 
99m
Tc tricarbonyl (B), radiolabelled J591(scFv) 
before MiniTrap (C) and after MiniTrap (D). In each panel the upper tracing is UV absorbance 
at 280 nm and the lower panel is the radioactivity detector. The column used is a size-exclusion 
SEC-2000 and flow rate is 1 ml/min. 
Figure-4.3: Elution profiles of J591(scFv), tricarbonyl and free pertechnetate from MiniTrap 
column based on their sizes. 











It was also observed that the ITLC method in this case further strengthens the HPLC 
results. After the MiniTrap step no free pertechnetate or 
99m
Tc tricarbonyl was observed 





















































































Figure-4.5: iTLC-SA was used as a stationary phase and 0.1 M citrate buffer as a 
running buffer. iTLC of free pertechnetate (A), 
99m
Tc tricarbonyl (B), radiolabelled 
J591(scFv) before MiniTrap (C), radiolabelled J591(scFv) after MiniTrap (D). 
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just consider the solvent front in Figure 4.5-C and -D. The peak at the solvent front in  
Figure 4.5-C disappeared in Figure 4.5-D. However, there was a small peak at origin 
with 
99m
Tc tricarbonyl on its own, which might represent colloid. The MiniTrap column 
is an effective way for buffer exchange and clean up of biological samples if required. 
The different components were separated on the basis of their size. The recovery of 
protein was between 90-98% depending upon the concentration of the protein applied to 
the column: the higher the concentration the more is the recovery. A small amount of 
radioactivity remained stuck on the column but 90-95% was always recovered from 
column. The activity which stuck on the column could be free pertechnetate, 
99m
Tc 
tricarbonyl or radiolabelled protein.  
4.9.4-Radiolabelling of different concentrations of J591(scFv) 
Different concentrations of J591(scFv) were taken, ranging from 72.2 µM to 3.61 µM, 
and radiolabelled with tricarbonyl (30 MBq, ~10 µl). Samples were taken out at 30 and 
60 min and analysed by iTLC-SA. As can be seen in Figure 4.6, even a low 
concentration such as 3.61 µM gave ~70% radiolabelling yield within 60 min. To 
further verify the results HPLC analysis was performed and Figures 4.7-4.11 show 
HPLC radiochromatograms for the different concentrations of J591(scFv) when 
radiolabelled with 
99m
Tc-tricarbonyl. It was observed in each case that by decreasing the 
amount of single chain, the UV signal is gradually decreased. The HPLC column used 
was size-exclusion (SEC-2000) and it separates the protein on the basis of size, so the 
monomer fraction of the J591(scFv) elutes around 9 min and dimer around 8 min. PBS 
was used as running buffer. 
99m
Tc tricarbonyl and free pertechnetate eluted around 10.5-
12 min and 14 min respectively. The ITLC method in this case is in agreement with the 
HPLC results, as the amount of radiolabelled protein decreased in the sample with the 
Rf value of 0, the amount of unreacted 
99m
Tc tricarbonyl increased with the Rf value of 
1. As shown in Figure 4.6, the radiolabelling yield decreased with the decrease in the 
concentration of the protein. 





























Figure-4.6: Different concentrations of protein are radiolabelled J591(scFv )at 30 min and 60 
min and analysed by ITLC. 
Figure-4.7: 72.2 µM protein radiolabelled with tricarbonyl. Radiolabelled J591(scFv) eluted 
around 9 min in SEC-2000 column in HPLC. 










































Figure-4.8: 36.1 µM protein radiolabelled with tricarbonyl. Radiolabelled J591(scFv) eluted 
around 9 min in SEC-2000 column in HPLC. 
 
Figure-4.9: 18.2 µM protein radiolabelled with tricarbonyl. Radiolabelled J591(scFv) eluted 
around 9 min in SEC-2000 column in HPLC. 
 








   
At higher protein concentrations there was no unreacted 
99m
Tc tricarbonyl detected in 
the chromatograms (Fig-4.8, 4.7) but as the concentration of the protein decreased the 
unreacted 
99m
Tc tricarbonyl peak became prominent around 10.5 minutes in the 
radiochromatogram (Fig-4.10, 4.11). A small amount of free pertechnetate was also 
observed in the radiochromatograms. There was no clear peak around 14 minutes but 
still we can see some activity in the form of streak. We cannot find this peak in the 





























Figure-4.11: 3.61 µM protein radiolabelled with tricarbonyl. Radiolabelled J591(scFv) eluted 
around 9 min in SEC-2000 column in HPLC. 
 
Figure-4.10: 7.22 µM protein radiolabelled with tricarbonyl. Radiolabelled J591(scFv) eluted 
around 9 min in SEC-2000 column in HPLC. 
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ITLC method for higher protein concentration but for low protein concentration there 
was a peak at the solvent front, which most probably represents the unreacted 
99m
Tc 
tricarbonyl instead of free pertechnetate. 
 4.9.5-Difference between 140 mM and 500 mM salt concentration 
Two different concentrations of J591(scFv), 1 mg/ml and 0.5 mg/ml, each at two 
different salt concentrations, 140 mM and 500 mM, were radiolabelled with 
99m
Tc 
tricarbonyl to check the effect of salt concentration on radiolabelling yield [141]. It was 
observed that high salt concentration resulted in modestly higher radiolabelling yield at 
both protein concentrations. In the case of 1 mg/ml protein, with higher salt 
concentration the radiolabelling yield was 95% and at lower salt concentration 88% 






























Figure-4.12: J591(scFv) 1 mg/ml radiolabelling yield with 500 mM salt conc is better 
than at 140 mM. 






Slightly larger differences in the radiolabelling yield were observed with the lower 
J591(scFv) concentration (Fig-4.13). Radiolabelling yield was 92% at 120 min with the 
higher salt concentration but only 80% with the lower salt concentration at the same 
time point. However, statistical analysis could not be applied as the experiments were 
single replicates. 
4.9.6-Serum stability  
Serum stability measurement was performed over the time period of 24 h. Samples were 
taken out at each time point for analysis by iTLC-SA (Fig-4.15) and stored at -80
o
C for 
24 h until the last sample was collected. These samples were then analysed by SDS-
PAGE and a cyclone phosphorimager. It was observed that radiolabelled J591(scFv) 
was quite stable. Even after 24 h there was no evidence by SDS-PAGE of dissociation 
of the label by iTLC-SA nor degradation of the labelled protein or transfer of 
99m
Tc 































Figure-4.13: J591(scFv) 0.5 mg/ml radiolabelling yield with 500 mM salt conc is better 
than at 140 mM. 
 














 10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10  10 
 10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 
 10  10 






Figure-4.14: SDS-PAGE gel for serum stability. Radiolabelled J591(scFv) is quite stable in 
serum even after 24 h. No dissociation between J591 and tricarbonyl was observed.  
1: Marker. 2: Human serum protein + tricarbonyl. 3: J591+tricarbonyl. 4: 
J591(scFv)+serum+tricarbonyl (0 min). 5: J591(scFv)+serum+tricarbonyl (30 min). 6: 
J591(scFv)+serum+tricarbonyl (60 min). 7: J591(scFv)+serum+tricarbonyl (120 min). 8: 
J591(scFv)+serum+tricarbonyl (180 min). 9: J591(scFv)+serum+tricarbonyl (240 min).10: 
J591(scFv)+serum+tricarbonyl (340 min). 11: J591(scFv)+serum+tricarbonyl (24 h). 
 
1 3 4 5 6 11 8 9 10 7 






It was observed that labelled J591(scFv) was kinetically stable and did not lose 
radioactivity in the form of 
99m
Tc tricarbonyl or pertechnetate. 
4.9.7-FACS 
FACS analysis was performed for both PSMA positive and negative cell lines before 
the cell binding experiment with radiolabelled J591(scFv) to confirm that cells were still 
showing specific binding to J591(scFv). In FACS analysis three samples were used for 
each cell line. One was just cells alone, the second was cells with Penta-His-Alexa 
Fluor 488 conjugate and the last sample contained cells with Penta-His-Alexa Fluor 488 
conjugate and J591(scFv). In flow cytometers separate fluorescence (FL-) channels are 
used to detect light emitted. In this case it was FL1 (488 nm). These detectors are 
usually photomultiplier tubes (PMTs) and are sensitive to scatter and fluorescence. In a 
graph (Fig-4.16-D and -C), the left quadrant represents the negative events and right 
shows positive events. PC3LN3-PSMA showed a positive shift in a graph towards the 
Figure-4.15: Radiochromatograms showing the result of strong binding of J591(scFv) with 
99m
Tc 
tricarbonyl in the presence of human serum at different time points. 
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right in FL1 as compared to the PC3LN3 cells, which are PSMA negative. Histogram A 
in Figure 4.16 illustrates the entire population of cells present in a sample. This graph 
plots the side scatter (SSC), which is a measure of the cells’ granularity and general 
shape, against forward scatter (FSC), a measure of cell size. Being able to view the 
entire population enables the gating and separation of sub-populations that one wishes 
to analyse. Apoptosing cells and cell debris are indicated at the bottom left and can be 
excluded from analysis by the gating system. Histogram B shows the gated population 
of cells. Histogram C illustrates the level of fluorescence due to cell-associated Penta-
His-Alexa Fluor 488 conjugate  (FL1). The sample with cells alone and Penta-His-
Alexa Fluor 488 conjugates was used to measure the background. Histogram D, which 
contains cells, Penta-His-Alexa Fluor 488 conjugate and J591(scFv) shows the shift 
towards right with increasing fluorescence, indicating positive cells for the target of 
interest. Negative cells do not possess the fluorescent marker and thus remain on the 















     
 
 
Figure-4.16: FACS analysis of PC3LN3-PSMA using J591(scFv) and 
penta-His alexa 488 conjugate 
A: Just cells. FSC-H vs.SSC-H. 
B: FSC-H of gated cells. 
C: His-tag (FL1). 
D: His-tag and J591(scFv) (FL1) Cells showing positive shift towards right. 












Once the J591(scFv) was radiolabelled with 
99m
Tc tricarbonyl, 10 serial dilutions were 
prepared in triplicate in order to determine whether it has retained its receptor-binding 
affinity, and it had not been compromised in any way. This affinity was measured in a 





Figure-4.17: FACS analysis of PC3LN3 using J591(scFv) and 
Penta His alexa 488 conjugate 
 
A: Just cells. FSC-H vs.SSC-H. 
B: FSC-H of gated cells. 
C: His-tag (FL1). 
D: His-tag and J591(scFv) ( FL1) Cells showing no shift towards 
right. 



























Serial dilutions of the radiolabelled J591(scFv) were incubated with the cells at 4°C (to 
minimise internalisation) for 60 min in order for binding equilibrium to be reached. As 
well as specific binding to the receptors, non-specific binding can also occur due to 
hydrophobic and ionic interactions with other sites on the cell surface, and it is 
important to identify the proportions that are specific and non-specific from the total 
binding observed. Non-specific binding was measured using a negative cell line. The 
24-well plate was prepared at least 24 h before to obtain a uniform layer of cells which 
adhere to the surface. Different concentrations of the radiolabelled protein were added 
to the both positive and negative cell lines to measure total and nonspecific binding 
respectively. Specific binding with the receptors increased with the decrease in the 
concentration of the J591(scFv) in PSMA positive cell lines (PC3LN3-PSMA) and in 
comparison no such increased binding was observed in negative cell line (PC3LN3) 
(Fig-4.18). The results were analysed by plotting % binding against concentration of 
radiolabelled antibody in PRISM software, using non-linear regression fit (one-site 
total) and a Kd value was calculated, which was 3.72 nM in the case of PC3LN3-
PSMA. 
Figure-4.18: Non-specific binding with negative cell lines (PC3LN3) vs total binding with PSMA 
positive cell lines (PC3LN3-PSMA). Increase in cell labelling in positive cell lines with the 
decrease in concentration of J591. Kd value is 3.72 nM in case of PC3LN3-PSMA. 




The mass spectral data from the direct injection of the J591(scFv) shows the strong peak 
at 27700, which corresponds with the molecular weight of the J591(scFv), 27.7 kDa 
(Fig-4.19). A dimer fraction was also observed at 55401.45, which corresponds with the 





For radiolabelling of the protein with 
99m
Tc, J591(scFv) incorporating a His-tag was 
radiolabelled using an Isolink 
99m
Tc tricarbonyl kit from Covidien. QC was performed 
by using TLC to determine the radiolabelling yield (Fig-4.1). 
99m
Tc tricarbonyl gives an 
Rf value of 0.4, while any free pertechnetate moves with the solvent front because of its 
hydrophilic nature. J591(scFv) was radiolabelled with 
99m
Tc tricarbonyl at 37
o
C and 
samples were taken out at different time points to check the radiolabelling yield. It was 
observed that radiolabelling yield increased from 50% at 30 min to almost 70% at 60 
min and 90% at 180 min (Fig-4.2) when labelling was performed at the normal 140 mM 
salt concentration. In later experiments, 500 mM salt concentration was used and a 
comparative study of 140 mM and 500 mM salt concentration and its effect on the 
radiolabelling yield was studied.  It was observed that increasing the salt concentration 
from 140 mM to 500 mM resulted in an increase in yield. At 60 min 0.5 mg/ml with 
Figure-4.19: Mass-spectrum of J591(scFv). A strong peak at 27700, which corresponds with the 
molecular weight of the monomer J591(scFv). A small peak at 55401.45 showed the prescence 
of dimer. 
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500 mM salt concentration the radiolabelling yield was 80% and for same amount of 
protein in the case of 140 mM salt concentration it was 59% (Fig-4.12, 4.13). By 
increasing the salt concentration the radiolabelling yield was increased, which further 
reduced the need to purify the protein through a MiniTrap column. In this regard salt 
concentration in a protein sample is important factor, as demonstrated recently in our 
department [141]. It was also observed that different concentrations of the protein react 
at different rates when incubated with 
99m
Tc tricarbonyl. A higher concentration of the 
protein produced greater radiolabelling yields in less time. The main reason for this is 
the simple statistics of the law of mass-action. The rate of reaction is higher at high 
concentration of the protein, the chances of the interaction between the 
99m
Tc 
tricarbonyl and protein is greater at high protein concentration and there is greater 
probability of forming the radiolabelled complex. At 72.2 µM the radiolabelling yield 
was 100% at 30 min; on the other hand it was 25% with 3.61 µM protein. By increasing 
the time to 60 min the radiolabelling yield at higher concentration was still 100% and 
lower concentration increased to almost 80% (Fig-4.6). In order to remove any 
unreacted 
99m
Tc tricarbonyl or free pertechnetate a MiniTrap column was used through 
a gravity protocol (Fig-4.3, 4.4, 4.5). Although this step may result in a loss of protein, 
it is important to remove any unreacted 
99m
Tc tricarbonyl or free pertechnetate, 
especially for experiments such as serum stability, as it binds with the serum protein and 
produces a strong band at 60 KDa on the SDS-PAGE gel and it would be difficult to 
interpret the results. In the long term the main point of removing the tricarbonyl is to 
avoid injecting it into the patient. A PD-10 MiniTrap column contains G-25 medium 
Sephadex and it separates the small molecules like salt, free labels and other impurities 
from high molecular weight compounds. Two protocols are available to use this 
column: spin and gravity. In the spin protocol the sample is not diluted but recovery is 
90%. In the gravity protocol although the sample is diluted the recovery is 98%. 
Recovery of the protein is 95-98% in a volume of 300 µl. It was also observed on ITLC 
and HPLC analysis that protein samples were without any free pertechnetate and 
99m
Tc 
tricarbonyl as shown in Figure 4.4 and 4.5. 
Serum stability was analysed by SDS-PAGE (Fig-4.14). Since any unreacted 
tricarbonyl and free pertechnetate had been removed through the MiniTrap step, if there 
was any binding between serum protein and 
99m
Tc tricarbonyl then it was because of 
dissociation between protein and 
99m
Tc tricarbonyl. The radiolabelled complex was 
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quite stable over time (Fig-4.14, 4.15). In SDS-PAGE gel it was observed that there was 
strong band at 30 KDa (corresponding to the molecular weight of the monomer fraction 
of protein) and nothing at 60 KDa (serum protein and dimers) as there was no binding 
of these with 
99m
Tc tricarbonyl. The main conclusion from serum stability is that it is 
stable in serum even after 24 h and this test makes it a strong candidate to proceed 
towards an in vivo study. It also means the chelator (His tag sequence) is behaving well 
under challenging conditions. 
For the cell binding study, PC3LN3 (PSMA negative cell line) and PC3LN3-PSMA 
(PSMA positive cell line) were used, which were kindly provided by Dr John Maher 
(King’s College London). Radiolabelled proteins must retain their receptor-binding 
capacity if they are to function as effective radiopharmaceuticals. The radioligand 
binding assay was  performed on both negative and positive cell lines to get the  binding 
affinity (Kd) which was found to be 3.72 nM by non-linear regression, by analysis of 
non-specific binding and total binding. Non-specific binding, importantly, occurs in 
many types of binding assay. In addition to specific binding to target receptors, 
radioligands may also bind non-specifically to other sites, notably the cell membrane. 
The details of the molecular interactions remain unclear, but charge and hydrophobicity 
of the ligand are involved, more so than sequence-specific binding. Non-specific 
interactions may also occur to other receptors and transporters expressed on the surface 
of the cell membrane, and is usually directly proportional to the concentration of the 
radioligand (the addition of twice the concentration of radioligand doubles the amount 
non-specifically bound) [127]. This experiment did demonstrate that there was effective 
cell binding with PSMA positive cell line as compared to the negative cell lines (Figure 
4.18). 
Mass-spectroscopy was also performed on J591(sdFv). A non-radiolabelled sample of 
protein on direct injection gave a strong peak at 27700 (molecular weight of the protein) 
for monomer fraction of the protein and there was also small peak for dimer around 
55401.45 (Fig-4.19), which further confirms the SDS-PAGE and HPLC results. 
  




J591(scFv) was radiolabelled with 
99m
Tc tricarbonyl. The radiolabelled complex was 
purified uing a MiniTrap column, and ~98% of the radiolabelled complex was 
recovered with high purity (without any unreacted 
99m
Tc tricarbonyl and free 
pertechnetate). This radiolabelled complex was highly stable in human serum even after 
24 h as analysed by SDS-PAGE and showed specific binding to a PSMA positive cell 
line (PC3LN3-PSMA) but not to the PSMA negative cell line (PC3LN3). This provides 
justification for evaluation of the potential new radiopharmaceutical in vivo in a tumour 
model.




Chapter 5: Radiolabelling and in vivo biodistribution of 
J591c(scFv) with Gallium-68 
5.0-Introduction 
PET (positron emission tomography) is rapidly becoming a most important imaging 
modality. The most commonly used PET radioisotope is 
18
F, which is accelerator 
produced. However, recently many alternative PET radioisotopes have been explored. 
Gallium-68 is one of them. It is a generator produced PET radioisotope with a half-life 
of 68 minutes. It is used to radiolabel biomolecules using bifunctional chelators. In this 
project instead of a whole antibody, J591, a single chain fragment, J591c(scFv), is used. 
The half-life of 
68
Ga matches perfectly with the expected pharmacokinetic properties of 
the scFv. The scFv contains a His-tag and one cysteine is present near the His tag. This 
cysteine can be used to conjugate it with the maleamide group of bifunctional version 
(YM103) of the in-house produced chelator (CP256) for radiolabelling with 
68
Ga. The 
main aim of the work described in this chapter involved the conjugation of the scFv and 
bifunctional chelator, followed by radiolabelling with 
68
Ga. Its serum stability was 
analysed by SDS-PAGE and in vitro work using PSMA positive and negative cell lines 
followed by in vivo work using male SCID mice having PSMA positive and negative 
tumours.  
5.1-Methods 
5.1.1- Reduction of J591c(scFv) with TCEP 
The sulfhydryl in J591c(scFv) can form a disulfide bond (-S-S-) with another 
J591(scFv) to form a dimer. In order to reduce these disulfide bonds so that the 
sulphydryl (-SH) groups are available for conjugation with maleimide, TCEP was used 
as a reducing agent. In order to optimise the concentration of TCEP which is required to 
reduce these disulfide bonds, different amounts of TCEP were used, ranging from 0.5 
fold molar excess over protein to 30 fold molar excess. After incubating these different 
molar amounts of TCEP with the same amount (5 µg) of J591c(scFv) for 90 min at 
room temperature, aliquots were loaded onto a 12% Neupage gel and run for 45 min 
with a constant voltage of 200 V and a current of 100-125 mA in MES buffer. The gel 
was developed in simple blue safe stain. 
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5.1.2- Conjugation of J591c(scFv) with Fluorescein-5-maleimide (F-5-
M) and YM103 
After reduction with TCEP (1.7 µl), sulfhydryl (-SH) groups were free for conjugation 
with the maleimide group of YM103 (1 mg) dissolved in 10 µl of DMSO. However, 
before performing the conjugation with YM103, J591c(scFv) (819 µg/600 µl, ~887 
nmol) was conjugated with the  F-5-M (1 mg) dissolved in 10 µl of DMSO, to optimise 
the conditions for conjugations, as F-5-M also contains a maleimide group. A 35-fold 
molar excess of F-5-M and YM103 was used for conjugation with respect to the molar 
amount of J591c(scFv) [5]. In the case of F-5-M incubation was done in the dark 
because of light sensitivity. The incubation time with F-5-M and YM103 was 4 h at 
room temperature. After incubation, the excess of YM103 and F-5-M was removed 
using a size-exclusion column (Superdex 75 10/300 GL from GE, flow rate 0.5 ml/min 
and max pressure 1.8 MPa). The column was equilibrated with water followed by PBS. 
J591c(scFv) (500 µl) was injected and 1 ml fractions were collected automatically. 
Afterward the column was washed with water and stored in ethanol. The fractions of 
conjugated J591c(scFv) ready for radiolabelling were stored at -80
o
C.   
5.2-
68








Ga wet column generator was used for elution of 
68
Ga. It was eluted 
with 5 ml of 0.1 N HCl of high purity (hydrochloric acid, 0.1 N, BioChemica, 84428-
500ML, Sigma-Aldrich-Fluka) without using a metal needle over the time period of 2 
min. 
68
Ga was further concentrated using a SCX cartridge (Varian, BondElut-SCX, 100 
mg, 1 ml). The cartridge was preconditioned with 1 ml of 5.5 M HCl and then further 
with 10 ml of distilled water. The generator eluate was applied to the column using a 5 
ml syringe and a Chromabond adapter (Macherey-Nagel). The entire radioactivity 
bound to the column. The radioactivity trapped on column was then eluted with a 
mixture of 12.5 µl of 5.5 M HCl and 500 µl of 5 M NaCl [102]. 
68
Ga eluted from the 
SCX column was acidic with pH ~3. The pH was then adjusted to 7 using ammonium 
acetate buffer (1 M). A volume of 200 µl of 
68
Ga required 300 µl of ammonium acetate 
to neutralise it. For radiolabelling J591c(scFv)-YM103 (10 µg/20 µl) was incubated 
with 
68
Ga (12 MBq/50 µl) for 10-15 min at room temperature (25
o
C). However, at 
lower concentrations more time may be required to achieve maximum radiolabelling 
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yield. Conjugated J591c(scFv) radiolabelled with 
68
Ga was then analysed using a size-
exclusion column (SEC-2000) by injecting 20 µl into the HPLC. PBS was used as a 
running buffer at a flow rate of 1 ml/min, with UV detection at 280 nm and gamma 
detection through an HPLC gamma detector. Further, the radiolabelled complex was 
also analysed using TLC. ITLC-SA was used as a stationary phase and 0.1 M sodium 
citrate as running buffer. 
68
Ga acetate moved with the solvent front with the Rf value of 
1 and radiolabelled conjugated protein stayed at the origin with Rf value of 0. 
5.3-Effect of time and temperature on radiolabelling of different 
concentrations of J591c(scFv)-YM103 with 
68
Ga 
Different concentrations of J591c(scFv)-YM103 ranging from 1 µg/µl to 0.1 µg/µl were 
incubated with  7 MBq of 
68
Ga for 60 min. Samples were taken at different time points 
(0, 5, 10, 20, 30, 40 and 60 min) and analysed for the formation of radioactive complex 
(J591c(scFv)-YM103-
68
Ga) with the help ITLC-SG developed with 0.1 M  sodium 
citrate buffer (pH 6). To check the effect of temperature on radiolabelling, 25 µg/50 µl 
of J591c(scFv)-YM103 was incubated with 90 MBq 
68
Ga in volume of 150 µl at two 




C) and samples were taken at 
different time points (0, 5, 10, 20, 30, 40 and 60 min). CP256 (25 µg/50 µl) and 
unconjugated J591c(scFv) (25 µg/50 µl) were also incubated with same amount of 
68
Ga 
as controls.  
5.4- Mass spectroscopy 
 20 µl (30 µg) of J591c(scFv)-YM103 was assessed by mass-spectroscopy using direct 
injection. Two samples of unconjugated J591c(scFv) were also analysed by direct 
injection, one of which had been incubated with a 30-fold molar excess of TCEP 
reducing agent for 60 min to reduce the covalent dimers. 
5.5- Serum stability 
A volume of 300 µl of 
68
Ga acetate (60 MBq) prepared as described above was added to 
200 µl of J591c(scFv)-YM103 (0.4 µg/µl) and kept for 15-20 min at room temperature. 
Samples were taken at 20 min and analysed by ITLC-SA in 0.1 M citrate buffer and 
HPLC using a size-exclusion column (SEC-2000), PBS as running buffer, flow rate of 1 
ml/min and UV detection at 280 nm and gamma detection with gamma detector of 
HPLC. The radiolabelled conjugated J591c (100 µl) was mixed with serum (200 µl of 
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serum and 100 µl of 0.9% saline). The mixture was incubated at 37
o
C and samples were 
collected at 30, 60, 120, 180, 240 and 300 min (5 µl in each case) and stored at -80
o
C 
until all the time points were collected. 
The behaviour of unchelated Ga-68 in serum was determined by adding 10 µl of 
68
Ga-
acetate to 50 µl of serum protein, incubating for 60 min at 37
o
C and taking out 5 µl and 
storing at -80
o
C until all the time points were collected for gel analysis. J591c(scFv)-
YM103 (2 µg/5 µl) was radiolabelled with 
68
Ga acetate (2 MBq/~10 µl) and a 5 µl 
sample was taken out after incubation of 20 min at room temperature and stored at -
80
o
C as a reference. For analysis by SDS-PAGE, the samples (5 µl) were mixed with 10 
µl of LDS buffer (lithium dodecyl sulfate, pH 8.4) and applied on the gel (10 µl). The 
gel was developed in MES buffer (2-ethanesulfonic acid) for 40 min at 200 V and 120-
130 A. Afterwards the gel was removed, activity markers were placed and it was 
analysed by phosphorimager and then stained with Coomassie blue. 
5.6- FACS analysis 
FACS analysis was performed to measure the PSMA expression on the cell lines. For 
FACS analysis, the medium was removed from 75-cm
3
 flasks containing Du145 
(PSMA negative) and Du145-PSMA (PSMA positive) cell lines, and replaced with 10 
ml of PBS. After a few minutes the PBS was discarded. A 1 ml aliquot of 0.25% w/v 
trypsin-0.53mM EDTA was added and incubated for 60 s at 37
o
C. Addition of 10 ml of 
fresh media (RPMI) terminated the reaction. The cells were scraped and homogenised 
with pipetting to resuspend them. A volume of 8 ml of cell suspension was removed 
from the flask and added to a 15 ml polypropylene tube. The tube was centrifuged for 4 
min at 1000 rpm to obtain a pellet. The supernatant was discarded and the pellet was 
resuspended in PBS and the cells were counted in a Cell Countess. There were three 
samples each for PSMA positive (Du145-PSMA) and PSMA negative (Du145) cell 
lines: cells alone and anti-PSMA antibody (Phycoerythrin, Abcam) in two different 
concentrations. 
For FACS analysis, 950 µl of cells were placed in FACS tubes and centrifuged at 1000 
rpm for 4 min. The supernatant was discarded and the pellet was resuspended in 500 µl 
of PBS by vortexing and 1 µl of monoclonal anti-PSMA antibody was added in two 
different quantities, 500 ng and 100 ng. After mixing tubes were incubated on ice for 20 
min. The tubes were then centrifuged for 4 min, the supernatant discarded, and the 
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pellet resuspended in 2 ml of PBS. This process was repeated twice. Finally, the pellet 
was resuspended in 300 µl of PBS and analysed by FACS. 
5.7- Cell binding of 
68
Ga-J591c(scFv)-YM103 
For cell binding experiment, a 96-well plate was prepared 24 h before the experiment, 
seeded with 5x10
4
 cells per well. For preparation of the plates RPMI-1640 media was 
removed from the T-75 cm
3
 flasks in which the cells were growing and the bottles were 
washed with 5 ml of PBS to remove any dead cells. Then 1 ml of trypsin-EDTA was 
added to loosen the cells from the bottle surface. The flask was kept at 37
o
C for 60 s in 
an incubator. Then 10 ml of fresh RPMI-1640 was added and the cells were scraped and 
mixed using a pipette to obtain a homogeneous suspension of cells. In order to measure 
the number of cells, an aliquot of 10 µl of the cell suspension was transferred to a 
microcentrifuge tube and mixed with 10 µl of Trypan blue for few seconds and an 
aliquot of 10 µl was placed on the slide to measure the number of cells using Cell 
Countess. The bulk cell suspension was then diluted with RPMI-1640 so that each well 
in the 96-well plate received an equal number of cells (5x10
4
) in a volume of 100 µl. 
The 24-well plate was incubated at 37
o
C for 24 h. After 24 h it was removed from the 
incubator and the supernatant was removed carefully without disturbing the cells. A 
serial dilution of cold antibody was prepared in a volume of 75 µl in triplicate [7220 nM 
(15 µg in 75 µl), 2410 nM (5 µg in 75 µl), 770 nM (1.6 µg in 75 µl), 240 nM (0.5 µg in 
75 µl), 89.05 nM (0.185 µg in 75 µl), 28.88 nM (0.06 µg in 75 µl), 9.63 nM (0.02 µg in 
75 µl), 4.81 nM (0.01 µg in 75 µl), 1.44 nM (0.003 µg in 75 µl), and 0.4 nM (0.001 µg 
in 75 µl)]. 
 The cells were washed with 100 µl of HBSS. In cell binding experiments 
68
Ga-
J591c(scFv)-YM103 was prepared as described above. After 20 min the formation of 
radiolabelled complex was checked by ITLC-SA using 0.1 M citrate buffer as running 
buffer. The stock solution of radiolabelled antibody was composed of 5 µg/900 µl. The 
radiolabelled antibody was added at a constant 2 nM (0.33 MBq/~1 µl) concentration 
into the serial dilution of cold antibody and incubated with the cells at 4
o
C for 40 min. 
The reduced temperature will result in less internalisation and reflects the binding of the 
antibody to the cell surface better. After incubating for 40 min, the cells were washed 
three times carefully with 100 μl HBSS to remove any unbound radioactivity. The cells 
A New Gallium-68 Labelled Imaging Agent For Prostate Cancer                        Chapter 5 
139 
 
were then lysed with 0.5 M NaOH (200 μl) and lysate was collected in tubes and 
counted in a gamma counter.  
5.8- In vivo experiment 
All in vivo experiments were performed according to the animal ethics under a home 
office licence in accordance with the Animals (Scientific Procedures) Act 1986. For in 
vivo analysis, 4 male SCID mice (age 8 weeks, ~20 g) were injected subcutaneously on 
the left flank with 3.5x10
6
 (90 µl) of Du145-PSMA (PSMA positive) cells. One of them 
was used for imaging and four were used for biodistribution studies. For imaging of 
Du145 tumours (PSMA negative) one male SCID (age 8 weeks, ~20 g) mouse was 
injected with Du145 cells on both right and left flank with 3.5x10
6
 (90 µl) of Du145 
(PSMA negative) cells. For biodistribution studies 4 male mice (age 8 weeks) were 
injected on the left flank with 3.5x10
6
 (90 µl) of Du145 (PSMA negative) cells. For 
injection cells were grown over the period of 2 weeks in 175 cm
3
 flasks, splitting the 
cells after every 3
rd
 day and replacing the media with fresh RPMI-1640. Eight flasks 
were prepared for both PSMA positive and negative cell lines. For injection the cells 
were first washed with PBS, trypsinised and resuspended in 10 ml of fresh RPMI 
medium, pelleted by centrifugation for 5 min at 1100 rpm, resuspended in 5 ml of PBS 
and counted by combining 10 µl of cell suspension with 10 µl of trypan blue and then 
counting cells in a Cell Countess. Again, the cells were centrifuged and resuspended in 
PBS to get the desired concentration in required volume (3.5x10
6 
in 90 µl). Slowly, 90 
µl of cell suspension was withdrawn into the insulin syringe which was the kept on ice. 
Before injecting the cells, animals (n = 4 for PSMA+ and n = 5 for PSMA-) were 
anaesthesised using isoflurane. Cells were injected into the flank (by pinching the the 
skin of the animal between index finger and thumb and pulling the skin away from the 
body of the mouse) slowly and evenly into the pouch created by fingers, creating a 
single bubble of cells beneath the skin and avoiding too much spread of the cells. The 
mice were regularly monitored over the period of 4 weeks until the tumours were ~5 
mm in size. The size of tumours was monitored through visual inspection and a vernier 
calliper. J591c(scFv)-YM103 was radiolabelled with 
68
Ga as described earlier and 
quality control was performed with HPLC and ITLC before administration to the mice 
by tail vein injection. The amount of radioactivity injected into each mouse was 7 MBq 
in a volume of 90 µl and containing 10 µg of protein. Imaging (n = 1 each group) was 
performed with a Bioscan Mediso NanoPET/CT scanner over the time period of 4 h 
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from the time of injection using PET dynamic scan, 3 weeks and 4 days after tumour 
inoculation. Biodistribution studies with the group of mice bearing PSMA positive 
tumours (n = 4) and with the group bearing negative tumours (n = 4) were performed 
after 4 weeks of growth with sacrifice at 90 min post injection of 7 MBq of the labelled 
antibody. Mice were culled by dislocation of the neck and organs and tissues were 
excised and collected in pre-weighed scintillation tubes to be measured in the gamma 
counter. At the same time, 90 µl of the injectate was taken in another syringe and ten 
1:3 serial dilutions were prepared from it. They were measured at the same time in the 
gamma counter along with organs. The counts obtained in the standards were then used 





Ga-CP256 imaging and biodistribution were also performed in normal 
mice as an additional control. For 
68
Ga acetate one male balb/c  mouse (8 weeks, ~20 g) 
was used for the imaging and then biodistribution of the same mouse was done at the 
end of the 4 h scan. For the preparation of the 
68
Ga acetate, the generator was eluted 
according to the procedure mentioned above, and concentrated using a BondElut 
column.  A volume of 100 µl (60 MBq) of this concentrated generator eluate was taken 
and neutralised by adding 500 µl of acetate buffer (pH 6). A volume of 70 µl of this 
neutralised 
68
Ga-acetate (7 MBq) was injected into the mouse. The mouse was culled 
and biodistribution studies were performed as mentioned above at the end of the 4 h 
scan. For 
68
Ga-CP256 two normal balb/c mice were used (age 8 weeks, ~20 g). They 
were injected simultaneously with 
68
Ga-CP256. One of them was used for imaging 
purposes and other was kept in the cage for 4 h. At the end of the scan (after 4 h) both 
mice were culled and biodistribution studies were performed as mentioned above. For 
the preparation of 
68
Ga-CP256, radiolabelling was done according to the method in 
Chapter 3 and the radiolabelled complex (4 µg, 7 MBq) was injected into the tail vein. 
5.9-Results: 
5.9.1- Reduction of J591c with TCEP 
J591c(scFv) forms both covalent and non-covalent dimers. In order to reduce these 
dimers TCEP was used as a reducing agent. The reaction of the TCEP with disulfides 
involved initial cleavage of disulfide bond (–S-S) accompanied by the oxidation of 
phosphine. The phosphine oxide bond formed is quite stable. Different amounts of 
TCEP were used to see the extent of reduction of these dimers, so as to find out the 
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appropriate amount of TCEP to reduce the protein. As seen in Figure 5.1, in lower 
concentrations of TCEP there was not much reduction of dimers observed but as the 
amount of TCEP was increased there was gradual decrease in the extent of dimerisation 
of the protein. The dimer band at 60 kDa was quite weak at 5 and 10-fold molar excess 
of TCEP with respect to J591c(scFv) as compared to the lower molar concentrations of 
TCEP. The dimer band was negligible in 15, 20 and 30 fold molar excess of TCEP. 
 
 
    
  
 
However, for subsequent experiments we have used 30-fold molar excess in respect to 
concentration of protein to reduce the dimerisation for maleimide conjugation. One of 
the benefits of using the TCEP as a reducing agent is that it did not require removal 
prior to the conjugation reaction with the maleimide (YM103) because there is no –SH 
compound added or formed as in the case of DTT (dithiothreitol), which interfere in the 
maleimide conjugation and must be removed before conjugation reaction resulting in 
possible loss of protein, so conjugation of these sulfhydryl group with the maleimide 
group of YM103 can be done without any need for the removal of TCEP. However, one 
research group in a recent study observed the formation of byproduct somatostatin-
maleimide-TCEP conjugates by MS analysis in the case of halomaleimides [128]. 
Figure-5.1: Showing the effect of different molar concentrations of TCEP on dimerisation in 
J591c (scFv). 
1: Marker.  2: Protein (not reduced). 3: Reduced protein (Neupage reducing agent). 4: 0.5 fold 
molar excess of TCEP. 5: 1 fold molar excess of TCEP. 6: 2 fold molar excess of TCEP. 7: 5 fold 
molar excess of TCEP. 8: 10 fold molar excess of TCEP. 9: 15 fold molar excess of TCEP. 10: 20 
fold molar excess of TCEP. 11: 30 fold molar excess of TCEP. 
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5.9.2- Conjugation of J591c(scFv) with F-5-M and YM103 
After reduction with 30-fold molar excess of TCEP, sulfhydryl (-SH) groups in 
J591c(scFv) are free to conjugate with maleimide. J591c(scFv) was first conjugated 
with fluorescein-5-maleimide (F-5-M) to check the binding and then later on with 
YM103. A 35-fold molar excess of F-5-M or YM103 was incubated for 4 h with 
J591c(scFv) for conjugation. The excess of F-5-M or YM103 was removed using FPLC 
and a Superdex 75 10/300 GL size-exclusion column. The conjugated protein eluted in 
the form of a single peak from 9-11 ml as it is heavier in molecular weight as compared 
to the free YM103 and F-5-M which eluted from 15-20 ml (Fig-5.2). Conjugation of 
YM103 was further verified using radiolabelling with 
68
Ga and HPLC using a SEC-
2000 column and by SDS-PAGE. Both the UV and radioactive peaks eluted at 9 min 
(Fig-5.5) and on SDS-PAGE there was a strong band at 30 kDa. Conjugation with F-5-
M was analysed using SDS-PAGE and G-box (Syngene). It showed a strong band of 
fluorescent protein at 30 kDa (Fig-5.3). After conjugation the protein concentration was 
measured using Nano-drop and stored in appropriate aliquots (100 µg/200 µl) at -80
o
C. 








Figure-5.2: After reduction with TCEP and conjugation with maleimide the excess of 
unreacted maleimide was removed using Sephadex GL column via FPLC. Conjugated 
protein elutes first followed by the unreacted maleimide. 














Following the elution and preconcentration protocol described in the method section, 
95-99% of the eluted 
68
Ga activity was recovered from the Bond Elut column [102]. 
The eluate was neutralised with acetate buffer to pH 7 and then used for radiolabelling 
of protein. Neutralisation required 300 µl buffer to 200 µl of column eluate giving a 
final concentration of 0.24 MBq/µl. The conjugation of YM103 with J591c(scFv) was 
determined by radiolabelling with 
68
Ga. For that purpose, 
68
Ga acetate (12 MBq, ~50 
µl) was incubated with J591c(scFv)-YM103 (20 µl, ~5 µg) for 15-20 min and then 
analysed by HPLC using a size-exclusion column (SEC-2000, flow rate 1 ml/min, UV 
detection at 280 nm). 
68
Ga acetate eluted at 12 min (Fig-5.4) and both the radiolabelled 
and UV peaks of 
68
Ga-J591c(scFv)-YM103 eluted at 9 min (Fig-5.5). The small UV and 
radioactive peaks at 8 and 9 min in Figure 5.4 are most probably residual 
68
Ga-
J591(scFv) from a previous injection, as we have analysed 
68
Ga acetate after 
68
Ga-
J591(scFv), so most probably some protein remained stuck on the column and eluted 
with the 
68




Figure-5.3: J591c(ScFv) conjugated with fluorecein-5-maleimide (F-5-M). Strong band 
at 30 KDa. 
1: Marker.      2: Reduced protein conjugated with F-5-M. J591c-scFv conjugated with 
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The radiolabelling reaction between the 
68
Ga and J591c(scFv)-YM103 is quite quick, it 
was complete in 5 min at room temperature (25
o
C), compared to the other available 
chelators for 
68
Ga such as DOTA can require heating for up to 30 min at 100
o
C. 
Radiochemical yield was close to 100% and a high purity radiochemical complex was 
obtained as seen in the HPLC chromatogram. Although there is dimer peak in the UV, 
radiolabelling of the dimer was minimal, with most of the 
68
Ga binding the monomer 
fraction of the scFv. 
5.9.4- Effect of time and temperature on radiolabelling of different 
concentrations of J591c(scFv)-YM103 with 
68
Ga 
J591c(scFv)-YM103 (25 µg/100 µl) was incubated with 
68
Ga acetate (70 MBq, ~120 µl) 




C and samples were 
taken out at different time points (<1, 5, 10, 15, 20, 30 and 40 min). The samples were 














































































Ga acetate elutes at 11.5 min in size-exclusion column (A) in HPLC. 
68
Ga 
acetate moves to the solvent front with Rf value of 1 in ITLC-SA and 0.1 M citrate buffer 
(B).       
Figure-5.5: 
68
Ga J591c(scFv) elutes at 9 min in size-exclusion column (A) in HPLC. 
68
Ga 
J591c-scFv stays at the origin with Rf value of 0 in ITLC-SA and 0.1 M citrate buffer (B).             
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analysed by ITLC-SG and 0.1 M citrate buffer. However, it was observed that 
temperature had no effect on the radiolabelling yield with time. Radiolabelling yield 
was ~100% at both the temperatures. In fact, within a few seconds 100% radiolabelling 
yield was obtained at room temperature (Fig-5.6-B). Free CP256 (0.2 µg/µl) and 
unconjugated J591c(scFv) (0.2 µg/µl) were also radiolabelled with 
68
Ga as controls. 
J591c(scFv) showed no binding with 
68
Ga as there was no YM103 (bifunctional 
chelator) attached to it. CP256 (free chelator) showed binding with 
68
Ga in a similar 
















































Figure-5.6: (A) shows two controls, CP256 which showed radiolabelling with 
68
Ga and 
J591c(scFv) without YM103, which showed no binding with 
68
Ga. (B) shows that there 
was no effect of temperature on the radiolabelling yield of conjugated J591c(scFv)-
YM103 with time using iTLC-SG and mobile phase of 0.1 M citrate buffer. 
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The above experiment indicates that efficient radiolabelling of conjugated J591(scFv)  
with 
68
Ga can be obtained at room temperature with 100% radiolabelling yield at a 
protein concentration of 0.2 µg/µl, pH 7 and a change in temperature did not affect the 
radiolabelling yield. 
In another experiment to understand the effect of change in concentration of conjugated 
protein on radiolabelling yield, different concentrations of J591c(scFv)-YM103 ranging 
from 1 µg/µl to 0.125 µg/µl  were radiolabelled with 
68
Ga acetate (0.5 MBq) at room 
temperature. Quantitative radiolabelling was obtained at higher concentrations of 
protein (1 µg/µl to 0.25 µg/µl) at all the time points measured (<1, 5, 10, 20, 30, 40, 50 
and 60 min). However, at a lower concentration (0.125 µg/µl), the radiolabelling yield 
increased with time from 70% at 5 min to almost 90% at 40 min (Fig-5.7). From this 
experiment we have concluded that at concentrations higher than 0.25 µg/µl, there was 
100% radiolabelling with in a few seconds, however at 0.125 µg/µl, we had to wait for 

































     
A: 68Ga-acetate. control to show specifity of Ga-binding to the chelator (5 min) 
     




































































Figure -5.7: (A) shows no change in radiolabelling yield with time at higher 
concentrations of J591(scFv)-YM103. At lower concentration it increases from 
70% at 5 min to 90% at 40 min (B). 
Figure-5.8: Two controls to show the specificity of 
68
Ga-binding to the chelator. iTLC-SG 
with mobile phase of 0.1 M citrate buffer. A: shows 
68
Ga acetate moves with the solvent 





acetate moves with the solvent front with Rf value of 1. 
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A: 0.2 µg/µl of  68Ga-CP256 (5 min) 
     
 B: 0.2 µg/µl of  68Ga-conjugated J591c(scFv) (5 min) 
 
 
 5.9.5- Mass spectroscopy 
Unconjugated J591c(scFv) gives a peak at 27803, which represents the molecular mass 
of unconjugated J591c(scFv). However, J591c(scFv) can  bind to other thiols, including 
other J591(scFv) molecules and cysteine in the media, by forming disulfide bonds, as 
they are grown in the media containing human serum. The disulfide bonds can be 
reduced by adding TCEP, which make cysteine of J591c(scFv) available for 
conjugation with the maleimide in YM103 instead of holding other cysteines in the 
system via disulfide bond and generates the MS peak corresponding to the correct mass 
of the J591c(scFv) as shown in Fig-5.10A and 5.10C. 
Fig-5.10B (top panel) shows the mass spectrum of the chelator YM103 with molecular 
mass of 920.414. The second panel in Fig-5.10B shows the spectrum of unconjugated 
J591c(scFv) before reduction with TCEP  with increased molecular mass of 27923.20 
and the presence of corresponding dimer at 55845.62. The increase in molecular weight 
corresponds to the formation of a disulfide bond between the cysteine residue of the 
protein and another cysteine. This indicates that TCEP should be added into this sample 
to reduce the disulfide bond and make sure that cysteine in J591c(scFv) is available for 
conjugation with the YM103 (Fig-5.10C, second panel). A small amount of dimers can 










































Ga-CP256 stays at origin with Rf value of 0. B: Conjugated 
J591c(scFv) radiolabelled with 
68
Ga stays at origin with Rf value of 0. 
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be observed at 55606.50 (molecular weight of dimer). Fig-5.10C, first panel, shows 
reduced J591(scFv) conjugated to YM103. Again a small amount of dimer is observed 











The above experiments indicated that J591c(scFv) was vulnerable to form disulfides 
with other thiols and could also form dimers with itself, which would lead to blocking 
of the conjugation with the maleimide of YM-103. However, this could be removed by 
using reducing agent TCEP, which reduced these disulfide bonds ensure that the 
cysteine in J591c(scFv) was available to bind covalently with one YM-103 molecule. 
5.9.6- Serum stability 
Gel electrophoresis (Fig-5.11) showed that J591c(scFv)-YM103 when radiolabelled 
with 
68
Ga and incubated in human serum protein was quite stable even after 6 h. There 
was no dissociation between 
68
Ga and J591c(scFv)-YM103 or transfer of 
68
Ga to human 
serum protein. Lane 1 is a MW marker. Lane 2 showed radiolabelled human serum 
protein, with a strong band at 60 KDa. Lane 3 indicates radiolabelled conjugated 
J591c(scFv) with a strong band at 30 KDa. Lanes 4-10 are samples taken from the 
serum incubation at different time points. It is observed that there is strong band at 30 
KDa, which matches with the lane 3 of the gel, and there is nothing at the 60 KDa, 
which indicates that there is no association between the 
68
Ga and human serum proteins. 
Figure-5.10: Mass-spectra of conjugated and unconjugated J591c(scFv).  A: Diagrammatic 
representation of the J591c(scFv) with two cysteines and conjugation with YM103 
(bifunctional chelator). B: Mass-spectrum of YM103, unconjugated J591c(scFv) before 
reduction with TCEP. C:   J591c(scFv) conjugated to J591c after reduction with TCEP and 
unconjugated J591c(scFv) after reduction with TCEP .  








5.9.7- FACS analysis 
FACS analysis was performed before the cell binding and in vivo experiment to check 
the PSMA expression on cell lines. For this purpose monoclonal anti-PSMA antibody 
conjugated to Phycoerythrin (Abcam) (PE, FL2) was used. Phycoerythrin is a member 
of a family of proteins called phycobiliproteins, which are derived from cyanobacteria 
and eukaryotic algae and exhibit extremely bright fluorescence. In flow cytometers 
separate fluorescence (FL-) channels are used to detect light emitted. In this case it is 
FL2 (560-590 nm). Both Du145 and Du145(PSMA) cell lines were incubated with 
monoclonal antibody in two different concentrations. It was observed that the Du145 
cell line (PSMA negative) did not show any positive shift in FL2 in contrast to the 
Du145(PSMA) cell line (PSMA positive). Figure 5.12 shows the comparison of the 
geometric mean of the shifts of PSMA positive and negative cell lines at two different 
concentrations of monoclonal anti-PSMA antibody. Figure 5.12 clearly shows that anti-
PSMA monoclonal antibody conjugated to Phycoerythrin bound with the cell surface 
recptors on the PSMA positive cell lines (Du145-PSMA) and it was detected in the flow 
cytometry by positive shift in FL2 in contrast to the PSMA negative cell line (Du145), 
which did not show any binding with the same antibody. Enhancement in the binding 
was also observed in PSMA positive cell lines by increasing the amount of anti-PSMA 
monoclonal antibody conjugated to Phycoerythrin from 100 ng to 500 ng, 
30KDa 
60KDa 
 Figure-5.11: SDS-PAGE for serum stability of 
68
Ga-J591c(scFv)-YM103. A: Radioactive gel 
analysed with Cyclone phosphorimager. B: SDS-PAGE gel is stained with Coomassie blue. 1: 
Marker. 2: Human serum radiolabelled with 
68
Ga. 3: Conjugated radiolabelled J591c(scFv). 4-
10: Radiolabelled conjugated J591c(scFv) incubated in human serum protein at different time-
points, 30 min, 60 min, 120 min, 180 min, 240 min and 360 min respectively. 





                                                                                                                                                              
 
5.9.8-Cell binding 
Serial dilutions of different concentrations of cold antibody were mixed with a constant 
amount of 
68
Ga-J591c(scFv)-YM103 (2 nmol). Cells were incubated with this mixture 
of radiolabelled and cold antibody at 4
o
C for 45 min. It was incubated at 4
o
C to 
minimise internalisation of scFv. The result demonstrated the competition between cold 
and radiolabelled antibody (Fig-5.13). Non-specific binding was measured using the 
Du145 (PSMA negative) cell line and total binding was measured using the Du145-
PSMA (PSMA positive) cell line. As there was competition between the cold and 
radiolabelled antibody, the total binding of radiolabelled antibody increased as the 
amount cold antibody decreased in the mixture. Kd (31.52 nM) value was calculated 
using Prism software for the PSMA positive cell line using non-linear regression fit 
(one-site total). This result indicated that radiolabelled J591c(scFv)-YM103 showed 
specific binding and high affinty to the PSMA positive cell line (Du145-PSMA) but not 
to the PSMA negative cell line (Du145). Furthermore, the conjugation reaction between 
the YM103 and J591c(scFv) and radiolabelling between the 
68
Ga and J591c(scFv)-
YM103 did not interfere with the binding ability with the PSMA positive cell lines 
(Du145-PSMA). 
Figure-5.12: Comparative study of PSMA positive and negative cell lines, when they were 
incubated with anti-PSMA monoclonal antibody. These results show the specificity of the 
PSMA positive cell lines for anti-PSMA antibody. The higher the value of monoclonal 
antibody the greater is the shift shown by PSMA positive cell lines in FL2 (PE). Each value 
is mean ± SD for three measurements. 
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5.9.9- In vivo experiments 
For in vivo experiments mice were injected with 7 MBq and 10 µg of 
68
Ga-J591c(scFv)-
YM103 in a volume of 90 µl. For the imaging of 
68
Ga acetate and 
68
Ga CP256, 7 MBq 
was injected intravenously in normal mice. For 
68
Ga CP256, the amount of CP256 
injected was 4 µg. Imaging (dynamic scans) was done over the time period of 4 h with 
PET/CT scanner. At the end of 4 h mice were culled and organs were weighed and 
measured in a gamma counter in pre-weighed scintillation tubes along with standards. 
The imaging data of 
68
Ga acetate after 4 h (Fig-5.14A) showed the accumulation of 
radioactivity in all the soft tissues, bone, bladder and lungs. A large amount of activity 
also accumulated in urinary bladder. Biodistribution data corresponded with the 
imaging data with the highest amount of activity located in bladder followed by trachea, 
thyroid and bones (Fig-5.15). 
Figure-5.13: Graph shows the competitive binding of conjugated J591c with PSMA positive cell 
line. Du-145 (PSMA negative) shows non-specific cell binding.  
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 A: 
68
Ga acetate                                  B: 
68
Ga CP256 (60sec)                                 C:  
68
Ga CP256 (4 hr)     
                
D: Changes in radioactivity in kidneys and bladder over the time-period of 10 min in mouse injected with 
68






















Figure-5.14: PET/CT Imaging data for 
68
Ga acetate and 
68
Ga CP256. A: 
68
Ga-acetate, most of the 
activity is dispersed in the soft tissues, trachea, thyroid and bones. B: Reconstruction of 
68
Ga-CP256 
images at 60 sec showing activity in the kidneys and bladder, which represents fast clearance from 
the system. C: 
68
Ga CP256 after 4 h post injection, all the activity is in bladder. D: Time course of 
activity in bladder and kidneys with 
68
Ga CP256. 
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In the case of 
68
Ga-CP256 (Fig-5.14B, 5.14C), it was observed that all the activity 
rapidly cleared from the system and accumulated in the urinary bladder. Although 
images showed activity only in the bladder and biodistribution data corresponded with 
the imaging data with the highest amount of activity in the bladder (Fig- 5.16), at the 4 h 
time of sacrifice this activity was only 3% of the injected dose due to excretion of urine 
over the intervening period. The time course of activity in bladder and kidneys was 
plotted for the first 10 min in the case of 
68
Ga-CP256 and it was observed that 
68
Ga-





















Figure- 5.15: Biodistribution data for 
68
Ga-acetate after 4 h. Most of activity is in bladder 
followed by trachea, thyroid, bone and soft tissue. A:% injected dose. B:% injected dose/g.  
N=1 
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In Du145 (PSMA negative), imaging was carried out with one mouse over the time 
period of 4 h (Fig-5.17, 5.18, 5.19) and on the basis of that imaging data it was observed 

















Figure- 5.16: Biodistribution data of 
68
Ga-CP256 after 4 h. All the activity is accumulated in 
the bladder after 4 h. A: %age injected dose. B: %age injected dose/g.   
N=2 
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four mice were injected with 7 MBq of activity on 10 µg of protein and culled at 90 min 
post-injection.  
                                                                                              




                            
                      (A)                                         (B)                                     (C) 
 
 
Figure-5.18: Transverse view of PSMA negative tumour. 
68
Ga-J591c-YM103 was injected 
followed by scanning for 3.5 h.  No accumulation of activity at different time points was 
observed in both right and left tumour. A: 0-30 min, B: 60-90 min, C: 180-210 min. 
Figure-5. 17: PET/CT image of the mouse containing tumours on right and left flank produced 
from Du145 (PSMA negative) cells at 90 min. There was no accumulation in the tumours as 
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Uptake in the PSMA negative tumour increased with time and then decreased, although 
it is quite negligible as compared to the PSMA positive tumour (Fig-5.17, 5.18, 5.19, 
5.20). Biodistribution data showed that activity cleared through kidneys (Fig-5.19). 




















Figure-5.19: Graph shows the biodistribution data based on four mice bearing PSMA negative 
tumours on left and right flanks, they were injected with 
68
Ga-J591c-YM103 and then culled at 90 
min. Highest concentration of activity was in kidneys, as ScFv clears through kidneys. Uptake in 
PSMA negative tumours was very low. 
N=4 
Figure- 5.20: Four mice with PSMA negative tumour was injected with 
68
Ga-J591c-YM103 and 
culled at 90 min. Uptake in the bladder and kidneys were removed from the above graph to 
show the uptake in rest of the organs and tumour. It was clear from the above graph that there 
was not much uptake in the negative tumour, besides liver and lung also showed uptake. This 
finding also corresponds with the imaging data (Fig-5.17 and 5.18). 
N=4 
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(A)  MIP view                         (B) without CT Coronal view                                                             
    
 
                                                             
(A)                                         (B)                                  (C) 
  Figure-5.22: Tranverse view of mouse with PSMA positive tumour (left flank) injected with 
68
Ga-J591c-YM103 and scanned for 4 h. Transverse view of PSMA positive tumour. Shows 
accumulation of activity in PSMA positive tumour at different time points. A: 0-30 min, B: 60-
90 min, C: 180-210 min. 
                                      
Figure-5.21: Mouse with PSMA positive tumour (left flank) injected with 
68
Ga-J591c-YM103 
and scanned for 4 h. MIP view (A) shows uptake in kidneys and bladder and tumour at 90 min. 
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In contrast to the results with the PSMA negative tumour, accumulation of 
68
Ga-
J591c(scFv)-YM103 in the PSMA positive Du145(PSMA) xenografts was much higher 
(Fig-5.21, 5.22). The complex showed rapid clearance from all organs except kidneys. It 
is quite clear from the imaging and biodistribution data that uptake in the PSMA 
positive tumour was higher than the PSMA negative tumour and it showed selective 
localisation in the PSMA expressing prostate tumour xenograft with high tumour/blood 
(5.00) and tumour/muscle (9.25) ratios (Fig-5.23, 5.24, 5.25, 5.26). In contrast, for the 
PSMA negative tumour these values were tumour/blood (0.34) and tumour/muscle 
(2.74). The kinetics of the complex are suitable for the 68-min half life of 
68
Ga. Uptake 
gradually increased with time and was maximum at 90 min, after which it started 
declining as seen in the imaging data (Fig-5.26). The ratio of specific/nonspecific 
uptake was also quite high at 9.1 (Fig-5.25). Specific-uptake was calculated on the basis 
of the uptake in PSMA positive tumour and non-specific on the basis of uptake in the 





Figure-5.23: Four mice with PSMA positive tumour (left flank) injected with 
68
Ga-J591c-YM103 
and then culled at 90 min for biodistribution studies. Most of the activity was in kidneys, as ScFv 
clears through kidneys. It showed uptake in PSMA positive tumours. 
 
N=4 







In Fig-5.20 and 5.24, data for kidneys and bladder were removed from the 
biodistribution data of PSMA positive and negative mice. It is observed that in PSMA 
negative biodistribution data, after the kidneys the lungs, liver and spleen showed 
highest uptake and there was not much uptake in the negative tumour. On the other 
hand, the PSMA positive tumour showed highest uptake after kidneys, followed by 
liver, lungs and spleen. The high uptake in the kidneys is normal and was expected as 















Figure- 5.24: Four mice with PSMA positive tumour injected with 
68
Ga-J591c-YM103 and 
culled at 90 min. Uptake in the bladder and kidneys were removed from the above graph to 
show the uptake in rest of the organs and tumour. It was clear from the above graph that 
after kidneys PSMA positive tumour show highest uptake in mice, besides liver and lung also 
showed uptake. 
 



















Figure-5.25: This graph shows specific vs non-specific uptake in PSMA positive and PSMA 
negative tumours. This data are based on 4 mice in each group and the ratio of specific to non-
specific is 9.1. It also depicts the tumour/blood and tumour/muscle ratio of both PSMA positive 
and negative tumours.  
 
 
Figure -5.26: Comparison of uptake in PSMA positive and negative tumour based on imaging 
data (one mouse each for PSMA positive and negative tumour) over the period of 4 h. The 
PSMA positive tumour showed higher uptake as opposed to the PSMA negative tumour. Mice 
were injected with 
68
Ga-J591c-YM103 and scanned for 4 h. Both PSMA positive and negative 













Specific Vs Non-specific Ratio=9.1 
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The imaging and biodistribution data indicates that there was specific uptake in the 
PSMA positive tumour but not in the PSMA negative tumour.  
5.10-Discussion 
For J591c(scFv) radiolabelling was done with 
68
Ga. Cysteine was introduced along with 
a His-Tag and used to conjugate the protein with an in-house produced bifunctional 
68
Ga chelator (YM103) containing a maleimide group. J591c(scFv) can form dimers 
which are both covalent and non-covalent in nature. Covalent dimers can be reduced by 
incubating with a reducing agent such as TCEP (Fig-5.1). Different concentrations of 
TCEP were evaluated to reduce the dimers. Out of those concentrations 15-fold reduced 
the dimers considerably but we have adopted 30-fold molar concentration to completely 
remove the dimers. However, non-covalent dimers were not affected by the reducing 
agent; to some extent their formation depended upon the handling of the protein and 
temperature. If the protein was frozen down to -80
o
C immediately after purification then 
it was observed from our experience that there will be less chance of the formation of 
dimers or aggregation in the protein sample.  
As was observed in the mass-spec of the J591c(scFv), the mass of conjugated protein 
was 28723.74. The unconjugated protein with an extra cysteine linked by a disulfide 
bond gave the molecular weight of 27923.20 and if reducing agent was added to the 
same sample then it gave the exact molecular weight of the protein with no disulfide 
bond (27803.91) (Fig-5.10). There was also no evidence for trace metal binding to the 
conjugate (e.g. scavenging iron). In the case of J591c(scFv) small amount of dimers 
were also observed around 55606. 
The radioisotope used here was 
68
Ga which is a generator produced radionuclide. The 
generator is eluted with 0.1 M HCl followed by pre-concentration of the eluate [102]. 
This new method of concentrating the generator eluate involved a combination of 













 by adding 
acetate buffer [102]. Another important finding was that 
68
Ge breakthrough from the 





found in the SCX wash through waste, and even if a small amount of 
68
Ge was retained 
on the column it was not eluted with NaCl/HCl solution [102]. 
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As in the case of radiolabelling of J591(scFv) with 
99m
Tc tricarbonyl, different 
concentrations of the conjugated protein were radiolabelled with the same amount of 
68
Ga and a similar result was observed. At higher concentrations of protein, time was 
not an important factor and 100% radiolabelling yield was obtained within a few 
minutes. However, at a lower concentration of 0.125 µg/µl time was a vital factor in 
increasing the radiolabelling yield. As we increased the time from 5 min to 20 min, 
radiolabelling yield increased from 70% to 80% (Fig-5.7). For serum stability SDS-
PAGE was used to analyse the results (Fig-5.11). The results showed that radiolabelled 
conjugated protein was quite stable even in human serum protein. It was also observed 
that no radioactivity was released as small molecules or complexes, nor was it 
transferred to other proteins in human serum. 
Cell binding assays were performed using both PSMA positive (Du145-PSMA) and 
negative cell lines (Du145) at 4
o
C. The main reason for keeping the samples at low 
temperature was less internalisation of the protein at low temperature. In this 
experiment a sigmoid curve was obtained and it was possible to calculate the Kd (31.2 
nM) value using PRISM software (Fig-5.13). This result indicated the specific binding 
of radiolabelled complex with the PSMA positive cell lines (Du145-PSMA) as opposite 
to the PSMA negative cell lines (Du145), which did not show any such binding. 
5.10.1-In vivo work 
For in vivo experiments two groups of 4 mice were used, one with PSMA positive and 
other with negative tumours. The animals were injected with the positive cells on left 
flank and both flanks in the case of PSMA-negative cells. The tumours were allowed to 
grow over the time period of 4 weeks. During this time animals were kept under 
supervision and their tumour growth was regularly monitored using vernier calliper and 
visual inspection until they were 5 mm in diameter. The pharmacokinetics of 
radiopharmaceutical uptake by tumours is particularly dependent on vascularity and 
tumour size. It is generally observed that smaller tumours show proportionately greater 
uptake of radiolabelled protein than larger ones, possibly due to their greater proportion 
of proliferating cells and better vascularisation. With an increase in tumour size, regions 
of necrosis become common, and poor vascularisation has been seen within them [129]. 
Along with imaging and biodistribution of radiolabelled conjugated protein in mice with 
PSMA positive and negative tumour, imaging and biodistribution of 
68
Ga-acetate was 
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also done in one mouse without tumour and 
68
Ga-CP256 with two mice without tumour.  
These served as controls for the free label and untargeted chelator respectively. In the 
case of animals with tumours, imaging was done on one animal and for biodistribution 4 
animals were used.  
In the case of 
68
Ga-acetate, the activity was distributed in the whole animal (Fig-5.14A), 
showing uptake in the soft tissues, bones and a large amount was visible in the bladder, 
with biodistribution data corresponding to the imaging data and it is typical for gallium 
(Fig-5.15). In the case of imaging data for 
68
Ga-CP256, we were expecting some 
accumulation in the brain, as the CP256 complex is uncharged and quite hydrophobic so 
we were assuming that it would cross the blood brain barrier. Instead of this, it washed 
out very quickly from the animal system and within 60 s we could see activity in the 
kidneys and bladder (Fig-5.14C). After 4 h all the activity was in the bladder (Fig-
5.14B) and biodistribution data corresponded with the imaging data (Fig-5.16). This 
behaviour was highly unexpected. In the future it could be evaluated as an imaging 
agent for kidney function. 
In the case of the animals with PSMA positive (Fig-5.21, 5.22) and negative tumours 
(Fig-5.17, 5.18) imaging was done over the time period of 4 h and images were 
reconstructed for every 30 min. It is observed that the PSMA positive tumour showed 
higher uptake than the PSMA negative tumour and the imaging data was further 
supported by the biodistribution data (Fig-5.25, 5.26, 5.23, 5.24). It was also observed 
that accumulation of activity in the tumours increased with time, reaching a maximum 
around 90 min and then started decreasing (Fig-5.19, 5.20). The ratio of specific to non-
specific binding was 9.1 (Fig-5.25), which reflected specific binding to the PSMA 
positive tumour as opposed to the PSMA negative tumour.  
Labelling of J591c(YM103) with 
68
Ga was quite simple and straightforward. It did not 
require any heating because of the novel chelator (YM103), in contrast to DOTA, or any 
purification step after the labelling. J591c(scFv)-YM103 required a few minutes 





GaJ591c(scFv)-YM103 is a new radiopharmaceutical for imaging prostate cancer. 
J591c(scFv) can easily be prepared in the supernatant of mammalian cell culture, 
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yielding almost 6 mg/L. The radiolabelling procedure is quite simple and straight- 
forward and it is carried out at room temperature (25
o
C). Almost 100% radiolabelling 
yield is obtained within a few minutes of incubation. The radiolabelled complex is 
highly stable in serum even after 6 h of incubation. 
68
Ga prefers to bind with the 
conjugated J591c(scFv) instead of serum protein. In in vivo studies J591c(scFv)-YM103 
radiolabelled with 
68
Ga showed specific binding to PSMA positive tumours as 
compared to PSMA negative tumours and biodistribution data also showed that there is  
clear uptake in the PSMA positive tumour as opposed to the PSMA negative tumour. 
 




Chapter 6: Discussion 
6.1-Aims of the project 
The main aims of this project were: firstly, to evaluate the full potential of the new 
68
Ga 
chelator (CP256) and its bifunctional derivative (YM103) suitable for linkage to a 
cysteine residue in a protein or peptide; secondly, to produce an anti-PSMA scFv with a 
modification for site specific incorporation of radiolabel; finally, to evaluate the 




Ga labelled bioconjugates in cultured cell lines 
relevant to prostate cancer, and select the tracers that show promise in vitro and evaluate 
them in animal xenograft models of PCa using PET imaging and biodistribution studies. 
Based on the in vivo data a decision could be made on the potential for these tracers to 
be evaluated in the clinic. 
 6.2-Thesis Discussion 
Various techniques are employed for the early diagnosis and treatment of PCa. The PET 
radionuclide mainly employed in this project is 
68
Ga with a half-life of 68 minutes, 
matching the kinetics of scFv, which clears quite quickly from the system. 
68
Ga is a 
generator produced radioisotope and currently in the market there are various generators 
available for 
68
Ga but the one which is used in this project is IGG-100 from Eckert and 
Ziegler via Imaging Equipment Ltd. However, 
68
Ga was not the only radioisotope used 
in this project. 
99m
Tc, which is a SPECT radioisotope, was also used to radiolabel the 
J591(scFv) via His-tag without the requirement for a bifunctional chelator. In contrast, 
68
Ga does require a bifunctional chelator to introduce it into a biomolecule. The chelator 
used in this project was YM103, which is a bifunctional derivative of a new in-house 
produced 
68
Ga chelator CP256. YM103 was first conjugated with J591c(scFv) and then 
subsequently radiolabelled with 
68
Ga. 
There are various chelators available for 
68
Ga in market or presented in the literature, 
such as DOTA, NOTA, HBED and most recently, TRAP [11,96,111,112]. A 
comparative study of CP256 with the traditional 
68
Ga chelators showed that CP256 was 
a unique chelator and its behaviour created advantages over the traditional chelators. 
DOTA requires heating for 30 min at 100
o
C, NOTA and HBED showed radiolabelling 
with 
68
Ga at room temperature but they require 7 and 10 min respectively and the % 
radiolabelling yield was also lower than CP256. TRAP, which is a recent 
68
Ga chelator, 
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requires low pH. On the other hand CP256 can radiolabel with 
68
Ga at room 
temperature (25
o
C), neutral pH within 5 min or even less depending upon the 
concentration of the chelator and can give 100% radiolabelling yield. It can also be 
radiolabelled with the 
68
Ga in small quantitities. At 1 µM CP256 still showed 
radiolabelling yield of more than 80% after 5 min where HBED gave radiolabelling 
yield of 70% after 10 min. NOTA at pH 7 gave ~40% after 7 min. For both DOTA after 
30 min and NOTA (pH 4.5) after 7 min there was almost no binding at this 
concentration (Table 5). The characteristics of CP256 are especially suitable for 
68
Ga, as 
this radionuclide has a short half life (68 min) so it requires a chelator with which it can 
bind rapidly. Radiolabelling at room temperature and neutral pH is especially suitable 
for a biological compound for which heating at high temperature may lead to 
denaturation. It was also observed that the 
68
Ga complexes of CP256, HBED and 
NOTA were stable in human serum when analysed at two different time-points i.e. 5 
min and 60 min (Fig-2.2, 2.3, 2.4, 2.5). In addition to this, CP256 can also be 








Zr, although it has not been fully evaluated for these metals and its 
utility for them is likely to be less than for 
68
Ga. CP256 showed binding with all these 




Zr. Stability with 
99m
Tc was not analysed and with 
90
Y it was not very stable in human 
serum. The stability of these radionuclides will need to be evaluated over longer time 
periods as these isotopes have longer half-lives. 
However, the unique characteristics of CP256 make it very unusual chelator leading to 
its evaluation in a novel “pretargeting” mode, because the chelation of 68Ga can occur in 
serum even when 
68
Ga has already been bound by serum protein. In the putative 
pretargeting approach, an antibody derivatised with YM103 (bifunctional version of 
CP256) would be administered to the patient, allowed to distribute for several days, then 
a simple 
68
Ga chelate such as citrate or acetate would be given. In theory the 
68
Ga would 
rapidly distribute, find the derivatised antibody in the tumour, and bind to the chelator 
allowing imaging within the half life of 
68
Ga. Although pretargeting is well-established 
(e.g. with the avidin-biotin interaction) it has never been done before using the binding 
between a metal and its chelator. In one study, it was observed that the half-life for 
dissociation of an antibody-ligand complex is more than an order of magnitude lower 
than the half-life times for decay of medically useful radiometal ions [130]. A metal 
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chelate-based ligand will not be bound to its receptor long enough for all of the bound 
radiometal to decay. One approach to solve this problem is to add mildly reactive group 
on the metal chelate adjacent to a complementary reactive group on the antibody when 
the complex is formed. The partners are chosen to be sufficiently unreactive so that they 
coexist with other molecules in living systems without undergoing reaction. When the 
antibody-chelate complex is formed the effective local concentrations of the two groups 
can be non-physically large, so that a permanent link is formed in the complex even 
though no reaction occurs when the partners are free in solution [130].   In one review a 
pretargetting technique was used for the noninvasive measurement of human islet cell 
mass in pancreas or following islet transplantation [131]. In this pretargeting strategy 
anti-human islet cell antibody HPi1 was conjugated to a phosphorodiamidate 
morpholino oligomer (MORF) that binds specifically to a 
99m
Tc labelled complementary 
MORF (cMORF). Sensitivity and specificity of pretargeting were first validated in 
culture using a human beta cell line (betalox5) and a negative control human cell line 
(HEK293). Pretargeting was then used to target and visualize these two cell lines and 
human islets transplanted subcutaneously in NOD-scid mice. In culture, 
99m
Tc 
accumulation on the betalox5 cells pretargeted by MORF-HPi1 was 100-fold higher 
than on untreated betalox5 cells or following treatment with native HPi1 and much 
higher than on the MORF-HPi1 pretargeted control HEK293 cells. Small animal 
imaging readily localized the transplanted betalox5 cells and human islets, but not the 
HEK293 cells. Ex vivo counting demonstrated 3-fold higher 
99m
Tc accumulation in the 
transplanted betalox5 cells and human islets than in the control HEK293 cells [131]. 
The same group further extended the model to predict the effector behavior, in 
particular, its maximum percent tumour accumulation (MPTA) in mice pretargeted with 
three different MORF-conjugated antibodies (MN14, B72.3, and CC49). The MN14 
and the CC49 target different antigens in the same tumour, whereas the CC49 and the 
B72.3 target the same antigen but with very different tumour accumulation. By 
comparing the pretargeting results of these three antibodies, the authors found that 
MPTA of the radiolabelled cMORF effector in the LS174T tumor was independent of 
the antibodies. In conclusion, the MPTA cannot be improved through the use of 
different pretargeting antibodies, although different antibodies may improve the 
maximum absolute tumour accumulation, the heterogeneity, and/or the tumour-to-
normal tissue ratios of the effector [132]. 
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In one of the most recent reviews on pretargetting by Goldenberg et al, they focused on 
a highly flexible anti-hapten bsMAb platform that has been used to target a variety of 
radionuclides to image (SPECT and PET) as well as treat tumours [133]. Radiometals 
are usually coupled to antibodies through an intermediate, a chelating agent. Chelating 
agents often have differing affinities for various metals, and thus the in vivo stability of 
one radiometal bound to a particular antibody-chelate conjugate might not be the same 
as another radiometal bound to the same conjugate. Radiometals that are brought into 
cells by an antibody are retained for long periods, because cells tend to retain metals, 
but metals held by chelates also are inhibited from being expelled. Thus, radiometal-
labelled antibodies will have significantly higher uptake in the liver and kidneys for IgG 
or smaller fragments, respectively. For optimal targeting, systemically-administered, 
directly-radiolabelled antibodies might need to use two different forms, e.g., a fragment 
for imaging and an IgG for therapy. They explained pretargeting as a multi-step process, 
firstly an unlabeled bispecific antibody (bsMAb) localize within a tumor by virtue of its 
anti-tumor binding site(s) before administering a small, fast-clearing radiolabelled 
compound that then attaches to the other portion of the bsMAb. The compound's rapid 
clearance significantly reduces radiation exposure outside of the tumour and its small 
size permits speedy delivery to the tumour, creating excellent tumour/nontumour ratios 
in less than 1 h. Haptens that bind to an anti-hapten antibody, biotin that binds to 
streptavidin, or an oligonucleotide binding to a complementary oligonucleotide 
sequence have all been radiolabelled for use by pretargeting [133,138]. 
We have developed an in vitro model to check the binding and stability of the 
68
Ga with 
CP256 in human blood serum, with analysis by a PD-10 column (Fig-2.21-E). In the 
first set of experiments, human serum was exposed to the chelator first and then 
68
Ga 
was added (instead of the usual method of radiolabelling the chelator first and then 
adding it to human serum). It was observed that 
68
Ga preferred to bind with the chelator 
even in the presence of the human serum. Even after 60 min and at chelator 
concentrations as low as 0.02 mg/ml 
68
Ga preferred to bind with the chelator (Fig-2.22, 
2.24). In the second set of experiments, human blood serum was exposed to free 
68
Ga 
first (allowing the 
68
Ga to bind to transferrin) and then the chelator was added and it 
was observed that not only the low molecular weight 
68
Ga in the pre-sample bound with 
the chelator, almost all of the 
68
Ga which bound with the human serum in the pre-
sample (
68
Ga+human serum) detached from it and preferred to bind with the chelator in 





Ga+human serum+CP256) (Fig-2.25). The same pretargeting model 
was evaluated with HBED and NOTA, two other chelators which bind 
68
Ga at room 
temperature. However, NOTA showed no promise for pretargeting using the same 
technique. However, the behaviour of the HBED was somewhat more complex. Some 
of the activity remained bound to serum and some preferred to bind with the HBED in 
pretargeting techniques and the results shown by HBED are not as clear as in the case of 
CP256 (Fig-2.29, 2.30). 
Based on above mentioned work Prof Phil Blower’s group have done some in vivo 
studies in which the macrophage binding antibody SER4 was coupled with YM103. 
Three groups of 2-3 wild type or sialoadhesin knockout mice were studied. Group 1 was 
a positive control and were injected with prelabelled 
67/68
Ga-YM103-SER4, Group 2 
was a negative control injected with unmodified SER4 followed by 
67/68
Ga citrate, and 
Group 3 was a pretargeting group in which mice were injected with YM103-SER4 
followed by 
67/68
Ga citrate. It was observed that CP256 rapidly and efficiently bound 
68
Ga in the presence of serum, even if the 
68
Ga had been incubated with serum and 
bound to transferrin prior to addition of CP256. Under the same conditions no labelling 
of NOTA was detectable. In the wild type mice, Group 1 showed targeting of 
macrophages in the spleen (36% ID/g) whereas Group 2 showed only 4% in the spleen. 
Group 3, with pretargeting, showed 10% in the spleen. In the sialoadhesin knockout 
mice there were no differences in splenic activity between groups, indicating the role of 
macrophage sialoadhesin in targeting. NanoPET/CT images showed spleen and liver 
activity in Group 3 but only blood pool and joints in Group 2. This would make 
antibody targeting feasible despite the short half life of 
68
Ga [134]. 
The other aspect of this study was PSMA (prostate specific membrane antigen), which 
is an extensively studied antigen in PCa [29] and has attracted a lot of interest due to its 
potential for being both a diagnostic and therapeutic target [135]. J591 is a monoclonal 
antibody which recognises an external epitope of PSMA. In one recent study, results of 
flow cytometry analysis, competitive binding experimental assays, Western, and 
immunoblot analysis of the J591(scFv) confirmed its functionality and PSMA 
specificity [121]. J591(scFv) not only bound specifically to PSMA but also competed 
for the same extracellular epitope of PSMA as the J591 mAb [121]. We have used 
J591(scFv) with His-tag attached to it for binding with 
99m
Tc tricarbonyl and 
J591c(scFv), in which an additional cysteine is attached to the His-tag for attachment of 
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a chelator for 
68
Ga. The protein was produced using mammalian 293-T cells and 
purified through Ni-NTA and size exclusion columns. The final yield of the protein 
obtained was 12 mg/L J591(scFv) and 4-6mg/L J591c(scFv). It was analysed using 
SDS-PAGE as it appeared around 30KDa and with HPLC using size-exclusion column, 
in which it eluted around 9 min using PBS as a running a buffer. One of the problems 
which we have encountered is the formation of dimers in the protein sample. We have 
observed that if we immediately kept the protein at low temperature (-80
o
C) in a diluted 
form then to some extent this problem can be resolved (Fig-3.12). J591(scFv) was 
radiolabelled with 
99m
Tc tricarbonyl via the His-tag attached to the J591(scFv).  
99m
Tc is commonly used by different groups to radiolabel the scFv because of their 
rapid tumour penetration and high tumour-to-tissue ratios at early time points. Free thiol 
groups necessary for labelling with 
99m
Tc are not normally found on these molecules. 
Marlics et al have attached free cysteines to the C-terminus of MFE-23, an scFv 
directed against carcinoembryonic antigen (CEA). They demonstrated that the 
radiolabelled product was stable in vivo and in vitro and but showed high kidney uptake 
[136]. 
We have used quite simple and straightforward radiolabelling procedure; it is done by 
incubating the protein with 
99m
Tc tricarbonyl at 37
o
C for 60 min. After this the protein 
was purified using a MiniTrap column, which removed the excess of unreacted 
99m
Tc 
tricarbonyl or free pertechnetate if present in the sample (Fig-4.4, 4.5). It was also 
observed that by increasing the salt concentration from 140 mM to 500 mM, the extent 
of radiolabelling yield was also increased (Fig-4.13, 4.12). The radiolabelled complex 
was quite stable when incubated with human serum even after 24 h. It was analysed by 
SDS-PAGE and ITLC method (Fig-4.14, 4.15). It was observed that 
99m
Tc tricarbonyl 
remained bound to the J591(scFv) and that J591(scFv) showed specific binding to 
PSMA positive cell lines as opposed to PSMA negative cell lines, with a Kd value of 
3.72 nM (Fig-4.16,4.17,4.18) when analysed by FACS and a cell binding experiment. 
J591c(scFv) was conjugated with YM103. The conjugation reaction was quite simple 
and straightforward. It involved incubating the protein with reducing agent (TCEP) for 
60 min to break the disulfide bonds, making free cysteine available to form a bond with 
the maleimide of the YM103 (3-4 h). Schumacher et al have proved that prolonged 
reaction times did not improve the isolated yield of product [128]. They analysed the 
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different reagents which can be suitable for disulphide cleavage bridging and at the 
same time reagents should be tolarent of the reducing agent TCEP. They observed that 
the halomaleimides showed a greater reactivity toward TCEP than the 
dithiomaleimides. They also observed the formation of side products, somatostatin-
maleimide-TCEP conjugates by MS analysis in case of halomaleimides [128]. In recent 
years many groups have shown different methods of conjugation. Many of the methods 
which are available for the conjugation of chelator with antibody are not very effective. 
Kerry Chester’s group overcame this problem by using 3,4-substituted maleimides to 
bridge and thus functionalize disulfide bonds to generate homogeneous antibody 
conjugates. They reported a one-step conjugation reaction, which was fast, site-specific, 
quantitative and gave products with full binding activity, good plasma stability and the 
desired functional properties. They also described that the rigid nature of this 
modification by disulfide bridging enables the successful detection of antigen with a 
spin labelled antibody fragment by continuous-wave electron paramagnetic resonance 
(cw-EPR) [137]. 
Radiolabelling of the conjugated J591c(scFv) is done with 
68
Ga, simply by incubating 
the conjugated protein with 
68
Ga at room temperature for 5-10 minutes at neutral pH. 
Quantitative radiolabelling was obtained, which means that no purification step was 
required. One of the benefits of using the 
68
Ga as a radionuclide is that it is easily 
available from a generator, which is comparatively cheap and easily available as 
compared to the cyclotron produced radionuclides. Its half life is 68 min, which is 
comparable with the pharmacokinetic properties of the single chain. The radiolabelling 
reaction was simple, quick and straightforward as opposed to the other chelators 
available for the 
68
Ga, like for DOTA required heating at 100
o
C for up to 30 min, which 
is first not very compatable with the half-life of 
68
Ga and besides also not good for 
biological molecules as high temperature may lead to their denaturation.  Furthermore, 
the radiolabelled complex did not require any further purification (Fig-5.2, 5.5). This is 
a major advantage of the new chelator used. It was observed that at lower 
concentrations (0.125 µg/µl), the radiolabelling yield increased with time from 70% at 5 
min to almost 90% at 40 min (Fig-5.8, 5.9). The serum stability gel (Fig-5.11) showed 
that J591c(scFv)-YM103 when radiolabelled with 
68
Ga and incubated in human serum 
was quite stable even after 6 h. There was no dissociation between 
68
Ga and J591c 
(scFv)-YM103 or transfer of 
68
Ga to human serum. In addition, cell binding 
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experiments were performed with PSMA positive cell lines (Du145-PSMA) and PSMA 
negative cell lines (Du145) and it was observed that conjugated radiolabelled protein 
showed binding with the PSMA positive cell lines with a Kd value calculated to be 31.2 
nM. 
68
Ga-CP256 is quite hydrophobic, so we were expecting it might be able to cross the 
blood brain barrier when we injected mice with 
68
Ga-CP256 but in fact it cleared from 
the body within 10 min and accumulated in bladder (Fig-5.14-B). In future this could be 
evaluated as a imaging agent for kidney function. In mice with PSMA negative tumours 
(Du145) no accumulation of radioactive complex was observed either in imaging or 
biodistribution data (Fig-5.17, 5.18, 5.19, 5.20). On the other hand, in mice with PSMA 
positive tumours high uptake and specific binding was observed. The imaging and 
biodistribution data showed no evidence of release of 
68
Ga from the chelator but as 
required they probably reflect the distribution of the antibody. As expected, high uptake 
was observed in the kidneys, as this is known to be the route of excretion of scFv 
proteins (Fig-5.21, 5.22, 5.23, 5.24). 
6.3- Summary 
We have in fact been able to develop two new potential radiopharmaceuticals for 
imaging prostate cancer. Although clearly there is more work to be done, it is a big step 
forward. We have produced J591(scFv), which can be radiolabelled with 
99m
Tc 
tricarbonyl and in the future there is a possibility of using it as a SPECT  imaging agent 
for prostate cancer and J591c(scFv)-YM103 radiolabelled with 
68
Ga and used as a PET 
imaging agent for prostate cancer. The radiolabelling method in both the cases is very 
simple and efficient, especially in the case of 
68
Ga. Using YM103 it is possible to obtain 
high radiolabelling yield within 5 min at room temperature and neutral pH. The 
importance of this bifunctional chelator is further enhanced because of its peculiar 
behaviour in metal based pretargetting. The use of 
68
Ga will likely grow in the next few 
years as the generator gains marketing authorization and there will be a need for truly 
kit-based formulations for radiolabelling biomolecules with 
68
Ga. We have observed 
that this new tracer has the potential to be useful in imaging prostate cancer. In future it 
might be clinically helpful in staging, monitoring and treatment of prostate cancer in 
humans.  




It would be good to do histochemical analysis of the tumours after the in vivo 
experiments as it would give an idea about the tumour vascularisation and necrosis. 
Maximum uptake can be observed in tumours without necrosis. It might give some 
useful information for planning of next in vivo experiment. 
Another important thing to accomplish is the production of the protein which is fit to 
use in humans (cGMP). Also, scaling up the labelling procedure to produce sufficient 
activity for human studies and finally, to evaluate the imaging potential of this new 
radiopharmaceutical in clinical trials. 
Furthermore, it would also be useful to do radiolabelling with other diagnostic and 
therapeutic radionuclides and explore the possibility of using this chelator and scFv 
complex for therapeutic purposes, although this might be limited because of the high 
uptake in kidneys. There are other ways which we can explore to reduce the kidney 
uptake, such as preparation of a diabody. Moreover, to further explore the full potential 
of the chelator and to determine the extent of the possibilities allowed by the ability of 
the chelator to bind 
68
Ga in serum and ultimately in vivo - pretargeting by metal 
chelation. 
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